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Ab t ract  
Hepatocel lu lar carcinoma i one of the mo t common health problem that is  d ifficult 
to treat. a r ult of the ide effect frequently experienced with convent ional 
cancer treatment , there ha b en a growing interest to de elop control led drug 
del i \  er) ) tem that an reduce the mortal i t  rate of l iver cancer pat ients and un­
harm healthy ti sue . Magnetite nanopartic le are potentia l ly important in  
hepatocel lular carcinoma tr  atment. ince the can be used as del i  ery system. Pure 
and coated magnet i te nanopartic les were synthesized via modified co-precipi tat ion 
method in  air at low temperature. Various reaction parameters and coating material s 
have been i nve tigated and characterized . Among these parameters and coating 
material . l .0 % of dextran was selected as an optimum coating for nanopartic les 
USll1g a low feeding rate for the Fe2� lFe3-r- reactants, maintaining the sti rring and 
oaking temperature at 60°C . After that dextran-coated magneti te nanopartic1es were 
bound to crocin ,  a phamlacological ly active component of saffron, via cross-l i nker. 
Croci n  alone has hown anti-cancer acti i ty in d ifferent in vitro and in vi)'o settings 
by several tudies. The a im of thi study was to synthesize dextran-coated magnetite 
nanopart ic 1es contain ing crocin  with a higher therapeutic index for hepatocel lular 
carci noma treatment. The nanopartic1es with crocin were tested in vitro and in vh o 
for their anti -cancer effects as compared to free crocin .  HepG2 cel ls treated with 
crocin-dextran-coated magnetite nanopartic1es showed a decrease in cel l prol iferation 
compared to contro l  ( non-treated cel l s )  or to those treated with free crocin or 
dextran-coated nanopart ic les. The anti -cancer act ivity of crocin-dextran-coated 
nanopartic1es was also evaluated in Balb/c mice. These mice were injected with 
carcinogenic agent, diethylni trosamine. H istological examination revealed several 
pre an erou change . The immunohi t ch mi al anal) u mg antib di 
vii 
indi ati n of cel l  pr l ireration (Ki -67) .  ap pto i ( 130- )1odeath and BcI-2 ) .  
in flammat ion (C) clo X)  g na e-2 ) and angi gene i (va cular endoth l ial gro\\1h 
fact r). i ndicated that magneti te nan particle onjugated with dextran plu crocm 
doe i ndeed impr \ it anti -tumorigenic act i\  it) o\ er fre crocm. The e r ult 
pr \ ide the ba i for d igning ne\\- modalit ie for tr atment of I i \' r cancer \\ hich 
c uld h peful l) reduce it high mortal i ty rate. 
Key" o rd : Magnetite nanoparti Ie . dextran. precancerou change . crocm. 
d ieth) Ini tro amine.  immunohi to chemical tudie . 
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1 . 1 .  a n cer 
C h a  pter 1 :  I n t rod uct ion  
1 
ancer i a di ea e characterized by c 11 that uncontrol lably outgrow their 
normal counterpart . The term tumor and cancer are sometimes used synonymou ly. 
\\ hi h can be mi  leading. tumor is not nece sari ly a cancer. The word tumor refer 
to a mas or lump that may refer to benign or mal ignant growths. eoplasm is a 
) nonym of tumor. benign tumor is a non-mal ignantfnon-cancerous tumor and is 
usual !)  local ized. grow 10\-\'1 . and rarely spreads to other parts of the body. 
Mal ignant tumor i however. a cancer that is re i stant to treatment. i nvades adjoining 
part of the body, and might reoccur after remo al [ 1  2] . There are se eral hal lmarks 
of cancer cel l s  i nc lude stimulate their own growth, resist growth inhibitory signals, 
a\ oid apoptosis. stimu late angiogenesis. mult iply endless by i nvade adjacent t issues 
and meta ta ize. and avoiding inunw1e destruction [ 1 ,  2 ] .  
Cancer i s  among the leading causes of  death worldwide, accounting for 8 .2  
m i l l ion deaths and 32 .6 mi l l ion people l iv ing and suffering from cancer in 20 1 2  
alone. I t  was est imated that annual cancer case would rise from 1 4  mi l l ion in 20 1 2  
to 22 m i l l ion \vi thin the next two decades. The most common causes of cancer death 
are lung [ 3 ] .  l iver ( 745 000 deaths). stomach (723 000 deaths), colorectal (694 000 
deaths) and breast ( 5 2 1 000 deaths) cancers [4] . In the United Arab Emirates (UAE)  
cancer is the third leading cause of death after cardiovascular diseases and accidents. 
Data from the Health Authority of Abu Dhabi i ndicated that cancer accounts for 
approximately 474 deaths cases i n  20 1 2, with 53% male and 47% female. and the 
majority are expatriates. M i l l ions of d irhams are invested an ual ly  to treat cancer 
cases in the UAE [ 5 ] .  There are over 1 00 different types of cancer. and each 
2 
cla died a rding t the t) pe of el l  that i init ial l) affect d .  Each organ con i t of 
differ nt c I I  t) pc that rna} affi cted b) ancer. L iYer i on of the \ ital rgan that 
might de\ elop cancer. 
1 .2 .  Li\ r 
The l i , er i a \ ital organ [ the dige tiY ) tern . I t  i the large t gland in the 
bod) and the hea\ ie t internal organ ( LOO- 1 500 g). It maintain man, of the bod\" '-' - -
home tatic and ph} iological fun tion . The E, er receive a l l  ab orbed ub tance 
fr m inte t ine \\ here m [or ign material may fi lter via pOlial vein .  y temical ly  it 
r cel '  e if OX) gen \ ia arterial b lood up ply (hepatic artery ) .  The l iver tore the 
nutrient and control their r leas to the ) tem ic circulation [6-9] . 
L i \  er fun tion are vanou and can be cat gorized into metabol ic.  catabol ic .  
ynthetic .  t rage and excretory flmction . The l iver ha a c ntral role in  the 
regulation of m tabo l i  m of nutrient l ike carbohydrate ( glycogenol and 
gluc neogen i ). protein .  fat, honnone and vanou xenobiotic . uch as food 
additi ve . drug . or environmental pol lutant . Liver produce albumin.  blood 
coagulation factor . v i tamin l ike vi tamin  and i ron. In  addition. it sore glycogen. 
triglyceride . i ron. copper and l ip id soluble i tamins. I t  also catabol izes endogenou 
ub tance inc luding hormone . erum proteins. old red blood cel ls .  haemoglobin and 
b i l i rubin and mainta in a balance between their production and remo a! . Drugs are 
catabol ized and detoxi fied. then excreted via the kidney or the b i l iary ystem. The 
main excretory product of the l iver i b i le whi le tored in the gal lbladd r. The bi le 
help i n  heme catabol ism and absorption of fat in  the mal l i ntestine [8 .  9] . 
3 
1 .2 . 1 .  L i ,  r truct u re 
The l i,cr r mUltiple I be : left. right ( th large t ). caudate. and 
quadrate r middle I be . audate and quadrate I b are located in the back of right 
I be . Parietal and \ i ceral f the I i, r are cover by a cap ule. It is  a thin  
conne t i \ e ti u la) er co\ ered b)  p riton a l  me othel ial cel l . L i \ er ha a dual 
blo d uppl) . the hepati portal \ ein  and hepat ic artery [ 1 0] .  
The h i  tological or tructural unit [ the l iver i a pol, hedral anatomical 
lobule ( Fioure 1 ) . ach lobule contain a central vein. and radiating inu oid 
eparated from each other by plate of hepatocyte . and peripheral portal tract or 
triad . Portal triad include branche of hepatic artery. portal vein and bile duct. The 
blood flow from p rtal vein into central vein .  and the branche of central vein unit 
to fom1 three main \ ein  that enter the inferior vena cava. The bi le flows in  opposite 
d irection from hepatoC}1e into the bi le duct and eventua l ly  tore in gal l bladder 
[ 1 0] . 
The mam parenchymal cel lu lar units of the I i  er are hepatocytes. The 
hepatocyte are arranged in plate or cords that radiate from the central vein to the 
portal area ( Figu re 1 ) . Hepatocyte . on one side. they are eparated from the 
inu oidal wal l  by pace of Di  e. where they are expo ed to t i s  ue cytopla m. On 
the oppo i te  side. b i le  canal icul i  are formed with hepatocytes in  an adjacent hepatic 
cord. Desmosomes. and gap j unctions connect neighbouring hepatocytes within a 
plate. I n  addit ion to hepatocytes and blood cel ls that exist i n  the inusoid and blood 
\ e  el . the l iver inc ludes everal other type of cel ls. including b i l iary duct cell . 
oval cel l . endothel ial  cel l s. Kupffer cel ls .  Ito cel ls  (stel late cel ls) .  and pit cel ls [ 1 0] .  
B i l iary cel ls  form the b i le  ducts i n  the portal area . Oval cel l are stem cel ls 
located in Herring canals. the area where the bi l iary duct ystem connected with 
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he pat C) te . It ha been h \\ n that 0\  al cell ha\ e a potenC) to generate and 
regenl:ratc not onl) hepat C)1e after injur) . but al 0 bi le duct c 11 . inte tinal 
epithe l ium and pancreati a inar cell [9- 1 1 ] . Fene trated endothel ial cel l l ine the 
inu oid and ) nthe ilC pr taglandin [ 1 0] .  Kuppfer cell are mononuclear 
macrophage fom1ing 1 00 0 of al l  l iver cell . The cell ar phagoC)1ic. 
in flammation mediator . and catabol ize l ipid and protein . The) are al o e  entia I 
l'or paracrine interaction between hepatocyte and I to cel l . I to cell are p n -
1 J1 U  idal cel l that tore \ itamin  and fat and are the main source of  col l agen i n  
the I i \  er. P i t  cel l  are lymphocyt that have characteri tic features of natural k i l ler 
cell and therefore xert C)10toxic act ivity again t tumor cel l . and are mo t ly located 
in periportal area [ 1 0] .  
Common Bile duct (BO) 
Portal vein ( P\,) 
/'� 
Branch o f  HA 1 
Branch of BO 
Portal Triad 
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Cholang locyte 
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Canal 01 Herring 
Hepatocyte 
Kuplfer Cell 
-. Blood now 
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Figure 1 :  Diagrammatic representation of anatomical lobule which i s  the structural 
unit of the l iver. Each lobule inc ludes plates of hepatocytes, hepatic i nusoidal 
endothe l ial cel l ( H  EC) ;  Hepatic ste l late cel ls  ( H  C ). and kupffer cell [ 1 2] .  
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1 . 2 .2 .  L i, er n e  p ia  m 
o pite the l i \  r capa it) � r regenerati \  e gro\\1h b) o\al 1 l . it i a target 
organ f r damage induced b) a \ ariel) of fa tor uch a toxin . ale hoI . chronic 
inflammati n . drug . and geneti mutation . The e ma) lead to \anou l iver 
di ea 'c · including acute l i , er fai l ure. v i ral h patit i . c irrhosi . teatosi or fibro i . I f  
the e di ea e not treat d earl) . ma) lead to  development of  l iv r cancer. Primar) 
I i ,  er cancer oc ur in d iff! rent fi rm. uch a hepatocellular carcinoma ( HC ) .  
i ntrahepati ch langi carc inoma ( I  C )  and hepatobla toma [ 1 3 ] .  
1 .2 .2 . 1 .  H 
H i one of the 010 t common primary malignant Ii er I ion . account ing 
for 70- 00 0 of primar; l iver cancer ca e [ 1 3 . 1 4] .  HC i s  the fi fth common cancer 
in the world.  It k i l l  almo t half-mi l l ion people around the world every y ar. and i t  
the third mo t common cau e of cancer-related deaths [ 1 3- 1 7] .  Th Health 
uthoritJ of Abu Dhabi reported in  _0 1 3  that in  AE there are 1 7% of cancer 
patient died becau e of l iwr cancer and ICC.  Among the e patient 1 3% are men 
and 4 0 0 \\ omen [ 5 ] . 
bout 800 0 of H C develop i n  c i rrhotic l i ver and chronic hepatit is .  Chronic 
viral infections. includ ing the hepatit i  B and h patit is C viru e are major ri k 
factor contributing to HCC development .  Hepatit is B 1ru infection i most 
relevant in mo t part of A ia and Africa. with i nge tion of aflatoxin B 1 from 
contaminated food an additional contributory factor. In the West and Japan. hepati t is  
C viru infection i the main risk factor. Apart from hepatotropic viru e . other major 
r i  k factor leading to c i rrhosis includes exces alcohol intake. HCC i s  an aggre ive 
cancer with a poor progno i [ 1 4 . 1 7-2 1 ] . 
Late diagno i f I I 
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u ual l )  I ad to a \ er ' hort Uf\ i\  al t ime. Enhan ing 
the uf\ i \  al rate requir d te tion f mall tumor at earl) tage . oft n pre nt in  
a ) mpt matic indi\  idual ltra onograph) i the preferr d imaging method for 
crcening. becau e it an be t lerated and \\ id Iy acce ibl . Howe\,er. 
ultra' nograph) en i t i \  it) for H detection is 10";. b eau e mal l nodule can be 
ca i l) mi cd in a c i rrhot ic I i \' r. ontra t-enhanced ultra onography can be u ed to 
impro\ e the diagn tic peril mlan e of ul tra onograph) for H C .  The mo t common 
u d er I gi al te t for creening i alpha-fetoprotein. but it i no longer con idered 
a a ury i l lanc te t becau of it low en it i \ ' ity. Contra t -enhanced computed 
t mograph) and magnetic re onance imaging ( RI ) have a high sen it ivit ( 55%-
9 1 ° 0) and peci fici t) ( 77°'0-96° 0) in  diagnosing HCC.  The diagno is of HC Ie ion 
m a uring bet\\ een 1 and 2 cm i confirmed when typical a cular pattern detected 
on CT and R I .  Othenvi e. th e lesion should not be treated as HCC without 
hi tological i ndication becau e of a rate of fal e posi t ive i as high as 20% [ 1 9, 2 1 ,  
Th rapeutic trategies for HCC patient include surgical resection or l i ver 
tran plantation. which are only appl icable to a small proportion of patient around 
25°;0 with early tumors. Oth r therapeutic method are percutaneous ethanol 
i njection. percutaneou radiofrequency ablation, and trans-arterial embol ization. Due 
to late detection and ad anced underl ing l iver disease , the e treatments are 
normal ly not recommended to the majority of the patients [ 1 8 , 22-24 ] .  
Regarding the chemotherapy, the only drug that i s  currently being u ed for 
HCC i sorafenib. However, the patients survival remains low. and orafenib may 
only improve l i fe expectancy by approximately 3 month 0\ er placebo control [ 1 8 . 
22-24] . orafenib (also known as exavar), i a mult ikinase inhibitor that targets the 
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\'a cular end thel ial gro\\1h fact r recept r fami l )  ( EGFR-2 and EGFR-3 ) and 
plate let-deri \ cd gr \\1h fa t r re eptor fami l )  ( PD FR-beta ) .  The e receptor pIa) 
ke) role'  in  an er  pr  gre i n .  I t  a l  inhibit acti\'ati n of on og n ic  RAF 
l:rine threonine kina e along the RAFI � KlERK pathwa) ( Ra IRAF 
path\\ a) ). \, hi h \\ i l l  inhibit  pro l ifi  rat i\ e ignal re ult ing in  blocking in  tumour 
gr \\1h and devel pment [2 ] .  
Pri r orafenib. doxorubicin wa routinel )  u d a a ingle drug for advanced 
I I  . but ha been ho\\'n in ffecti \ e. with a re pon e rate of about 1 5 -200 0 [26] . 
ther h motherap) agent . uch a epirubi in.  ci plat in .  5 -fluorouraciL  etopo ide 
and their c mbinat ion . demon trate even lo\\ er efficacy [ 1 8 . 22. 23 , 26] .  
ne of th mal l1 rea on for \\ h ich the patient with HCC have poor 
pr gno 1 the mult icentric occurrence of HCC in  the l iver of patient with chroni 
hepatit i  r c i rrho i cau ed b, infection of hepatiti viru e . Thu . even if the fir t 
cancer I diagno d and removed another malignant cel l  clone ma arise to fonn a 
econd primary cancer ( Moriwaki 2002 ). Therefore. due to the fact that the current 
treatment for HCC are not effecti e. new trategie are needed not only to prevent 
the development or po t-therapeutic recurrence of HCC but also to prevent further 
deterioration of l iver function [_2-24. 27 ) .  
1 .3 .  L iver neopJa m a nd  Animal  Model  
The i nc rea e i n  the burden of l iver cancer and specificall HCC reqllJre 
under tanding the aetiology. cel lular and molecular mechani ms leading to i t .  Thu . 
the development of animal model for better under tanding i e ential [ 1 3 . 1 4. 1 6] .  
Currentl, . a wide range o f  HCC animal models are exist ing. which have pro ided 
researcher with the opportunity to: 1 )  evaluate cancer-host i nteractions. 2) perfonn 
drug creening and testing. 3 )  mimic the complex multistep proces of l iver 
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carcinogene is  in human, and 4 )  conduct anou therapeutic experiments [ 1 3 . 1 4 . 1 6 : 
2 8 ] .  
Mice model are one of the preferred and con enient experimental ystems, 
o\\ mg to the phy iologic, molecular and genetic s imi larities to human . their 
bre ding capacity. short l i fe pan, affordable. ea ier to be handle and the unl imited 
option offered by genetic engineering. Mice are also smal l .  ea i ly  hou ed. and 
maintained, and adapt wel l to the ne surroundings [ 1 3 , 1 6] .  There are many ways 
to produc HCC using mice models. such as chemical ly-induced. xenograft 
implantat ion and genetical ly  modi fied model [ 1 7] .  
1 .3. 1 .  Chem ical ly-in d u ced model  
everal chemical reagent induce l iver damage and HCC fonnation and 
development of tumours when t imely administered in sufficient doses. There are tv 0 
types of carci nogens: ( 1 )  Genotoxic compounds which are characterized by their 
abi l i ty to i nduce direct structural DNA changes. ( 2 )  Promoting compounds which 
enhance tumour fonnation after in i tiation. and lack direct genotoxic capabi l ity. 
Treatment with tumour promoting agent faci l i tates the clonal expansion of the 
preneopiastic cel ls .  The ad antage of chemica l ly -induced models is that it mimics 
pathological  events such as i njury and malignancy steps that occur in humans. This 
makes them the preferred models for BCC research [ 1 3 , 28 ] .  
1 .3. 1 . 1 .  D iethy ln itrosa m in e  
A s  mentioned earl ier l i ver i s  the primary target location for many chemicals 
including pest ic ides. food addit ives, phannaceuticals and industrial intennediates 
[ 1 3 ] .  The genotoxic compound N-Nitrosodiethylamin, also known as 
diethyln itrosamine (DE ).  IS categorized as a potent hepatotoxin and 
hepatocarci nogen producing reproducible tumors after repeated admini strat ion i n  
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e. perimental animal . DE induce lesion in animal that mimic the proce of 
di ffer nt ty p of mal ignant cancer in human [29] . 
I n  1 956,  the Sriti h John Same and Peter Magee are the first scienti ts who 
report d that D E  produced l iver tumom i n  rat during toxicity creening te t of 
ch mical . These chemical were being proposed for the use as solvents in the dry 
c leaning indu tr) [ 30 ] .  DE belong to nitro amine fami ly .  This family is 
tructural ly d i\'jded i nto -nitrosanl ides and -nitro odialkylarnines and both groups 
can induce D A dan1age. DE belongs to -nitrosodialkylamines that require 
m tabol i  acti ation mediated by cytochrome P450 (CYP450)  enzymes, in order to 
induce D A damage. It i a s l ightly eHow l iquid and soluble in water, sal ine. 
ethanol .  diethyl ether and organic solvents [3 1 . 32 ] .  
A DE i s  knO\\TI to  produce cancer in  many different species and due to  its 
'widespread occurrence in a variet of products consumed by human, the possibi l ity 
of DE bei ng a main cause of cancer in  humans has been the concem of publ ic 
health agencies for a long time. DE is found in  various foods l ike cheese, mi lk and 
diary product. soybean. smoked. salted and dried fish, cmed meat, fried bacon, soft 
drinks and alcohol ic  beverages l ike whiskey and beers [29, 32,  3 3 ] .  DE is also 
found i n  tobacco smoke at a concentration ranging from 1 to 28 ng/cigarette. and in  
baby bottle n ipples at  a level of 1 0  ppb. I t  i s  used also in  the production of some 
cosmetics. pest ic ides, metal indush'y, and in most rubber and latex products such as 
bal loons [29, 3 1 ] . 
DE i s  metabol ical ly  activated to  carcinogens by  CYP2E l isoforms (one of  
C YP450 enzymes). This isoform is h ighly conserved, having a high degree of  
sequence homology between various species. including humans. DE causes 
carci nogenic act ivity in several different ways as the fol lowing: 
1 )  DE ha capabi l i t) of alk) lating D 
1 1  
tructure leading to the formation of 
mutagenic D adduct . In  the fir t tep. DE hydroxylated to a-
h) dro�) [nitro amine. Th is bio-activation tep i oxygen- and DPH- dependent. 
n electrophi l ic ethyldiazonium ion is fomled po t c leavage of acetaldehyde. This 
eth) Id iazonium ion cau es D damage by reacting with D A-ba es. The resulting 
6-eth) Iguanine lead to GC- T tran itions [ 1 6. 3 1 .  34] . 
2 )  DE can cau e reactive ox gen pecies ( RO ) formation. The generated 
RO inc luding hydrogen pero ide and uperoxide anions induce ox idative stress and 
cau e carcinogenesi by destroying D A. protein and l ipid [ 1 3 . 1 6. 1 7, 3 3 ] .  
Oxidati" e  stre play a vital role 111 hepatocarcinogenesis. particularly in the 
in i tiation and progression steps. ROS-mediated DNA damage is associated with 
breaks in  ingle or double stranded D A chain, and al terations in deoxyribose or 
ni trogenou ba e .  uch increased eIToneous repl ication wi l l  lead to genomic 
i nstab i l i ty and eventua l ly  causing carc inogenesi s [ 34 ] .  
3 )  D E  develop cancer b inducing mutations i n  H-ras proto-oncogene ( also 
knov,n as Ha-ra gene) .  The mutation in  H-ras gene was attributed to specific single­
ba e substitut ions at d ifferent bases of codon 6 1 .  These point mutat ions either a 
transversion in  the first base ( substitution of a purine (A and G )  for a pyrimidine (C  
and T )  o r  v ice versa), o r  a transit ion in  the second base ( substitution of a purine for 
a purine. or pyrimidine for another pyrim idine ) [ 3 5 .  36] . H-ras gene produces H-ras 
protein that is in o lved in regulating normal cel l divi sion and prol iferation in  
response to growth factor stimulation l ike epidermal growth factor ( EGF) .  Then 
act ivates major effector pathways necessary for the propagation of the receptor's 
signaL such as Raf protein kinases and phosphatidyl inositol 3 -kinase ( P I3K) .  Raf 
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regulat ce l l  cy  Ie  progre ion  and tran cription. and P I3K play an  impoetant role 
in reguat l i ng cel l grwoth. prol i feration and survival [ 37 ] .  
4) DE alone lead to the formation of lesion that overexpre s the Bcl-2 gene 
[ 1 7 ] .  
5) DE I t imulates the pro l i ferat ion of hepat ic oval cell and bi le duct cell 
leading to hyperplasia and the fomlation of microscopic intrahepat ic 
cholangioma [38 .  39] . 
Th target organ in  which DEN generates tumours i s  speCles spec ific .  
Hartwel l  and hubik are the first who compi led a review of DE carcinogenic i t  
examin ing in  between 1 96 1 - 1 967 .  pon DEN exposure, mice ha e been sho\\'n to 
deyelop man i ly  HCC. in addition to gastrointestinal. skin. respiratory and 
haematopoietic tumours. Rats were also primar i ly HCC, besides gastrointestinal 
cancer. Guinea pigs and Syrian hamsters developed HCC. gastrointest inal and 
re piratory cancer. Rabbits. dogs and monkeys had only HCC whi le pigs had both 
HCC and hematopoietic cancer [ 1 7. 40] . 
The t ime needed after DE adminstration to  develop HCC depend on  sevral 
factors, i nc luding:  dose concentration. gender, age. animal strain. dose repeti tive 
admin istration. admin istrat ion period ( short or long term) ,  route of adminstration, and 
i nd i  idaul D E  injection o r  i n  associat ion with promoting agents. The younger the 
m ice. the faster HCC wi l l  develop because of the high hepatocyte pro l iferation rates of 
young animals. Due to the stimulati ng effect of androgens and the inhibitory effect of 
estrogens on hepatocarc inogenesis, HCC deveolps in  males more than females [ 1 3 . 1 6, 
1 7, 4 1 ] . 
Because of genetic variations between strains, the ir  susceptib i l ity to both 
spontaneous and DE - induced l iver cancer are d ifferent. CBA and C3H inbred mice 
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train arc c n ider d to b highl) u ceptible to pontan ou incidence of HC . 
\\ hi lc  inbred f 57BL 6 and Balb c mice are relati \ e ly re i tant to p ntaneou 
In idenc of I I  but relat i\ ely en i t i \" to D indu ed H ( Table 1 )  [42 ] .  
arc inogene i in mice develop in three tep : in it iation. promotion. and 
progre i n. Ba ed n th d of mul iple DE admin tration for around 8- 1 6  
\ .. ek . de\ elopm nt of l i \'er cancer an be det rmin d .  For e ample. do e b low 1 0  
mg 'kg [ b  d) weight onl) t imulat the in it iation of carcinogene i . Hepat ic fibro i 
i produc d at 1 0-_0 mg/kg of b dy weight. while promotion and progre ion of 
arcinogen i \ .. i l l  be de\ eloped at do e equal to or above 25-30 mg g of body 
\\ ight [43 ] .  
Th do e r quiremnet. t ime and percentage of cancer development vary 
among d ifferent trains. For example . C3HHE mice strain at concendtrat ion of 90 
mg kg D E  -indu ed 1 000'0 HCC after 45-75 week [44 ] .  DE - induced C5 7BL6 -1 
mice at concentration 5 mgt kg produecd 84% H C after 40-70 weeks [45 ] .  When 
adult mice are i njected v,:eekely for a hort time with DE . it lead to a higher 
tumour rate in a horter t ime ( Ta b le 1 ) . ix week of i ntraperi toneal injection ( i .p . )  
( 3  week '-V ith 75 mg- kg fol lowed b 3 weeks with 1 00 mWkg) lead to 1 00% tumour 
incidence after 7 month in  male mice [46] . Weekly admini  tration of 50 mWkg DEN 
to mice leads to 1 00% pre-neoplastic Ie ions d elopment after 8 month [47] .  
Hepatocarc inogene i s  model can be also be obtained by u ing i ni tiatione/promotion 
protocol that wi l l  leads to genomic alteration . While DE is usual ly the ini tator, 
promoter agents can be phenobarbital. carbon tetrachloride, partial hepatectomy. or a 
high fat diet [ 1 7] .  
Tabl ) : DE 1 admini  trati n t \\ i ld-t)- pe male mic train via i .p. injection. 
Do e 
\\ i ld- Do e H 
co ncentrat ion 
t) pe g repet i t ion de,  e lopment  Refe rence 
t ra i n  
( pe r  body 
weigh t )  
B a l b  c 1 - da) ingle 25  or 50  Ilglg 6- 1 0  month [ 4 S] 
Balb c 1 5  da) ingle I O llglg S months [ 49] 
5 month 
u l t i p l  , (pre-
75m a J...a 
Each d 
� e 
neopla t ic  
Balb/c 5 \\ eeJ... fo I I  0\\ ed by [46] 
Once/\\ eek Ie ion ) 
for 3\\ eeJ... 
1 00mg!J...g 
7 month -
HCC 
2 5 m  kg 
[ 50] C - 7B L 6 1 5  da) ingle Smonth 
6 month 
Once/\\ e k 
C 5 7 B L  6 .f \\ eeJ... 50m� J...g ( pre-
[ 4 7] for S \\ eeJ... 
neopla t ic  
lesion ) 
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H dey lopment u mg  DE model i a multi tep proce . \"'here DE 
work a a complete carcinogen to  induc HCC and cycle of  de-generation and re­
generation activate pre-neoplastic transfonnations. The progre ion of early 
dy pia tic Ie ion to mal ignant tumors i as ociated 'vvith an increa ed occurrence of 
g nomic alteration . uch genomic al terations are ver imi lar to those associated 
with HC development in  humans. Thu . 0 model is consider one of the be t 
model u ed to study HCC pathogenesis mechanism in human [ 1 7. 5 1 ] . 
1 .3. 1 .2 .  The  aflatoxin  model  
The aflatoxin B 1 h patotoxin produced by particular fungi of the 
pergi l lu  genu . for example A paragillus flavlIm and Aspergillus 
para fliclI which are widespread i n  nature. There are four of aflatoxin ( B  1 .  B2. G 1 
and G2) knovm to be carcinogenic to both humans and animals. Aflatoxin B 1 i s  the 
mo t potent hepatocarcinogenic  of those agents. The Aflatoxin B 1 is found in food. 
such a com. rice. o i l  seeds, dried fruits and peanuts, that have been stored in hot, 
humid and i nappropriate condi t ions. It is found in the mi lk .  meat and eggs of farm 
animals that feed on contaminated foods with aflatoxin [ 1 6, 1 7, 52, 53 ] .  
C YP450 i s  necessary for the metabolic activity of aflatoxin B 1 causing sister 
c hromatide exchange. chromosomal strand breaks, DNA-adducts, and uncontrol led 
D A synthesis [ 1 6. 1 7 . 52. 5 3 ] .  
1 .3. 1 .3. Carbon tetra ch loride 
Another potent hepatotoxin is carbon tetrachloride (CCl .. ) .  The hepatotoxicity 
of CC14 i s  exerted in several d ifferent ways. CCl4 damages hepatocytes d irectly by 
altering the penneabi l ity of the plasma, lysosomaL and mitochondrial membranes. 
CCl4 is metabol ized by CYP2E 1 ,  CYP2B 1 or CYP2B2 to fOlm trichloromethyl 
radicals. These radicals are h ighly reactive and can bind to cel lular molecules, such 
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a nucleic acid. pr  tein and l ipid impairing vital cel lular proce e such a l ipid 
metabo l i  m. with the re ult of fany degenerat ion ( teato i ) . dduct fomlation 
bet\\ en CCL� and D A lead to h pat ic cancer [ 1 6. ] 7. 54. 5 5 ] .  
1 .3. 1 "". ho l ine  defic ient  diet  
e\'eral tudies reported that mice ubjected to chol ine deficient diet could 
de\'elop H C in 1 3  month post 3 weeks continou adminstration of the diet [56] .  
Abnomlal pro l iferat ion of oval cel ls  ha been propo ed a the mechanism through 
which carc inogenicity by chol ine deficient diet wa developed. The abnormal 
pr l i ferat ion of oval cel ls  was a re ult of RO generation and oxidati e DNA 
danlage and chromosomal in tabi l ity because of the depletion of hepatic antiox idant 
mechani m [ 1 6. 1 7 ] .  
1 .3.2.  Xenograft models  
Xenograft tumours is one of the most widely used models  to stud HCe In 
thi model .  human cancer cel l s  are injected i nto immune deficient micesuch as 
athymic (nude) or severe combined immune deficient (SC ID)  mice. Depending on 
the mmlber of HCC cel l s  i njected. the cancer wi l l  take to develop around 1 -8 weeks. 
There are several types of xenograft models including: ( 1 )  The ectopic model ,  in  
which human cancer cel l s  are i njected subcutaneously in  the flanks of mice .  ( 2 )  The 
orthotopic modeL in willch tumour cel l s  are i njected directly into the mice l iver. (3 ) 
Hol low fibre assay. i n  which different cel l s  from d ifferent cancer cel l  l ines placed 
i nto small i nd ivial semi-permeable tubes [ 1 3  1 6. 1 7 . 57 ] .  The advantages of 
xenograft models are the rapid tumor grwoth and development. These models also 
al low i nvestigation of in vivo toxic ity. absorption and pharmacokinetics of the 
compounds/drugs. However. the pathological events of tumor development in these 
models do not mimic that occur in humans [ 1 6  1 7] .  
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1 .3.3. Genet ical ly mod ified model  
Genetica l l }  modified animal are engineered to resemble pathophy iological 
and molecular feature of H C. The genetic profile of these mice i changed, in  a 
\\i a} that ne or e eral gene that in olved in  the molecular stages leading to the 
cancer are mutated. deleted or overexpressed. Genetical ly modified animal enable 
detai led in e t igation of carcinogenic pathways, exmanine the effect of the modified 
gene alon or in combination with carc inogenic agents, and the therapeutic 
r pon e [ I " . ] 6 . ] 7, 57 ] .  
There are large numbers of  HCC tran genic mice, including transgenic mice 
over- xpre sing oncogenes l ike Myc protei n  (a transcription factor that upon 
mutation it force cel l  to pro l iferate continuously and prevent apoptosis). and mice 
over-ex pre ing growth factors, uch as Epidermal growth factor that regulate cell 
grov,;th. pro l iferation and differentiation [ 1 7, 58 ] .  
Because the e .  i st ing treatments for HCC are not efficient new treatment 
ources are needed to prevent the progress of HCC and deterioration of l iver 
functions. Many i nvestigations are being carried out worldwide to discover natural ly 
occurring compounds which can suppress or pre ent the development of I i  er 
carcinogenesis .  I t  i s  wel l  known that many ant icancer drugs derived from plants 
include Taxol (mitotic i nhibitor) from Pacific Yew tree, V inblastine (ant i ­
m icrotubule drug) from Catharanthus roseus, and Campothecin ( inhi bits DNA 
topoisomerase I )  from Camptotheca acuminate. The current research suggests that 
many herbs and spices contain chemicals that may decrease the incidence of cancer 
[59. 60] .  
1 04. affro n 
affron 
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world '  mo t expen ive spice that has been widel ' u ed a an 
herbal medicin . pice. food colouring, and a flavouring agent since ancient times 
be au e of it di t inct colour, odor, and ta teo It i obtained from the dried stigma 
derived from the flower of th plant rocZl at;ru Linnaeu (C at;\,us 1. ) [60-63 ] .  
The genu Crocu contain around 8 8  specie among which C afivlIs 1. is the most 
im e t igated speci . This herb is cult ivated in many di fferent countries. such as 
pain. Ka hmir, and epa I [ 60-62 . 64] .  HO\'vever, I ran accounts for 70% of saffron 
worldwide [65 ] .  
C at;1'11 1 .  grow under hot and dry weather i n  the summer. but its 
vegetat ive growth i dur ing cold winter. The seeding of saffron takes place in  the 
month of June and Jul , while harvest ing is end of October-beginning of November. 
affron can tolerate tempertaure of maximum 45°C and minimum of ' 1 8° C. The 
plant is pro l i ferati ng by bulbs, which divides to yield new plants, and each bulb 
produces one to seven flowers [65 ] .  
C ativus L. produces flowers once a year and the flower has three stigmas 
( Figure 2 ) .  The flowers should be col lected imm ediately because the stigmas might 
lose thei r  colour and thei r  volati le  aroma components might evaporate. Once the 
flowers are gathered. stigmas are removed from the rest of the flowers. The stigmas 
and their flowers must be hand-picked because they are delicate [60-62, 64] .  
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F igure 2 :  Each flower of C. sativus L .  has three stigmas [66] . 
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ore than 85 ,000 flo'v\ er ne d d to produce only one ki logram ( kg )  of 
t igma . It i nece ar} to dr ( roa t ing proce ) t igma wel l  for good preservation, 
becau c the, hay a high level of moisture . fier the roa ting, 1 kg of raw tigma 
\', i l l  obtain nearly _00 gram (g )  of affron [60, 62, 63. 66. 67] .  
Whi le affron can tolerate high temperature , i t  easi ly degrade III the 
pre ence of l i ght and oxidizing agent . Usual l y  the be t saffron sold as whole stigma 
( not powdered ) i n  a irt ight containers awa from l ight sources to maintain its 
i ntegrit) . The l imi ted product ion ield. t ime and difficult seeding and harvesting 
proc dure that hould be done b hand. these reasons make affron expensive, 
around 40-50 per g [60, 62, 63. 66, 67] . 
Chemical analysis has ho\Vl  the presence of est imated 1 50 volat i le and non­
volat i le compounds in saffron .  I t  has also some carbohydrates l ike starch, vitamins, 
ami no acids. and fats. Saffron' s  major components are as the fol lowing: 
1 )  Crocin (D i -gl cos I polyene e ters of crocetin, hydro-soluble) is  responsible 
for 80% of saffron colour. 
2) Crocetin ( Dicarboxyl ic  acid precursor of crocl11 , l i po-soluble) 1 S  also 
responsible for 20% of saffron colour. 
3 )  P icrocroci n  ( Monoterpene g lycoside precursor o f  safranal ) i s  responsible for 
the bitter taste. I t  i s  the second most abundant component i n  saffron.  
4)  afranal ( De-glycosylated form of picrocrocin)  is  an aromatic aldehyde that 
is responsible for saffron volat i le  o i l ' s  odor. 
Dehydration process is not only critical for the preservation of saffron,  but is  
important for the release of safranal from picrocrocin  via enzymatic act ivity. Then 
the reaction produces D-glucose and safranal [62] . Recent studies showed that 
saffron has many medicinal properties including anti -oxidants, anti -tumorigenic [68 ] ,  
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memo!) enhancer, ant i -d pre ant and cardio-protective agent [60. 6 _ .  67] .  a 
major component of affron, crocLl1 I S  a main contributing active ingredient to 
affTOn '  bioactivity. Thu . the fol lowing ection \vi l l  focu on crocin .  
1 .5. C rocin 
rocin i one of the � w water- oluble carotenoids found in  nature; therefore. 
it ha variou appl ication as a food colorant and medicinal propert ie . It is 
the die ter fomled from the di accharide gentiobiose and the dicarboxyl ic acid of 
cro et in .  Gent iobio e i a disaccharide composed of two units of D-glucose, and due 
to the e ugar moieties rocin has high water olubi l i ty [67. 69] . Crocin has a deep 
red colour. quickly dis o lves in water to foml an orange to yel low colour. Crocin  
chemical formula i C.l4H64024 ( Figu re 3 ). with molecular weight i s  976.96 g/mol .  
The recommended storage temperature i s  2-8 °C,  and i t  i s  l ight sensi tive. I t  fomls 
cr. stal 'wi th a melting point of 1 86 °C .  In addition to crocin water solubi l ity, i t i s  
al 0 oluble i n  methanol and ethanol .  [60. 62. 67 ] .  
::;5" 
Figure 3 :  chematic representation of crocin chemical structure [67] .  
2 2  
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1 .5 . 1 .  C roc in  metabol i  m 
Oral l )  admini tered cr c in hydrolyzed into croceti n  before circulated into the 
blo d. a fter a ingle do e or repeated do es for ix  da s of 40mg/kg crocin into rats 
and mic . roc in hydroly zed into crocet in before or during intestinal ab orption. 
rocetin v. a then part ly metabol ized into mono- and di-glucuronide conjugates. The 
pIa 111a concentration of crocet in  was decreasing, after 1 hr of single oral dose of 
crocin .  Thi indicate that crocet in  might rapidly be el iminated without accumulation 
in  the bod} . This i con i tent \ i th the short plasma half- l i fe of croceti n  [ 70-72] 
Crocin as intact foml wa largely present in feces and inte t inal contents, but 
not in the urine post 24 hr of admini  tration. The amount of crocin lost in the colon 
wa gr ater than other parts of intest ine ( Duodenum, Jejunum and I leum). that 
probably becaus of higher basic condition within the colon. Consequently, the 
i nte t inal tract erves as an important site for crocin hydrolysis [ 70, 7 1 ] . Howe er, 
another study reported that crocin  could be excreted by the urine after long term 
expo ure. 2 1  days, of 1 80mg/kg crocin  i .p. administrated ( Hosseinzadeh, Shariaty, 
ameni, & Vahabzadeh, 20 1 0 . 
1 . 5.2.  Crocin sources 
Croci n  found to be the main pigment of the saffron as mentioned earl ier. The 
amount of croci n  in saffron is varying depending on the growing conditions. drying 
processes, duration and storage methods. Greek and Kashmiri saffron have the 
h ighest concentration of crocin  fol lowed by I ndia and ew Zealand [67,  69] .  I n  
addit ion. crocin  obtained from the fruits and flowers of gardenia, in  speci fic 
Gardenia jasminoides Ellis species. This species has traditional ly used as a folk 
medic ine i n  few Asian countries l ike china. Japan, I ndia and Pakistan. This species is 
less common compared to C. safivus L. [ 73 ] .  
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1 .5.3. B iologica l act iv i t ie of crocin 
Man) benefi ial effect of crocin against different i l lne es have been 
reported inclduing being a pOL nt ant i -cardiovascular, ant i -cancer. ant i -oxidant, ant i ­
inOammator; . and anti -depre ant and as a promoting agent of learning and memory 
[ 67 ] .  
1 .5.3. 1 .  Ant icancer  effect  
everal studie hav hown that the crocin can inh ibit the growth of different 
type of cane rs uch a leukaemia. 0 teo sarcoma. fibrosarcoma and 0 arian 
carc inoma and brea t cel l  . Crocin  decrea ed M CF -7 and Hela cel l l ines by down­
regulating the expression of Bc l -2 .  and up-regulating the expression of Bax . Crocin 
induced apoptosis and G 1 cel l cycle  arrest in human pancreatic and tongue squamous 
cancer ce l l  l ines [67] . I t was also reported that crocin  inhibit the prol iferat ion of three 
col rectal cel l  l ine ( HCT- 1 1 6 . SW- 480. and HT-29) and human non-small  cell lung 
cancer ( CLC) cel ls .  On the other hand. no toxic effect was reported on nomlal 
cel l . non-cancer young adult mouse colon ( Y  AMC ) cells [ 74] . 
Croc in  also reduced the formation of mouse skin papi l lomas when they were 
i njected subcutaneously with 85 nmol of crocin [ 75 ] .  The l i fe span of rats was 
increa ed and colon tunlor growth was decreased in female rats without showing any 
significant toxic  effects. after long-term treatment of crocin .  The treatment was 
weekly for 1 3  weeks with subcutaneous administration of croci n  400mg/kg [ 76] . 
1 .5.3.2.  Effec t  on gastric disorders 
everal studies reported that crocin decreased the gastric diseases. K ianbakht 
et a l .  have shown that oral ly administrated of crocin  at 1 0mg/kg reduced ulcer 
fonnation, due to i t  i s  antioxidant properties. Crocin prevented indomethacin- induced 
gastric mucosa damage by i ncreasing glutathione levels and preventi ng l ip id 
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oxidation [ 77 ] .  imi lar rudy tested the capabi l ity of  crocin to  preyent tomach 
Ie ion in  rat treated with indomethacin,  an anti - inflammatory drug known to cau e 
ulcers, The r ult show ed that crocin protected the stomach muco a from damage 
compared to un-treated group [ 78 ] .  These rudies also emphasized the afety of 
crocin i nce the rat did not di play ga tric ulceration at the highest crocin dose of 
1 0  m .... kg or 50  mg/kg in  normal tested animal [77 ,  78 ] .  
1 .5.3.3. A n t iox idant  effect 
s a potential radical cavenging agent, crocin is a potent neuro-protective, 
anti-aging, ant i - inflammatory, and ant i -cancer biomolecule. Bors et a! . in 1 982 was 
the fir t to report the anit-oxidant activity of cracin [ 79] . The ant i-oxidant 
mechani m of croc in  are main l  attributed to its sca enging abi l i ty of superoxide 
anIOn and nitrite, 2 ,20-azino-bis ( 3 -eth Ibenzthiazol ine-6-sulfonic acid)  radical 
cations i nh ib it ion, superoxide d i  mutase- l ike activity and the reduction of 
intracel lular RO production [80 ] . 
anthosh et al . tudied the role of crOC I n  m treating the secondary 
compl1cations of snakebite. Rats treated i .p. with venom mixed crocin ,  The results 
indicated that in croc in  reduced the level of pro-inflammatory cytokines, such as I L­
l B. IL-6.  and TNF-a, and decreased the oxidative stress induced by venom [8 1 ] . The 
protective role  of crocin against bery l l ium chloride tox icity in rats was investigated 
at a dose of 200mg/kg i .p . treatment for 7 days prior to beryl l ium chloride intake 
resulted i n  significant reduction in bery l l ium chloride-induced oxidative stress, 
combined with in it iation of m RNA expression of catalase and superoxide dismutase 
genes. The hematological and biochemical parameters such as lactate dehydrogenase 
levels were restored near the normal levels  [82 ] .  
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I .S .3A. n t i - inflamm at ion  effect 
Recent tudie rev al d that cro In  ex rt ant i - inflammatory and ant i -
nociccpt i\  a t i \  i t ie . Tamadd nfard et a l .  t t d the effect of i .p. treatment of 
cr c in  at do r 25 .  -0. and 1 00 mg/kg on local inflammation and inflammatory 
indu d by intra-plantar injection of carrage nan in  rat . The re ult 
h \\ed ant i - in flammat r) and anti-nociceptive act i\  itie of crocin  in a d e 
dependent manner b) decr a ing the inflammatof) pain re pon e and number of 
neutr phi l i n  carrag enan mod I [ 3 ] .  
tud) b) 'u t al .  eval uated the ant i - inflammatory effect of crocin  in vitro 
and in "i" o .  In " itro. cy cloox gena e inh ibition a ay hov, ed that crocin 
oncentration (0 .0  L 0 . 1 .  l .0. 1 0 , 30.  and 1 00 ).lM)  di pIa) ed a dual inhibitof)' 
act i\ it) again t the cyc loox) gena e- l ( OX- I ) and cydooxygena e-2 (COX-2 ) 
enzyme i n  l i popoly a charide-chal lenged RAW 264.7 murine macrophag cell in 
a do e dependent manner. Crocin  al 0 uppr ed the productions of prostaglandin  
E �  [ 7  ] .  Anti- inflammatory act ivity in " iva examined using two animal edema model 
te t . Pre-treatment v,:i th crocin  at dose 1 2 . 25 .  and 50mg/kg were administered 
oralh .  inhibi ted the xYlene- induced ear edema i n  mice and carrageenan- induced paw 
- -
edema in  rat i n  a do e dependent manner. These results i ndicated that crocin 
exhibit obviou anti - inflan1l11atory effects [ 78 ] .  
1 .504. afety of crocin 
everal tudies conducted by re earchers to investigate the potential safety of 
crocin .  Wang et al . reported that croci n  cau ed rever ible and do e dependent black 
pigmentation of the l iver. and acute hepatic  damage related to di  coloration. In rat 
oral ly admin i  tered with croc in dail at do e of 50 mglkg for 8 day , the l iver 
function was normal . Ho ever, h igher dai ly dosage of 1 00 mg/kg for longer 
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durati n. 2 v. eek . induced re\ er ibl  hepatic damage and black pigmentation. The e 
re 'ults ugge t d that the cr in ha lo\', t xicit) in  rat even in  high experimental 
dosage. \\ hi  h \\ uld hard ly  happen in human practice: therefore. croc in i ati for 
human on umption [ 4 ] .  
1 10 einzad h a l .  report d a more comprehen ive tud) 111 20 ] 0 to 
im e tigate biochemical. hemat logical and pathologi al toxic effect of crocin 111 
mice and rat 1 11 maJ r organ . l ike heart. l iver. lung. pleen, and kidney. The acute 
toxicity tudied at do e .., g/kg gi \'en oral ly and i .p. once a day for 2 day . and the 
'ub-acute toxic i ty at do 1 5 . 45 .  90 and ] 80 mg/kg. i .p .  dai ly for 2 1  day 
( Ho einzadeh. hariat) . ameni .  & ahabzadeh. 20 1 0 ) .  Oral and i .p. dose of 3 
g kg croc in  did not cau e any pathological change and death within 2 day of tudy. 
H \\ e\ r. there \\ as a reduction in appetite. weight. and in  alveolar ize in  lung only 
at 1 80 mg kg group compared to control group. Regardle the excessive 10 of 
croc in  in 1 80 mg -g group that made the urine orange-yel low color, there was no 
pathologic change in k idney. The re ult obtained indicated that crocin at 
pharmacological do e les than 1 80 mg/kg did not cau e damage to all the major 
organ of the body. and it might has low toxic ity at 1 80mg/kg po t long t ime 
admin i  trat ion [ 8 � ] .  
I n  20 1 3 . croci n  tablet 20mg/day for 4 weeks were evaluated b 
Mohamadpour et a1 . .  for hort-tem1 afety and tolerabi l i ty in  healthy adult male and 
female volunteers. General health measures recorded before. after and during the 
tud) . uch as hematologicaL biochemicaL hormonal and urinary parameter . The 
re ul t  of this c l in ical afety e aluation howed a relati ely safe and nom1al profile 
for crocin  in health volunteers at the gi en do e within the trial period [ 86] . In 
addit ion. affron as a whole extract has a h igh LD50=20 g/kg, that is wh recentl y  
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\.IC  I g; r earcher con ider it to be afe for human intake. The amount u ed in 
dai l;  r d con umpti n I actual !)  much 10\\ er than the do e cau ing any of the 
r p ned ide effect [62 ] .  
ttaching o r  conjugating crocin on del i \ ery y tern l i k  nanoparticle ( 1  P ) 
an imprO\  e th therapeutic effi ct f cr c in a anticancer agent. rocin-conjugated 
P ma) offer e\ eral advantage including: ( 1 ) Prolonging crocin irculation time. 
( - )  Pre 'en ing crocin a inta t form not to convert to crocetin. ( 3 )  Reduc ing the 
rocin do e on entrati n. (4 )  pec ific delivering to cancer ite, due to pa sive 
targeting that I ad t increa e accumulation of crocin in  cancer tis ue, because of 
their leak) microve el and the lack of efficient lymphatic drainage that do not exi t 
in  nonnal ti ue, 
1 .6. anoparticle ( N P ) 
anotechnology i a multidi c ip l inary branch of clence. \\ hich i 
dynanlical l )  grov" ing field of both academic and industrial intere t I n  this branch 
ad\anced material are u ed for various appl ications such as biomedical .  
pharmaceutical. agriculturaL environmentaL and compri ed different fields of 
cience, engineering and medicine. A a re ult of rapid development in the e fields, 
there i a significant i ncrea e i n  the development of no el nanomaterials [ 87-89] . The 
prefix ' nano ' derives from the Greek meaning ' dwarf . The European Committee for 
tandardization defines nanomaterial as materials with an external d imension at the 
nanoscale. or that have nanoscale i nternal or surface structures. anoscale de cribe 
the ize range from approximately  1 to 1 00 nm ( lSOrrS 27687 :2008) [ 88 ] .  
Various structures of nanomaterials were produced and appl ied such as Ps. 
nanocap ule , nanotubes. and nanofibers, Ps are the one of the most widely studied 
and u ed nanomateria l . Ps  can be spherical . tubular. or i rregularly shaped. and can 
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ccur in the � m1 of fu ed or agglomerated [onn . P can b di\ ided into t\\ 0 main 
t) pc . natural and engineered . , atural P pre ent in the n\' ironment re ult  from 
t,:\ enL uch a terre trial du t toml , ro ion, and \ olcanic eruption that happen d 
natural h .  Whi l . engineered P \'v er manufactur d by human u ing differ nt 
material . J he material . inc luding metal ( g, Zn, u, i, Fe. and eu). metal 
o\.ide (Ti02. Fe, -I. i 2, and 12 3 ), non-metal ( i l ica and quantum dot ). carbon 
( nan tube_ ) ,  p Il mer (alginate. chito an, hydroxymeth, lcel lulo e. and 
p I) caprolacton ) ,  and l ipid ( o, bean lecithin and stearic acid)  [ 88 ,  89]. ome of 
the nanomaterial appro\' d b) Food and Drug Admini trat ion ( FDA) and 
commercial ized for biomedical application , e pecial ly  for the treatment of cancer. 
ar Ii ted in Table  2 [ 90 ,  9 1 ] . 1any engineer d P have be n de\'eloped for 
biom dical appl ication . 
uperparamagnet ic i ron-oxid P ( PIO ) are among the different types 
of Engineered p ,  that are con idered to be promi ing candidate in cancer 
th rapeutic and diagnost ic ( therano tic ) appl ications due to their unique properties. 
The e propertie include uperparamagnetic behaviour, biocompatibi l i ty, flexible 
urface-modification, and high urface to olume rat io by virtue of their smal l size. 
The e k ind of Ps are also biodegradable, becau e they can be metabol ized, 
tran ported, and tored in protein l ike ferrit in,  tran ferri t in and hemo iderin [92. 93 ] .  
Due to their unique features, P IO s have arious appl ication 111 
biomedical fields uch a magnetic separat ion. bio ensing. gene therapy, detection of 
biological entit ies l ike cel l s  and proteins. and ti sue repai r. Moreover, P IO s were 
im'e t igated in the area of cancer therapeutics, " here they were found to hav a 
potent ial i n  improving the contra t ing features in  MRL biological label l ing. drug 
del ivery. and hyperthennia .  Recentl , everal PIO formulations have been 
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appr " ed for C \ ini al u e. for 1 R I  a contr t agent and therapeuti purp e .  uch 
a · :  Lumiren for bov. el imaging. Ferid ,, 1  for l i\er and pi en imaging. Combidex 
r r I )  mph node meta ta e imaging. and F rumoxytol for iron replacem nt therapy 
[ 93 -95 ] . 
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Table 2 :  m e  o f  the appr \ ed o r  mark ted nan material for cancer treatment. 
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The oncept of u ing magnet ic 'P  for drug del iver) \\ a propo d in the late 
1 970s b) \\ idder and hi col leagu [96. 97] . Hov,,'e\ er. the id a of u ing magnetic 
'P  a a carri r that an b targ ted to a certain i te  u ing xtemal magnetic Ii ld  
date back t earl ) 1 940 . a a new methodolog m wa te v"ater t r  atment [98] .  
�1agnet ite i among the mo t commonly tudi d PIO [87.  99] . 
1 .  7. M a gnetite nan particle (M P )  
1 P ar ne of the mo t attractive u ed PIO in  cancer th rapy and other 
biomedical appl ication . du t their chemical tabi l i ty. biodegradabi l i t) . react ive 
urface that an be mod ifi  d. and magnetic propertie [ 89. 92-94 ] .  Magnetite ( MN )  
with a c h  mical fornlUla Fe30.. i a mineral and one of the three natural ly 
ccurring i r  n oxide ( magh mite; y-Fe203. and hematite: a-Fe203 ) [92 ] .  MN i 
con idered the m t magnetic of a l l  the natural ly occurring mineral on Earth [ 1 00 ] .  
i black or bro\\ni h-black \ i th molecular weight of 23 1 .55 g/mol. I t  ha 
a den it)' of 5 . 1 8  g/cm3• a m  Iting point of 1 5 83 - 1 597 0c. and a hardnes of 5-6 on 
10h cale of m ineral hardnes . The chemical name of MN according to 
I nternational Union of Pure and Appl ied Chemi try (I PAC ) is i ron ( l U l l )  
oxide. and the common name i ferrou -ferric oxide. The chemical fOlll ula o f  MN 
can al  0 be \\Titten a FeO· Fe203 [ 1 00- 1 03 ] .  MNPs have been widely i nve tigated in  
the la  t decades for a wide range of appl ication . I n  biomedical app l ications. they 
have been studied a MRl  contrast agent. immunoassay. detoxification of biological 
fluid . hyperthell11ia. ce l l  separation. and drug del ivery [ 87. 99. ] 04] .  
To be u ed i n  biomedical applications. the composition. ize. charge. and 
urface chemistry of the MN Ps are important and trongl affect both the blood 
c i rculation t ime a wel l  as bioavai labi l ity of these nanoparticles with in the bod . I n  
addi tion. magneti pr p rtie and internal ization proc 
on theIr ilC [94 ] .  
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of �0JP depend trongly 
F r the ) temic admini tration. mall r particle \\ ith diameter of mai ler 
than 1 0  nm can be rapidl) remo\ ed b) r nal c learance. On th other hand. particle 
\\ ith diameter bigger than 1 00-200 11m are u ual l]  qu tered by th pleen and 
l i \  er a a re ult f mechanical fi ltration and are \,entual l y  remO\ d by the cel l of 
the phagoc) t ) tem. re ult ing in  decrea ed blood circulation time . P in  the 
range f 1 0- 1 00 nm ar optimal . afe.  and demon trat the mo t prolonged blood 
ir ulation t ime . 10 t endothelial barrier al low MN P Ie s than 1 50 nm to pa . 
more tringent baITi r .  uch a the blood brain barri I' al low 1 5  to 50 IID1 to pa s 
v, ith mole ular \\'eight mai ler than 500 Da [92. 94. 1 05 - 1 07] [ 1 02. 1 08 ] .  
1 .7. 1 .  1\1 P Cry ta l  tructure 
MN ha a cubic i nver e pinel tructure . The large oxygen ion fonTI a close­
packed cubic lattice. with the Fe ions fi l l ing the gap between them. The iron ion in 
the gap arranged in two different site : ( 1 )  Tetrahedral ite: Fe ion is surrounded by 
four oxygen . and fom1 a magnetic ublattice. These ite are exclu ively occupied 
by the mai ler ferric i ron Fe'''' atom . (2 )  Octahedral sit : Fe ion i urrounded by i x  
oxygen . and fom1 B magnetic ublattice . These sites are randomly occupied b 
ubequal numbers of ferric ( FeJ+) and ferrous ( Fe2+) i ron atoms. 
The pin on the sublattice are anti paral lel to those on the B sublattice. The 
1\\'0 crystal ite are ery d ifferent and result in  complex fonns of exchange 
i nteraction of the i ron ion between and within the two type of site . MN exhibit a 
variety of characteristic that depend on the temperature [ 1 00, 1 09 ] .  
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1 . 7.2. up rpa ra m agnet i m prop rt)' of M P 
\1. i a Ii rrimagnet ic mat rial at room temperature. \\ ith population of 
at 111 \\ ith oppo ite dir ction of magnetic moment . Ferrimagnetic material can be 
magn ti7\.:d b� an external magnet ic field and remain magn tiz d after remo\ ing the 
e ternal field.  MN ha a uri temp rature of 8 0 K ( 57r ) . \ hich i temperature 
\\ here a material ' permanent magneti m change to induced magneti m [ 1 1 0] .  
1 P are a l  0 k n  \\ n a uperparamagn t ic :  P IO . The ternl uperparamagneti m 
refer- to a pec ific P lZ f 1 - 30 nm [ 1 1 1 ] . In other tudies the lze 1 maller 
than 1 0 11m at r om temperature [ 1 03 ] .  Goya et al . inve t igated the magnet ic 
propertie of �fNP of ize b t\\-een 5 and 1 50 nm and he concluded that the 
magnetizati n \\ a in rea d a th part ic le ize decreased [ 1 1 2] .  
Th bulk o f  MNP contain multiple domains and expre e ferromagnetic 
beha\ iour. The material \\ ith a higher number of domain produce less internal 
en rg� . and \ ic \ er a. the s ize of the particle decrea e to les than 30 nm. the 
number of domain decrea e to be ingle domain .  In uch a stat of 
uperparamagnetic behaviour. the MNP how ferromagnetic or paramagnetic 
propertie . according the pre ence or absence of external magnetic field. recept ively. 
Paranlagneti sm i the t pe of magnetism that occur only in  the pre ence of an 
external ly  appl ied magnetic field [93 .  1 1 1 ] .  
When an external magnetic field appl ied. the ingle-domain of MNP 
al ign a l l  thei r  magnetic moments in  the same direction as this external magnetic 
field. re ult ing in a h igh magneti zation ( Figu re �) .  Due to the superparamagnetic 
behaviour of MNP . they ha e been used a MRI  contra t agents in diagnosi . as heat 
mediator in hyperthermia treatments and addi tional ly as magnetic guidance in drug 
del i  ery appl ications [ 1 0 1 .  1 03 .  1 1 1 ] . 
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M P magnet ic pr p rt ie trongl) depend on the meth d u ed in their 
) nthesi . \1 re \ er. Teja et a! . reported that the magnetic propertie of ;V1NP 
appeared to depend tr ngl) on change in  th ry tal morphology. The cry tal 
morphol g: affect c erc i \  it} in the order: phere < cube < octahedra in l ine \\ ith 
the increa e in the number f magn tic axe along thi erie of hapes. oerci\  itl' i 
the inten it) of the appl ied magnetic fi ld requir d to reduce the magnetization of 
that material to zer after the magnetization of the ample ha b en driven to 
'aturat ion. 1 P \\ ith coerc i \  it ie ranging from 2 .4 to 20 kAJm have been produced 
by ontro l l ing their ) nthe i condition [ 1 0  L 1 03 ] .  
Ferro magnetic 
material  
uperparamagnetic 
M Ps 
CD CD CD 
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F igure 4 :  D iagrammatic repre entation of the behaviour of multiple domains of a 
ferromagnetic material .  and the single-domain of superparamagnetic MNPs in  the 
pre ence or ab ence of ex tema I magnetic field, modified from [ 1 1 3 ] .  
1 .  7.3. \ nthe i of 1\11 P 
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on idering the increa ing number f pot ntial appl ication for 1NP . it i not 
urpn i ng that \ ariou ) nthetic route ha\ e b en de cribed \\ ith d ifferent abi l i t i  to 
contr I the i7e and iz  di tribution. hape. pol) di per ity. urface charge. magnetic 
su ceptib i l it) . c ry tal l in ity. urfa e chemi try and the yield of production . The e 
method include: \\ et or co-precipitation. hydrothermal reaction . thermal 
dec mpo it ion. mi ro Illul  ion . ol -gel ) nthe e .  onochemical r action . h) droly i 
and thennoly i of pre cur or . flo\.\ injection ynthese and other [ 1 02. 1 03 . 1 07. 1 1 1 ] . 
ome of the e method are de cribed in  the fol lo",ing sections. 
1 . 7.3. 1 .  Co-precip itation method 
C -precipi tation i a method v" here Fe�+ and Fe3+ alt co-precipitate 1 11 the 
pr ence of an alka l in  aqu ou media. It is the imple t .  the mo t common. mo t 
efficient. and uni,er al ly u ed chemical pathway to obtain MNP . The precipitated 
jv1J\P are dark or bro\',:ni h-black in colour. The chemical reaction describing 
precipitation of Fej04 i given i n  the fol lowing eq uat io n :  
Fe�+ + 2FeJ+ + 80K � Fe304 + 4H�O Eq uation 1 
According to the thermodynamics of this reaction. a complete precipitation of 
MNP hould be expected at a pH between 8 and 1 4  \ here the precipitated MN P 
acquire negat ive charges on their surfaces. whi le maintaining a stoichiometric ratio of 
2: 1 ( Fe3+ Fe�+ ) under a non-oxidizing environment . Otherwise, MNPs might also be 
oxidized to other impure pha es l ike maghemite. Oxidation in air is  not the only way to 
tran form magnetite into maghemite (y-Fe203 ). Various electron or ion transfer 
incidents. depending upon the pH of the suspension. are in olved. according to the 
fol lowing eq uat io n :  
38 
Equat ion 2 
Thi \\ uld ritical l y  affe t th ph} ical and chemical propertie of the rNP . Bubbl ing 
ni tr gcn ga through the olution n t oni) pr \ent ritical oxidation of magnetite. but 
al reduce the part ic le ize \\ hen compared to method that u e an OX) gena ted 
em ironment [ 1 1 4- 1 1 7] .  
The ize. m nodi per i ty. and hape o f  MNP can be tai lored or adju ted by a 
number of fa tor . uch a pH.  addit ion of alkal ine olution before or after the addition 
of Fe.:! Fe3 ion oluti n. altering the feeding rate of the iron ion olution. ionic 
trength of Fe.:! and F 3+. t i rring and oaking temperatures. nature of the iron alt . and 
addition of th coat ing lay er before. dur ing or after MNP ynthe i [ 1 1 1 . 1 1 4 .  1 1 6-
1 1  ] .  D pite the above mention d advantages of the co-precipitation method. few 
di ad\ antage may ari e due to experimental parameters ariation. uch as large 
particle of \ ar) l I1g diameter . polydi per ity. and poor crystal l ization. The e 
di ad\ antage can be o\ercome b monitoring the previou mentioned factors [93 . 1 02 ] .  
e \  eral tudie explored the preparat ion of  MNPs in  an oxygen-free atmo phere. For 
example.  1\\'a aki et al . prepared MNP to te t the effect of pre sure on their size. The e 
P ynthe ized u ing the co-precipi tation method by adding alkal ine solution to ferric 
and ferrou ions i n  an argon atmosphere. After that, a cooled ball m i l l  was used as a 
synthe i reaction medi um in  which MNPs of about 1 0  IUTI were prepared by 
mechanochemical effect without heating the starting suspen ion and anneal ing the 
product [ 1 1 9] .  
Yazdani et al . sealed the reaction ves el  after being fi l led with iron ion then 
i njected with an alka l ine solution. fol lowing which different pressures of n itrogen gas 
were appl ied .  By i ncreasing the nitrogen reaction pressure from 300 to 6000 mbar. the 
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parti Ie lze increa d from 8.3 to 1 6 . 8  nm at 25°C [ 1 20] . In  addition. un t al . 
S) nthe i7ed 1 P \\ ith a ize range of 8 -20 11m u ing a modified. chemicall) control led 
o-precipitation method. dium oleate. a urfactant. \\ a added during the reaction to 
enhanc the mpatibi l it) of the nanopart ic Je [ 1 2 1 ] . 
1 . 7.3.2.  H y d rotherm a l  method 
hydrothermal proce was u ed to produce MNP due to it advantage in  
producing high ) ie ld  of P \\ ith xcel lent cry tal l in it), and control lable ize and 
morphol g) . Furthermore orgal1 lC  reagent are not needed, 0 thi method is 
comparat i \ e l)  environmental ly benign. and i r lati e ly co t-effective [ 1 1 6] .  I n  thi 
method. ) nthe i f MN Ps i usual l  carried out by precipitating ferrous and ferric ion 
in an alkal ine medium with a molar rat io 1 :2 imi lar to the co-precipitation method. 
Di lute acid i al 0 added to avoid the precipitation of other i ron oxide before the 
addition of alkal i ne o lution. The mixture i then added into a n itrogen gas blanketed 
three neck fla k and t irred at a con tant rate for a hort t ime. After that. the precipitated 
black product i immediatel) added into a Teflon- l ined tain le s steel autoc lave and 
ub equently placed in a furnace at high temperature (200°C ) [ 1 1 6. 1 22- 1 25 ] .  
Control o f  the part ic le size and morphology in  this hydrothermal method take 
place through the proce e of nucleation and grain growth. ucleation might be fa ter 
than grain gro'v'v1h at h igher temperatures and re ults in a decrease in particle size. In  
addition. prolonging the reaction t ime would favour grain growth [ 1 1 6, 1 22- 1 25 ] .  
MNPs with an average particle size o f  1 7 .22 n m  were obtained at 200°C and 
were coated \',:ith chitosan to modify their surfaces [ 1 22 ] .  AI 0, MNPs with a diameter of 
27 nm were prepared by thi method in the presence of a surfactant; sodium bis (2  
ethylhexy l )  sulfosuccinate [ 1 26] . In  addition, size control using lactate and sulfate ions 
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\\ a '  i m e  tigat d b) izutani et al . .  v. ho prepared al 0 MNP in an argon atmo phere 
and then aut c1a\ ed at 1 200 for 20 hr in  an lectric oven. The median particle iz 
obtained \ ari<;:d from 9 .5  to " .6 nm. Thi v" a found trongly d pendent on the tabi l i ty 
of iron c mple\:e and the urfa e p tential of anion -ad orbed precipi tate [ 1 27 ] .  
1 .7.3.3. Thermal  deco m po i t ion  
\1 P \\ ith a high le\ el of monodi per i ty  and ize control were al 0 obtained b. 
a thennal de mpo iti n procedure. In  thi method. ir  n precur or decompo d in  hot 
organic oh nt in  the pre ence of tabi l iz ing urfactants (e .g. oleylamine. oleic ac id. 
and . teric acid )  and organic olvent ( u  h a hexane and toluene ) .  I ron pr cur or 
include iron ( I I I )  acet) lacetonat : Fe(acach iron pentacarbony l :  Fe(CO)s . and i ron ( I I I )  
cupt! IT nate : Fe(Cup)) [ 1 1 4. 1 28 ] .  
un  et a 1 .  have de  cribed a high-temperature reaction of  Fe(acac)3 with 1 .2-
hexad canediol in the pre ence of oleic acid and ole) lamine to obtain monodisper ed 
I\fNP . The part ic le diameter could be tuned from 3 to 20 nm under a flow of nitrogen 
ga . and the hydrophobic partic les could be tran formed into hydrophi l ic one by adding 
a bipo lar urfactant [ 1 29- 1 3 1 ] . A lso. thermal decompo ition of Fe(CO)s i n  oct I ether 
o lution of oleic acid \\lth con ecutive aeration resulted in MNPs with a narrow size 
d i  tribution. [ 1 32 ] .  
L i  e t  a1. and other re earcher described the synthesis of  water-di persible MNP 
111 acidic or basic media by thermal decompo ition of Fe(acac )3 [ 1 3 3 - 1 36] or 
i nexpensive ferric chloride ( FeCi)) i n  refluxing 2-pyrrol idone. The latter i s  not only a 
h igh boi l ing olvent but also a stab i l i zer becau e of its coordination capacity \ ith metal 
I On . ccording to the reflux t ime. ize could be control led to obtain MNPs with 
diameters of 4 .  1 2  and 60 nm [ 1 34 ] .  
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1 .7.4.  Dc irable featu re o f  M l P 
1.. ing different manufacturing procedure , th de irable feature of ) nthe ized 
"1 P for biomedical appl ication . pecifical l )  can er treatment. are: table at 
ph) 5i logi al pH.  \\ itb high magneti7ation. lZ I 1 0- 1 00 nm in diameter to a\ oid 
e l iminati n from bi logi al ) tern. narrow size di tribution. high r active urface. 
biocompatible, biodegradable and abl to respond to timul i .  uch a magnetic field. 
heat. and pH .  
Howe\ er. there are igni ficant i ues with naked MNPs that affect and reduce 
their efTicac) in cancer treatment appl ication. i nc luding: 
) )  The) tend to agglomerate and aggregate. becau e of hydrophobic-hydrophobic 
interaction betwe n the MNP . and magnetic propertie with a l arge urface 
area to volume ratio .  
2 )  Becau e of their agglomeration. they wi l l  be rapidly el iminated from the 
c i rculation: hence their half- l i fe wi l l  be short .  
3 )  They have low tabi l ity and d ispersib i l ity. 
-+) They are tox ic .  becau e they c i rculate inside the body without any specific 
interaction with the organ or t issues. 
To overcome the e is ues. the development of a proper surface coating is needed 
to impro e MNPs efficacy in c l inical appl ications [ 1 1 6. 1 37- 1 4 1 ] .  
1 .  7.5.  u rface mod ification of M N P  
The surface coating o f  MNP with arious coating materials play an important 
role in the stabi l ization of aqueou MNPs suspensions, as wel l  as in their further 
funct ional ization. The surface modifications provide and offer the fol lo\ ing ad antages 
for MNPs [ 87. 99, 1 04.  1 42 .  1 43 ] :  
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1 )  Redu c th agglomeration. 
2) Impro\ c their tabi l i t) in vari u oh ent to extend their hal f- l i fe and blood 
c i rculation time in phy i logical condition . 
"I ) ontrol their gro\\1h and ize. 
4 )  Pre\ ent the oxidati n of  MNP . 
- ) Impr \ e their biocompati b i l ity and r duce toxic ity. 
6) Limit non- p cifi cel l binding b) being targeted. 
7) 10d i l) th phy ical and chemical propertie of MNP , uch a electronic .  
optical .  pectro copic .  and urface charge 
8 )  Pro\ ide functional group for further modification. uch as attaclU1lent of optical 
dye . therapeutic and target ing agent 
9) Reduce of the therapeutic drug dose quantity. 
The tabi l i zation of th MNP i crucial to obtain magnetic col loidal ferrofluids 
that are table again t aggregation in a biological medium and a magnetic field. MNP 
coati ng can b compri ed of everal types of materials. including monomeric tabi l i zers 
uch a carboxylate and pho phate . polymeric, non-pol menc l ike oleic acid. and 
tearic acid. l ipo orne . micel le . and i norganic materials such as s i l ica and gold [ 87, 89. 
94. 1 02 ] . The e material together with various surfactant . such a sodium oleate. 
dodecylamine and odium dodecyl u lfate ( DS) .  are a l l  used to enhance di per ibi l i ty 
of the P in the solut ion. and they bind differentl to their surfaces. orne researcher 
explored the u e of more than one coating materia ls ( such a co-polymers )  to coat MNP 
to perfoml peci fic functions. The Ps coati ng can be achie ed via a number of 
approaches. inc luding pre-synthesis. in itu coating and post-synthesis [94. 1 1 6. 1 44. 
43 
) 4 5 ] .  a ble 3 Ii t e 'ample f FD cl inical !)  appro\ d organic -material coat d �fNP 
[ 90. 9 1 .  1 46 ] .  
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T able 3 :  F 'ample of 0 cl i nical l y  apprO\ ed. commercia l l)  a\ ai lable organic­
material coated 1 P ,  ommonl)  u ed a contra t agent in 1Rl imaging (except 
an rhCn11 r r h) perth rmia treatment ) .  
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1 . 7 .5. 1 .  u rface mod ificat ion " ith polymeric  material  
P l y meric coating pre\ ent the agglomeration of th 1NP and l imit  their non­
'pec i fic cel l  binding in th bi logical y t m.  tructural feature of the pol) meric 
c at ing may affect the perfi nnan e of coated M P .  The inc lude the nature of the 
chemical tructure of the p 1) m r ( uch a h) drophobicity and biodegradation 
characteri t ic ) .  th length or molecular \\ eight of the polymer. the type of chemical 
bond in \\ hich the poly mer i attached ( for xample covalent bonding) .  the confomlat ion 
of the pol)  m r. and the d gree of part ic le urface coverage. Polymeric coating material 
are la died i nto natural and ynth t ic .  Example of natural polymer are dextran. 
chito an. tarch. and cel lulo e. The ynthetic polymer inc lude polyethylene glycol 
(P G ). poly-vinylpYlTol idone and poly-ethyleneimine .  Dextran and chito an are two of 
the mo t commonly  u ed natural and ynthetic polymer wi l l  be discu ed in  detai l s  in 
the foi l  wing ection [ I I -+ . 1 1 7. 1 1 8 . 1 -+-+,  1 47, 1 48 ] .  
1 . 7.5. 1 . 1 .  Dextra n 
Dextran i s  a natural branched poly  accharide pol mer comprised of glucose 
ubuni t  , \\hich can be prepared with izes ranging from 1 0  to 1 50 kDa. Dextran has 
been widel, used a a polymeric coating most! becau e of it is biocompatib i l i ty, non­
toxic i ty and polar interaction (che lation and hydrogen bonding) that give dextran a high 
afti ni!) towards MNPs urface . Dextran bind to MNPs surface by covalent bond 
between oxygen and i ron I I  and I I I  ions along the MNPs surfaces [94. 1 1 6. 1 1 8 . 1 49] . In  
1 982, Molday and Mackenzie were the first to report the fonnation of MNPs i n  the 
pre ence of dextran. They prepared MNPs by a co-precipitation method with in ilu 
coat ing b) dextran of 40 kDa molecular weight and produced MNPs with 1 5 -30 nm in  
d iameter. ince then.  various fOnTIS of dextran polymer , i nc luding carboxydextran and 
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carbox) mcth) I dextran \\ ere u ed to c at urface of M)JP \\ ith \ an ina h\ drod\ namic _ e _ _ 
sIZe [ 1 4 . 1 - 0 . 1 - 1 ] . 
ther appr ache \\ ere al 0 explored for appl)  ing de. tran coating onto MNP . 
11\ 1 et a ! .  mod i fi d the urface f MNP \\ ith amino-propyl i lane. fol lowed by 
c \'al nt conjugati n of part ial !) oxidized dextran \ ia a econdary amine bond. Another 
tud) perfomled b) Woo et aL \\ h modi fied the h) drophobic urface of MN P to 
hydrophi l i c  \ ia Fe- co\ alent bond \\ ith bi-functional 3 -mercaptopronic acid. and then 
the t rminal carb X) l i c  acid group wa e terified with dextran to improve 
biocompatibi l it) [ 1 49. 1 50 ] . 1 ) kha) l) k et a! . al 0 prepared MNP via prec ipitation 
from iron ( I l )  ulphate aqueou . Then the urface of freshly prepared MNPs were 
immediate ly modified by pontan ou ad orpt ion of dextran from aqueou olution. The 
modified MN P (14 nm in  dianleter) v" ere able to target rat gl ia l  tumors by disrupt ing 
the blood-brain barri r i nun diate ly prior to part ic le injection [ 1 37 .  1 52 ] .  
1 .7.5. 1 .2 .  C h i to a n  
hito a n  i one of the m o  t abundant natural l inear poly-aminosaccharide. 
h) droph i l ic .  non-toxic. biocompatible .  and biodegradable  polymer. It ha enormous 
appl ication in the phamlaceutical indu try. such as drug carrier. ab orption 
enhancement. gene del ivery. and is a metal chelating agent. Chitosan possesses both 
amino and hydroxyl functional groups. which can bind with other functional molecules 
that are c0l1U110nly used a targeti ng. imaging and therapeutic agent ( lana Chomoucka 
et a l . .  20 1 0: Dash. Chie l l in i .  Ottenbrite. & Chie l l in i .  20 1 1 ) . Chi to an i soluble in  acidic 
media and i al 0 used a a surfactant agent. Adding chitosan on the surface of the 
MNPs wi l l  enhance their stab i l i ty and biocompatibi l i ty to be used in different 
appl ications [94. 1 1 5 , 1 53 - 1 56] . 
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'c\eral tudie ha\ e im e t igated the preparation of chito an coated MNP for 
different appl ication . For example . Tran et a1 .  and B ddu et a! . fom1ed chito an coat d 
\1 Ps ( -\1  P )  to rem \ e  metal ion pol lutant from aqueou olution [ 1 - 7- 1 - 9] . C­
i\1 P were prepared b) co-pre ipitation of MN P in th pre ence of chito an fol lo\'·;ed 
b) h) dr thermal treatment. nother tudy u ed -MNP a MRI contra t agent. \', hich 
can be u ed for c II tracking. cancer detection and therapeutical l respon e as e ment 
[ 1 2_ .  1 60- 1 62 ] .  imi larl) . K im t a ! .  ynthe i z  d MNP b, onochemical method . From 
the e L P . they 1'nth ized ferrofluid for u e a MRI contrast agent by coat ing them 
\\ ith oleic acid a a cr - l i nker and then di sper ing th m in chito an. yielding 
ph ri a l l )  hap d MN P with 1 5  nm in  diameter [94. 1 63 ] .  I n  a study carried out by Qu 
et a1. - 1NP \\ith core- h II tructure with 1 1  nm i n  diameter have been prepared 
u ing ro - l i nking method. Oleic acid modified MN P v. ere firstl prepared and then 
chito an \\ a added to coat the urface of the MNPs by physical absorption. The C­
�1N P  \"ere obtain d b,  cro - l i nking the amino groups on the chito an u ing 
g lutaraldehyde (cros - l inker) [ 1 55 . 1 6 1 ,  1 64 ] .  
1 .7.5.2.  u rfactant  coat ing ma teria l  
1 . 7.5.2. 1 .  DS 
D i one of the mo t used anionic a lk I u lfate surfactants. DS synthesis is  a 
relat i \  e ly imple procedure invol ing the sulfation of I -dodecanol fol lowed by 
neutra l ization with a cation source. Because of its high reactive surface propertie . i t  i 
important i n  i ndustrial c leaner . and cosmetics. I n  addition. i t  has been u ed in  d ifferent 
k ind of indu tria l  manufacturing procedures. as a del iver aid in pharmaceuticals. and 
in biochemical research [ 1 65.  1 66] . I n  the physiological ystem. D can enhance 
absorption of chemicals through skin, gastrointe t inal mucosa. and other mucous 
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membrane . 0 i kn \\ n r r it fa t uptak . di tribution. and xcretion. It accumulate 
ele t i \ e l)  in the hepatopancrea and gal l  bladder. and get ab orbed via the inte t ine. 
colon. and kin .  Metabol i  m procedure of 0 take plac b) proceeding from initial 
omega-ox idation t a carbox) l ic  acid. then to beta-oxidation to but) ric acid 4- ulfate . 
\\ hich i 1Ina l l )  non-enzymatical ly de- u lfurated to gamma-butyrolacton and inorganic 
ulfate. 0 t imulate both ph) ical and bioch mical effect on cel l . and pec ifical \ )  
target' the mem brane [ 1 65 ] .  
hariati et a1 . inve tigated the abi l i ty o f  -MNP to efficienc remove the 
afranin 0 d) e from wast \\ ater. In thi tudy. M Ps v, ere synthe ized la co-
pre i pi tation method in the pre ence of 0 to the mixture olutions of i ron ion . The 
effect' of \ariou parameter on the r mo\'al fficiency of dye. such as the type and 
an10unt of urfactant. pH of olution. alt effect. and contact t ime v.ere studied and 
optimized. The re ul t  ugge ted that -MNPs with ize les than 40 nm can be u ed a 
an efficient ad orbent material for ad orpt ion of cationic dye from aqueou solution 
with high r moval at acidic media pH 2 [ 1 66] . On the other hand, -MNP were 
ynthe i zed b) del i  et  al . u ing a co-precipi tation method. -MNPs prepared herewith 
were app l ied for the removal and recovery of copper. nickel and zinc from industrial 
\Va te water due to high concentration of the e metal ions in the real samples. The 
obtained result  reported that -MN P  were effic ient ad orbent material for removal of 
the metal ion from wa tewater ample [ 1 67 ] .  
1 .7.6. u rface funct iona l izat ion of  M N P  
The modified urface of the MNPs not only stabi l ize the magnetic core. but the 
can al 0 provide functional groups for further modification. Those functional groups can 
bind to different molecules. such as target ing agents. optical dyes. therapeutic agent . 
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enL) mt.: . and nuc l ic acid . hen the M Tp functional ized \\ ith more than one type of 
molecule. the) are termed multi functional. The e mol cule can be conjugated on the 
urface or incorporated v. ithin 1 P .  The) al 0 can bind to the modifi d urface by 
chemical bond or b) a\ idin-biotin protein coupl ing technique . The e chemical bonds 
include amide. e ter. h) drogen and other bond . Th functional izat ion of MNP surfac 
i a method f, r tuning the o\ era l l  propert ie of particle to fit targeted appl ication [87.  
92-94 ] .  
urface m di fication of  MNP u ing  functional molecule ha  different tasks to 
ful fi l .  u h a : 
I )  Improve the mechanical and chemical performance of the modified urface of the 
1NP . 
2) Improve the effect of anti -cancer drug Ibioactive molecules. 
3) Target de i red chemical . physical . or biological environments. 
In the current study, crocin ha been selected to be added to the surface of 
dextran coated MNP . I t  was found that among several new drug del ivery sy terns. 
functional i zed MNP have emerged as a promising technology to del iver crocin to their 
ite of act ions. By reducing the uptake of croci n  by phagocytic cel ls ,  prolonging crocin 
c irculation t ime,  pre erv ing crocin a i ntact form and pas i e ly accumulate in  the tumour 
location. leading to improve the therapeutic effect of crocin ersus free crocin [ 87. 92-
94] . 
so 
1 .8. 1 m  of t he  tudy 
r 1 11 ha be n h \\ n to hav the potential of inhibiting tumorig ne i in a 
\ anct) or ancer inc luding hepatocel l ular carc1l10ma. mong everal drug deli\er) 
') lcm . M P c ated \\ ith natural p Iymer l ike dextran hav emerged a a promi ing 
tcchnolog) to d l iver biom I cule to their target ite of action . Coated MNP can 
impro\ c the therap uti effect of crocin  a anti -cancer agent ver u free crocin becau e 
or c\ eral rea on . The e rea on i nc lude that coat d M P can reduce the uptake by 
phag cytic c 11 . pr long th c i rculation t ime. and pa ively accumulate in the cancer 
area due to th leak) microva culature and th lack of efficient lymphatic drainage in  
tho e i tc . 
The main obj ctive of the pre ent tudy \ a et to mainly asse the anti -cancer 
effe t of cr c in- Ioaded P both in vitro and in vivo. 
The detai led objective are : 
1 .  To prepare and characterize MNP with uni foml part ic le size distribution. and to 
conj ugate thei r  urface with different biocompatible organic coatings. 
2. To load croci n  effic ient ly  onto the functional ized MNPs. 
3. To a e s ant i-cancer effects of crocin- Ioaded Ps in ritro uti l izing HepG1 cel l 
.t. To develop HCC animal model uti l izing Balb/c mice and then as ess the ant i ­
cancer effect of crocin- loaded Ps. 
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C h a pt e r  2 :  M a teri a l  a n d  M et h o d  
2 . 1 .  P u re M l P 
hemi al u ed to prepare pure MNP included i ron ( 1 1) chloride tetrahvdrate 
( Fe h-4H� ), i ron ( I I I )  ch loride (Fe 1 3 ) ,  odium hydroxide ( aOH ) and ammonia 
oluti n. 1 \  reagent \\ r anal)1ical -grade and were purcha ed from igma-Aldrich 
) I · f F "'+ d 3+ . queou 0 utI n 0 e- an Fe were eparately prepared by 
d i  oh ing the re pectiYe amount of FeCb-4H20 and FeCi) in  de- ionized water. An 
aqueou' olution f a H of pH 1 '"  wa al 0 prepared by di 01 i ng the corre ponding 
amount of aOH in de- ioniz d wat r .  50 ml aqueou aOH solution was heated at 
60-90" in  an open round fla k .  A mixture containing equal volumes of Fe�T and Fe3'" 
wa i njected into the aOH o lut ion at fe d ing rate of 20, 40 or 60 mllhr u ing syringe 
pump with \'igorou t i rring. t the end of addit ion, a brownish-black precipi tate \va 
fom1ed. The \\ hole o lut ion was vigorou Iy  t irred for 60 minutes at a constant 
temperature, \\ h ich i the ame a the t i rring temperature: 60-90°C.  MN uspen IOn 
were then oaked at 60, 75 or 90 °C for 24 hr in  the i ncubator. To tudy th effect of 
yarying the ionic strengths of the start ing solutions on the characterist ics of the formed 
NPs, Fe�-!fe3T solution containing 0 .075/0 . 1 5 . 0 . 1 5/0 .3 ,  0 .3/0.6 or 0 .61 1 .2 were 
prepared and in i t ia l ly i nj ected i n  the aOH aqueous solution at the opt imized feeding 
rate. t i rring and soaking temperatures. 
The MN suspensions were then centrifuged at 3000 rpm for 1 5  minutes fol lowed 
b} a succe i \ e  decantat ionlwa hing with 1 2% ammonia  solution for 3 t imes to maintain 
h igh basic conditions. After final decantation, MN deposits were collected and dried at 
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60 a for 24 hr . Dried p \\- der were fin Iy  gr und to be characterized for it 
ompo iti n. morphol g) . urface area. magnetic u ceptibi l i ty .  and magnetization. 
Ba ed on the experiment carried out in  th pre\ iou ection. I i  t of opt imiz d 
condit ion \\ ere obtain d .  mixture contain ing equal \ olume of ferrou and ferric alt 
\\a injected int the 5 1 aOH lution at feeding rate of 40 mllhr using a yringe 
pump \\ ith \ ig rou t irring. t the end of the addition. a brovmi h-black pr cipi tate was 
fomled. The \\ hole olution wa \ igorou ly t irred at the ame con tant temperature 
60° fi r 60 minut . M P oaked at 60°C for 24 hr without 
t i rring. The u pen ion were then centri fuged at 3000 rpm for 1 5  minut 
fol lowed b) ucc i \ e decantation/wa hing w ith 25% ammonia olution thr e times. 
fter the final decantation. the MN P depo it were collected and dried at 60°C in  the 
in ubat r for 24 hr . The dried powders were finel ground to be characterized 111 
re pect of their compo it ion. morphology. urface area. and magnetic properties. 
2.2.  Functiona l ization of M P 
\.fNPs were chemical ly functional ized by applying organlc coat ings onto its 
urface . Three type of biocompatible organic compound were considered: D .  
chito an and dextran. The chemical tructure of the e compounds are hO'vVTI in  Figu re 
5 .  I n  the fol lowing ections. the method of applying each of the coating wi l l  be 
explained: 
2.2. 1 .  D -coat ing o n to M N P  
To prepare D -coating M N P  . s imi lar process a described above wa repeated 
\\"ith the D being ini t ia l ly d issolved i n  50 ml water at concentrations of 0 .2 .  0 .5 .  1 .0 
and 2 .0°/0 by weight. Each of these olutions was added to 50 ml  of 5M aOH solution 
. . . , f h F 1+IF 3+ I t '  SD pnor to 1I1JectlOn 0 t e e- e so u Ion. dissolved gradual ly when the 
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temperature increa e to 60° . The injection of 0 . "  M of Fe:! and 0.6 M of Fe3- i ron ion 
into - �1 'aOH s luti n wa at a feeding rate of 40 mllhr at 60°C in  a normal 
almo phere. t the end of additi n .  a browni h precipi lat \\ a fonned . The \>"hole 
lution wa \ ig rou I) t in'ed at 600 for I hr. D -coat d 1NP (cal led -MNP 
hereafter) u pen ion v. ere then oaked at 60°C for 24 hr \\ ithout t i rring. The - 1NP 
u pen ion wer then centri fuged at " 000 rpm for 1 5  minute fol lowed b\ succe i\ e 
decantati l1J\\ a hing \\ ith ro o ammonia olution thr e t ime . Then -MNP depo its 
\\ re col lected and dri d at 60° in the incubator for 24 hr . The dried powders \\ er 
finel) ground to be characterized for their ompo it ion, morphology. urface area. and 
magnetic propert ie . 
2.2.2 .  Ch i to an coat ing onto MN P  
To prepare chito an-coating MN P . chito an olution containing 0.2. 0 . 5 .  1 .0 
and 2 .0  0 0 b) \\ eight were prepared by di solving the COITe ponding weight of chi to an 
i n  a 0 .2 0 0 acetic acid olution. An equal volume of each of the chito an olutions 
( around 50 m l )  \\ a vigorou ly blended with 0 .3  M of Fe:!T and 0.6 M of Fe3+ solutions 
(25ml  Fe:!· + 25 ml Fe3+) ,  and then injected i nto 5M aOH solution at a feeding rate of 
40 mllhr at 60°C in a nomlal atmo phere . At the end of addition, a brownish precipi tate 
was fonned. The whole olution was vigorously sti rred at a constant temperature of 
60°C for I hr .  u pensions of chitosan-coated M Ps (cal led C-MNP hereafter) were 
then left to cool to room temperature. The su pen ion was then decanted and centrifuged 
at 3 000 rpm for 1 5  minutes fol lowed by a succe sive decantationlwa hing with 25% 
ammonia o lution for 3 time . After washing out the un-attached chito an. a Benedict' s 
te t was used to confinn the complete removal of unattached chitosan. C -MNPs were 
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final I )  dried in air at 60° l' r 24 hr . mpletel) dri d p \', der \\ ere finel) ground and 
haracteri.lcd for their compo it i  n. morpholog) . thermal and magnetic propertie . 
2 .2.3.  Dc�tra n-coat ing  onto M N P  
To prepare de\.tran-c ating 1NP . dextran olution containing 0 .2 .  0 . 5 .  1 .0 and 
2 .0 0'0 b) \\ e ight were prepared b) di olving the one ponding \\- eight of dextran in  a 
- \1 aOI l olution (d i  oh ed ompletely at room temp rature) .  MN precur or (0 .'"  M 
of Fe:! and 0 .6  1 of Fe3 ir  n a l t  olution ) were eparatel) prepared. then injected into 
the I a ] I olution at a feeding rate of 40 mlflu' at 60° In  air. t the end a brov,;ni h 
precipitate \\'a fom1ed. The \\- hole olution wa vigor u Iy  t irred at 60°C for 1 hr. 
u pen ion of the dextran-c ated M P (cal led D-MNPs hereafter) v,ere then left to 
co I to room t mperature. Thi was fol lowed by decantat ion. washing the completely 
dried. Dry powder were finely ground and characterized for their compo it ion. 
morpho log) . th m1al and magnet ic propertie  . 
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Figure 5 :  Schematic representation of chemical structures of organic coatings. a) SDS, 
b)  chitosan and c )  dextran. 
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2.3. Benedict '  te t 
Benedict' s  le t ""va u ed to detect the un-attached chitosan and dextran in  the 
coated MNP olution . Benedict reagent wa prepared b) dissolving 1 73 g odium 
c itrat and 1 00 g sodium carbonate in  about 500 ml de-ionized water. eparately, 1 7 . 3  g 
copper u lfat wa dis  olved in about 1 00 ml de-ionized water. After that both olutions 
were mixed together with st i lTing and the volume was completed to 1 000 ml with de­
ionized \\ ater. To te t for unattached chi tosan or dextran, few drops of the test solution 
were added to 2ml of Ben diet r agent. and then boi led for five minutes in a water bath . 
Fonnati n of coloured precipitate qual i tatively indicates presence of chitosan or dextran 
in the olution. 
2 .... . Addit ion of cross l i n ker and crocin to D-M N Ps 
Based on the characterization results of the organic-coated MNPs, 1 .0 weight % 
of dextran coating MNPs were chosen for further functional ization with crocin .  
However. it was found that a l i nker molecule was required to be i nunobi l ized onto the 
D-MNPs prior to be functional ized with CfOCin .  To do that, pre-calculated amounts of 
1 .0°;0 D-MNPs were suspended i n  autocl aved de-ionize water and under steri l ized 
condition unt i l  completely dried . The dry powders were divided into two groups: one 
group D-MNPs with a l i nker but without croc in  (negative contro l ) ,  and another D-MN Ps 
group with l i nker and crocin .  The preparations of the D-MNPs groups were performed 
simultaneously. 
ynthes is  of the D-MNPs derivatives were carried out in a dry fresh 
d imethyl acetamide (DMAC).  as a solvent in the absence of moisture. Succinic 
anhydride was added to the groups in a l arge excess (D-MNPs: succinic anhydride, 
1 : 20) .  The succin ic anhydride-D-MNPs m ixture in DMAC was st irred at 90°C for 8 hrs 
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In  oil bath in  a clo ed environment. t thi point, the t",,'o group were treated 
d ifferentl , D-MNP with l i nker but without croc in :  unreacted uccinic anhydride. from 
the abo\ e mixture. \\ a remov d b) repeated washing of the D-MN Ps with teri le  de­
ioniz d and stored in fre h teri le de-ioni zed water. D-MNPs with l i nker but with crocin :  
the econd group of D-MNP was wa hed tlu'ee t imes with DMAC to remove un-bound 
uccin ic anh) dride. Each tep wa fol lowed by centrifugation at 3000 rpm for 1 5  
minute at room temperature and decantation for 3 times. After that. fresh DMAC and 2 
mmol of l -ethyl -3- (3 -dimethylam inopropyl )  carbodi imide hydrochloride ( EDCL HCI )  
were added to  D-MNP with st ining at room temperature for 1 2  hrs under moisture-free 
condition . 
Fol lowing that. 50  or 1 00 mg/ml Crocin ( Sigma-Aldrich, St. Louis, MO, USA) 
wa added to the D MAC mixture and stirred for 24 hrs at  room temperature. Coated NPs 
centrifugation and washing with steri le  de-ionized water were thoroughly  carried out 6 
times at 4000 rpm, 1 5°C for 1 5  minutes. The resultant crocin- Ioaded D-MNPs were 
precipi tated and re- uspended in de-ionized water. UV -V isible spectroscopy and Fourier 
transform infrared ( FTIR) spectroscopy were performed to confirm the presence of 
crocin onto the surfaces of D-MN Ps. It should be mentioned that D-MN Ps with crocin 
samples were named accord ing the concentration tested in  vifro or in  vivo, 2 mg/ml ,  3 
mg/ml or 4 mg/ml cracin- Ioaded D-MNPs fom1Ulations. 
2.5. Calculat ion of the croci n  loading 
Crocin conjugation efficiency was determined by an indirect method. I ndirect 
method in olved detection of total free crocin  concentration in the decanted solutions, 
after reaction. by measuring the absorbance at 440 nm (visible range) using a UV­
Visible spectrophotometer. The amount of cracin loaded in  (or entrapped within) the 0-
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P \\ a calculat d by the di fference betv;een the total amount of crocin init ial ly u ed 
to prepare the Ps and the amount of free crocin pre ent in the decant d solution [ 1 68.  
1 69 ] .  hen the loading effic iency was calculated a the fol lO\ving eq uat ion :  
Loading efficiency (%) = (amount o! !Oaded CrOCin) E (amount oJ Lnlt rally added crocin) X 1 00 q ua tion 3 
2.6. Charac teriza t ion techn ique  
Al l  neat and coated MN P were characterized for their composition. morphology 
and pr p rtie u ing various characterization techniques: 
The comp it ion wa studied by X-ray d iffraction (XRD), FTIR spectroscop 
and them10gra\ ' imetric analy is (TGA) .  An automated Phi l l ips X-ray diffractometer 
( Ph i l l ips. An1st rdam. etherland ). with a step size of 0 .020. scan rate of 20 per min.  and 
a can range from �e = 1 0° to 700 was used on dry sample. FTIR analysis was conducted 
u ing a icolet exus ·+70 infrared spectrophotometer ( Massachusetts. USA). where 
ample were pre-pressed with KBr. then scanned over the normal range of 4000--400 
cm· I , Them10gravimetric analysis (TGA) was carried out using a TGA-50 himadzu 
thermogravimetric anal ser ( Kyoto. Japan ). \ here pre-weighed powder samples were 
heated to 600DC at a heat ing rate of 20DC/min using alumin ium pan in air. and the 
percent weight loss was fol lowed and correlated with the original composition of the 
Ps. 
Sol id Ps samples were evaluated for their microstructures usmg a JEOL 
canning e lectron m icroscopy (SEM; XL-30 Phi l l ips. An1sterdam. Netherland) at  an 
accelerating voltage of 1 5  kV . Detai led description of the morphology of the Ps was 
examined b Transmission e lectron microscop ( TEM;  CM I O-Phi l l ips Amsterdam. 
etherland). Samples were prepared for imaging by spreading drops of NPs di luted 
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di per ion n a copper grid that wa coated with a thin  layer of carbon and then air 
dri d. 
Porosit) , pore size di tribution and pore volume of the dried ol id samples were 
mea ured u ing l iquid ni trogen ad orpt ion at 77 K employing a Quantochrome OVA 
1 000 vol umetric ga orption instrument; utosorb ( Boynton Beach, FL,U A) .  
agn t i c  propeli ies of the Ps were studied by m asuring the magnetic 
u ceptibi l ity of the neat and coat d NP a a function of coat ing concentration. 
More ver. the magnetizat ion of these Ps as a function of appl ied magl1etic field at 
room temperature and wa measured using a vibrat ing sample magnetometer (VSM 
Quantum de ign Inc. an Diego, CA.  USA) instrument. 
2.7.  III vitro release study of crocin 
Crocin relea e behaviour of the prepared crocin conjugated D-MN Ps was studied 
in  phI' iological pH ( 7 .4)  as wel l  as in  acidic media at pH 5 . 5 .  Two samples of 2 and 4 
ma m l  crocin loaded D-MN Ps with 3 mg Fe/ml were prepared in  1 . 5 ml  of 1 ' phosphate 
buffered sal i ne CPB ) at pH alues 5 .5  and 7 .4 .  The samples were kept in  the i ncubator 
at 3 7°C under constant mix ing. In order to determ ine crocin concentration, and thereby 
fol low up the t ime dependent crocin release profile. c lear 1 . 5 ml of supernatant samples 
were taken out after precipi tating the N Ps at pre-detennined t ime intervals. Each 
removed volume was replaced by 1 . 5 ml of fresh buffer solution of the same pH value. 
Then the NPs were maintained back at 3 7 °C after mixed and re-suspended properly .  
The concentration of drug released was detennined by UV -Visible spectrophotometry at 
440 nm and using cal ibrat ion curve of free crocin.  The percentage of crocin released was 
calculated as i n  the fol lowing equation : 
Release (%) = (amount off Tee CTocm in supernatant  after release test) ( t f , . . . II ' 0 f X 1 00 Eq uat ion .t amoun 0 eroe ln  I n l t la y i n - M  Ps be ore release test) 
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T calculate the percentage of cumulative release of crocin .  individual percentage 
relea e \'alu v, er added to each other. 
2.8 .  111 vitro cytotox icity 
HepG2, a human hepatocel lular carcl lloma cell l ine, was purchased from 
merican Type uJture Col lection (ATCC, Mana sa , V A. USA) .  The cel ls were 
maintained in 75 cm2 culture flasks using Dulbecco 's Modified Eagle ' s  Medium 
(D 1EM)  ( Life Technologie . Grand I sland. y, U A). supplemented with 1 0% heat-
ina t ivated fetal bovine erum ( Life Technologies, Grand I land, Y,  U A) and 1 %  
penici l l in! treptomyc in .  Cel ls  were grown i n  5% C02 at 3 7  DC and 1 00% humidity. 
Media v" ere changed ever 48 lu-s. and the cel l s  were sub-cultured after 5 - 6 days using 
Ix tryp in- Ethy1enediaminetetraacetic acid (EDTA). ( Life Technologies. Grand Is land. 
Y.  U A) .  
2.8. 1 .  l\lTT Assay 
The viab i l i ty of HepG2 cel l s  was determined by measuring the reduction of 3 -
[4.5-dimethylthiazol-2-y l ] -2 .5-d iphenyl tetrazol ium bromide ( MTT) to insoluble purple 
fom1azan ( igma-Aldrich, t .  Louis. MO, USA) .  The yel low tetrazol ium salt MTT is 
reduced by metabol ical ly acti e cel l s, in part by the action of dehydrogenase enzymes 
( reductase) in mi tochondria, to generate reduc ing equivalents such as NADH and 
ADPH.  The resulting intracel lular purple formazan can be solubi l ized and quantified 
by spectrophotometr . So the l iving cel ls were purple, whi le  dead cel ls were colourless. 
HepG2 cel l s  were seeded at density of 8000 cel l s/wel l  in  a 96-wel l  plate for 24 
hrs for the ce l ls  to attach to the plate. Then, the medium was changed into fresh medium 
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with D \ lowing treatment . Variou concentrat ion of crocin including O.O:? � .  0 .05.  O. � .  
3 .  5 .  8 .  1 0. 1 5  o r  2 0  mg/ml v"ere te ted . D ifferent i ron concentrations including 0 .05 .  
0.07. 0 .09 or 0 . 1 mg Fe/ml  in  D-MNP \\'ere tested . Cells were incubated with 3 mg/m] 
crocin .  D-MN P  and 3 mg/ml crocin- loaded D-MNPs. D-MNPs that have been tested 
contained 0 .09 mg/ml (9 Ilgl l 00 Il l )  i ron content in D-MNPs [ 3 ] .  After 72 hrs incubation 
period. cell were ,va hed \ ith 1 x PBS and then 1 00 J..l 1 new medium was added to each 
wel l  in addition to 20 J..l 1  of MTT ( 5  mg/ml ) .  Cel ls  were then i ncubated at 3 7°C for 1 hr. 
fter that th formazan olubi l ized using 1 00 III isopropanol for 30 minutes at room 
temperature and the ab orbance wa measured at 560 nm. 
All the te ted groups er well dissol ed/suspended in DMEM prior incubat ing 
them with the cel ls .  The relative cel l  viab i l i ty (%) re lated to control wel ls  containing 
cel ls  cul ture medium without an treatment was calculated as the fol lowing eq uat ion :  
CeL L  viability (0/0) = 
2.9. III vivo study 
2.9. 1 .  Animals  
(Absorbance of tested compound) 
X 100  (Absorbance o f  control) Equat ion 5 
Balb/c mice were obtained from the animal faci l i ty of the College of Medicine 
and Health Sc iences. UAE University. Animals were housed under a 1 2  hrs l ight/dark 
cycle each at 24-26°C. They were maintained on standard laboratory animal diet with 
food and water ad libitum . Al l  animal studies were carried out i n  accordance with, and 
after approval of, the Animal Research Ethics Comm ittee of the Col lege of Medicine 
and Health Sciences. UAE University. 
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2.9 .2 .  Experimenta l  de ign 
I n  the pre ent study. 3 -week old male Balb/c mice were used. These mice were 
randoml) divided into 2 group ; ormal  group (n=3 ) which did not recei e any 
treatment and experimenta l  group ( n=9) .  The experimental group wa treated with 50 
mglkg body weight of DE ( igma- Idrich. t .  Louis. MO. U A) dissol ed in  al ine 
(0 .90 0 a I )  and given i .p .  injections twice a week for 8 weeks, total of 1 6  injections. 
Then. th mice of experimenta l  group were randomly divided into four sub-groups 
( n=" ) and injected i ntravenously ( i .v . )  in the tai l  as the fol lowing: Su b-group 1 ( DEN­
i n d uced ) received 1 00 �I  of a l ine twice a week for two weeks, total of 4 i njections. 
u b-group  2 (Crocin )  received 1 00 � l  of crocin dis olved in sal ine twice a week for 
two \\"eek . total of -+ i njection . The i njected concentrations were 1 1  mg/kg or 22 mg/kg 
i n  two different experiments. Su b-group 3 (Crocin- Ioaded D-MNPs) received 1 00 � l  
of 1 1  mg/kg or �2 mg/kg crocin loaded D-MNPs formulations i n  sal ine twice a week for 
two v;eeks. total of -+ i njection . The injected concentrations were equivalent to 1 7  mg 
Felkg (0 .3  mg Fe/ l OO � l )  of D-MNPs as iron concentration in the two different 
formulation experiments. This dose was chosen 0 .3  mg/ 1 00�1 twice a week for two 
weeks was reported non-toxic [ 1 70 ] .  
A t  the end of  experimental period. that was 24  hrs after the last i .v .  injection. 
m ice were weighed. anesthetized by mi ld D iethyl ether and dissected ( Figure 6) .  The 
whole l iver was removed. weighed. and examined for the presence of visible lesions or 
tumour. The right lobe was cut into smal l parts and fixed in 1 0% buffered formal in  for 
24 hrs. F ixed t issues were then processed for dehydration i n  ascending grades of ethanol 
( 70% and 90% each for 1 hr, after that 1 00% twice and each was for 2 hrs) .  Tissues were 
then cleared in xylene and finally impregnated and embedded i n  paraffin. 
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t tal of 4 dif� rent l i \  r ( representati\,e of each normal and experimental 
gr up ) v,:ere embedded in the ame block. Paraffin ti sue block were cut at 5 micron 
thickne . mounted on gelatine-coated l ide and then used for histopathological and 
immun hi toch mical ( I H  ) tudie ( Figure 7) .  For histopathological examination the 
l id  were tained with hematoxyl in  and eosin ( H&E) .  
. ormal 
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Crocin 
Crocin -loaded 
D-' l � P  
acrifice 
3w 1 3\\ ! I I I I 
3" l l w  1 3W ! 
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t t t t t t t  t t t 
I I r I I I I I I I T I I," ! 
t t t t t t t  t t t 
I I r I I I I I I I T I r! 
t t t t t t  t t t t 
t : SOmglkg of DEN injected Lp. twice a week (w) 
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t : Ad ministration of different treatments according to the group by Lv. injection 
! : Sacrifice 24hrs post last inj ection 
Figure 6 :  A d iagram representing the treatment regime of the DE -induced animal 
model and groups assignment. 
H istopathological I ron detection 
H & E  stain 
Prussian blue stain 
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I mmunohistochemical 
GST-P 
Ki-67 
M 30-Cytodeath 
BcI-2 
COX-2 
VEGF 
Figure 7 :  D iagrammatic representations of l iver sections that were processed to 
perfoffi1 several studies. 
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2 .9.3. Pru ian b lue  ta in  
Pru ian b lu  ta ining was u ed to tud. the pre ence of iron. T i  sue ections 
\\ re deparaffinized in xylene, reh drated in descending grade of ethanol ( 1 00%, 95%. 
90° 0, 70°'0 and 50% each for 3 minute ), and wa hed in  di t i l led water. Equal parts of 
r ad) prepar d olution of 20% hydrochloric acid and 1 0% potassium ferrocyanide 
were mi:-..ed immediatel. before us d for slid incubation for 35 minutes. ection were 
wa hed with di t i l led water and counter tained with neutral red for 25 minutes or \ ith 
H&E tain .  
2 .9A. I m m u noh i  tochemis try ( I HC)  tud ies 
L iver t i  sue sections were deparaffinized in  xylene, rehydrated in descending 
grade of alcohol ( 1 00%. 95%, 90%. 70% and 50% each for 3 minute ) .  and washed in 
1 x PB , ection were incubated in  antigen retrie al solution 1 0  mM Citrate buffer at 
pH 6 and heated at 98°C for 45 minutes. To inhibit endogenous peroxidase activity. 
ections were incubated in  3% h drogen peroxide in  methanol for 1 hr at room 
temperature. A circ le ith a thin fi lm using PAP-pen (Dako. Glostrup, Denmark) was 
draw around the t issue sections to ensure that al l  tissue sections were exposed 
imultaneously to the same solution! reagents. 
To ensure s imi lar condit ions to al l t issue sections, all the tested groups were run 
at the same t ime and sl ide using simi lar condi tions. Tissue sections from al l tested 
animal groups were included on the same sl ide (NonnaL DE -induced. Crocin.  and 
Crocin- Ioaded D-MNPs) .  To block non-speci fic binding sections were incubated in 1 % 
bovine serum album in  containing 0 . 5% Tween-20 in  1 x PBS for 45 minutes. Sections 
were then incubated 1 hr at room temperature or overnight at 4°C with rabbit polycJonal 
primary ant ibodies as mentioned in Table 4. 
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Fol lowing a PB \\ a h. t i  ue ection \\'ere incubated with biotinylated donkey 
or heep anti -rabbit antibod ie ( Jackson lmmunoRe earch. West Grove. PA. U 
1 : 500)  [or 2 hI at ro 111 temperature. To use a\' idin -biotin-peroxidase complex (ABC) 
method. Extra\ id ine peroxida e conjugate ( igma-Aldrich. t .  Louis. MO. A: 
1 :  1 000 ) ,\- a added for 1 hI at room temperature in 1 % bovine serum albumin.  The 
antigen-antibody binding sites \\'ere revealed by using 3 . 3 '  -diaminobenzid ine 
tetrahydrochlorid ( D  B. igma-Alrdich. St .  Louis. MO. USA) .  Some of the ti ssues 
,\- ere counter tai ned briefly with the hematoxyl in being added for around 1 minute. After 
that section were dehydrated through graded ethanol .  c leared i n  xylene and mounted 
u ing DP 
with PB . 
egative control  sl ides were prepared by replacing the primary antibody 
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Table 4: Primary antibodie  u ed for IHC tudies. 
Ant ibody 
Di lu t ion  I ncu bat ion 
factor Time 
Manufacture 
Glutathione -tran fera e 1 :  1 500 MBL Co . .  Ltd . .  placental [oml (G  T-P) 1 hr agoya. Japan 
Abeam. 
Ki-67 1 :  1 000 1 hr Cambridge. MA. 
USA 
0-C)1odeath 1 :  1 00 Ovemight Roche. Penzberg. Germany 
Abeanl. 
Bcl-2 1 : 200 Ovemight Cambridge. MA. 
USA 
Abeam. 
COX-2 1 :200 o emight Cambridge. MA. 
USA 
Abeam. 
VEGF 1 :  1 00 Ovemight Cambridge. MAo 
USA 
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2 .9.5. Quant ificat ion ana ly i of pr imary an t i bod ie expre ion 
To provide a quanti fication evaluation of the primary antibodies expres ion in  the 
tained ti ue, D B labeled ti ue ections were calculated u ing a computerized 
method. This method depended on automated proce of quantification of D B tained 
1 1  in d iffl r nt ti ue ample . by using digital image proces ing via Image Pro 6 
oftw are. The method was estimating th percentage (%)  area of expression per image or 
tleld at 400 magni fIcation . total of 20 fields per antibody labeled ti ssue sections were 
quanti fied. The automated quantification was fol1O\ ed, because it minimized the human 
error and ga\ e more accurate data. 
2. 1 0. Stat i  t ic 
The resulted data were represented as mean ± the standard error of the means. 
The mean of the groups were compared using GraphPad Pri sm 5 software and one-way 
analysi of ariance ( A  OVA) with Tuckey post-hoc procedure . Data were considered 
sign ificantl y  d ifferent at a value of P � 0.05 and h ighly  significant at P � 0.00 1 . 
C h a p t e r  3 :  Re u l t  a n d  Di eu  ion 
3. 1 .  haracteriza tion o f  pure M P 
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MNP ","ere prepared in the current study using a modified wet method in  air. 
Fonnation of d ifferent t pe of iron oxides in aqueous media has been studied from 
the electrochemical point of view u ing Pourbaix diagrams [ 1 7 1 ] ; Figu re 8 .  In  highly 
ba ic aqueou media. Pourbaix diagrams indicated that other phases uch as FeO}- , 
F 203 . Fe(OHh and H FeO�- ma al 0 exist under these conditions. These phases 
could be di tingui hed from each other using various characterization techniques 
uch a XRD and FTIR.  In  add ition, MN . Fe30.j. has been viewed as an assembly of 
FeO and Fe203 \ i thin a w1ified crystal lattice of MN [ 1 72 ] .  
When ynthesized in  air. FeO gets oxidized to Fe203, leaving a phase-pure 
Fe203 . according to Equa tion 6 :  
2(FeO.Fe203 Y2 O2 ---+ 3 Fe203 
Fe30� -r J 4 O2 + 4Y2 H20 ---+ 3 Fe (0H)3 
Equation 6 
Equation 7 
Oxidation reactions shown i n  Equations 6 and 7 explain \ hy synthesi s  of 
1NPs i n  alkal ine media i n  air has been always abandoned to avoid the fom1ation of 
pha e- impure Fe30.j . However, i f  solutions were pre-adjusted to be highly alkal ine 
prior the addit ion of Fe2+ and Fe3+ ions then MN would be spontaneously 
precipitated as the highest thennodynamical ly  stable  phase despite the fact that al l 
preparations were carried out i n  air. I n  the current study, aqueous media used for the 
preparation of MNPs were pre-adj usted at a pH 1 3  using NaOH to avoid the 
fonnation of non-MN phases. 
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Figure 8: Pourbaix diagram for the iron-water system showing the 
thennodynamical ly stable phases in aqueous solutions with various pH alues. 
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Variou parameter were inve tigat d for their effect on  the purit) of the 
depo i ted M P .  Figure 9 how XRD patterns of the pha e evolved during the 
f0D11ation of M a a function of the feeding rate. \ hi le keeping the t irring and 
oaking temperature a wel l  a the tart ing concentrations of Fe2T and Fe3- con tant o 
The RD pattern in  Figure 9 compare the pha e purity and cry tal l in i ty of 
MN P form d at feeding rates 20. 40 or 60 mllhr. A standard JCPD pattern of pure 
MN i al 0 hO"111 for compari on. At a fast feeding rate of 60 mlJhr. the deposited 
MN nuclei rapidly forn1ed and accumulated without further cr stal l ization leading to 
an amorphou pha e, which al 0 ho\\'s a relatively weak intensity peak at 28 value 
of .., 5 .2° for the 3 1 1 plane. These results indicated the need for a slower rate of 
addition of the i ron reactants. At a slower feeding rate of 40 mllhr. relatively more 
t ime wa given for the deposited nuclei to crystal l ize. This was even increased by 
decrea ing the feeding rate to 20 11111hr. as i ndicated by the presence of the MNPs 
characteristic peaks at 28 alues of 29.9° (220). 3 5 .2° ( 3 ] 1 ). and 43 . 1 °  (400). I n  
addition to  these findings. no indication for the presence of  non-MN phases was 
observed despite the fact that the entire preparation process took place i n  air. 
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Figure 9 : X RD pattems of sol id MNPs prepared a t  d ifferent feeding rates of Fe
2+ 
and Fe3+ aqueous solut ions. JCPDS :  Joint Conu11ittee on Powder Diffraction 
tandards. 
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Figure 1 0  ho\\ M mi rograph of agglomerate of MNP prepared at 
di fferent � eding rate . The e micrograph indicate the formation of rounded P 
v, ith h mogeneou ize di tribution at al l feeding rate . The average agglomerate 
ize and urface area of the depo ited MNPs is hown in Table 5-black colour.  
De pite the d ifference in cry tal l init of the fomled P at different feeding rate . a 
Ie pronounced variation in  the average particle size was detected. 
Given the pha e puri ty of MNPs fomled at the e condit ions, a feeding rate of 
40 mllhr vv·a cho en for the optimization of the fol lowing preparation parameters. 
t i rring temperature during and after the addit ion of the Fe2+ and Fe3+ ions to the pre­
adj u ted alkal ine o lut ion was aried at 60, 70. 80 or 90 °C . This is shovm in Table 
5-b lue  colour to have a pronounced effect on the average particle size and surface 
area of the f0TI11ed N Ps v i thout affecting the overal l crysta l l i n i ty or purity of the 
MNPs. The least agglomerate average particle size of 55 nm was achieved at a 
t irr ing temperature of 60°C . S ize increased by rai sing the sti lTing temperature up to 
Figure 1 1  shows E M  micrographs of agglomerates of MNPs prepared under 
different t i rring temperatures. An overal l  homogeneous size distribution of the Ps 
forming these agglomerates is evident. Moreover, increasing the size of the Ps with 
i ncreasing the stilTing temperature was also reflected in  an i ncrease in the size of the 
agglomerates. 
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Figure 1 0 : SEM micrographs of agglomerates of MNPs prepared at d ifferent 
feeding rates. a) 20mllhr. b) 40mllhr and c) 60mllhr. 
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Figure 1 1 :  EM micrographs of agglomerates of MNPs prepared under different 
t i rring temperatures. a) 60°C, b )  70°C. c )  80°C and d )  90°C . 
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Previou re earcher h \V d that only kinet ic factor control the gro\\1h of 
the cr) tal . In a coprecipitation process where Fe2- and Fe3-'- ions are added at the 
ame time, the mechani m of pr c ipi tation of MNP takes place over two stage 
[ 1 02 ] .  Th fi r t tage involve a hort burst of nucleation as the concentration of the 
pecie  reached critical uper- aturation. This step is fol lowed by a slow gTowth of 
the nuc lei b) d iffu ion of the ionic pecies in  solution to the surface of the formed 
1 cry tal l i t  as in  Figure 1 2 . Thi step is bel ieved to be enhanced by increasing 
the t i rring t mperature during the addition of the iron species. 
Mor over. and in  contra t to an average size of 1 5  and 26.5 Illn of the MNPs 
btained at a t i rr ing temp rature of 80 DC under 2 gas in the work of Zhang et a1 .  
[ 1 73 ]  and Lee et a l . [ 1 74] .  the relatively h igher size obtained in the current study: at 
60 DC. could be attributed to the fact that al l  preparations were carried out in air. At a 
lower temperature range ( 4-3 7 DC ) .  and using a O2 as an oxidant. a control led 
oxidation of Fe2- in an alkal ine media under N2 gas took place forming MNPs with a 
ize range of 30- 1 00 Ill11 [ 1 75 ] .  Although reactants used in  thi s system were different 
from the current ly  studied one. its flOdings indicate that despite the presence of N2 
atmosphere. NPs with a relatively large size could be obtained at temperatures below 
60 DC. 
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Figure 1 2 : D iagrammatic  representation of the nucleation and growing process of 
MNP . modified from [ 1 76] . 
° 
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fter complet addition of reactant . precipitated MNPs were maintained in  
ntact \\ i th  their alkal ine olution [or �4hr at soaking temperatures of 60. 75 or 90 
( Tab le  5-red colou r). oaking of the MN Ps at relatively high temperature 
fol lo\\ ing th ir co-prec ipitation was previousl hovvn to enhance crystal l in ity. Vvhich 
wa al hown to be a function of th soaking temperature [ 1 77] . 
Th effect of varying the oaking temperature on the average particle ize and 
urface area of the P i given in Table 5-red co lour. No change as obser ed in 
the ize and mface area of the Ps when the suspensions were soaked at the same 
temperatur a that maintained during the addition and sti rring of reactants. 
l ncrea ing the soaking temperature up to 90°C led to an increase in the particle size 
accompanied by a consequent decrea e in  the urface area of the formed NPs. This 
i ndicate that the observed growth of the formed NPs is temperature-dependent. It 
hould be mentioned that varying the soaking temperature did not affect the 
cry tal l in i ty of the fom1ed P .  It was. therefore. recommended to maintain the 
t i rring and oaking temperatures at the same value whereas the optimized 
temperature was at 60°C at a 40 m l/hr feeding rate. 
Ba ed on these fmdings, MNPs prepared 1 11 solut ions containing different 
concentrations of Fe2� and Fe3+ were further characterized in more detai ls .  These 
concentrations inc luded : 0 .075/0. l 5 . 0. 1 510 .3 ,  0. 310.6 and 0.6/ 1 . 2  of Fe2+ and Fe3+, 
respectively .  The data shown in  Table 5-greeo colou r i ndicate that doubl ing the 
in i tial concentrations, while mainta ining a fixed solution volume, resulted in a 
pronounced i ncrease i n  the agglomerate average size of the precip itated Ps. with a 
con equent decrease in  the surface area of the NPs. This was also shown i n  the SEM 
micrographs of  these samples; as shown i n  Figure 1 3. This was also reflected in  an 
i ncrease i n  the crysta l l in i ty of the formed MNPs. 
80 
Figure 1 3 :  EM micrograph of d ifferent concentrations of Fe2+ and Fe3+. a) 
0 .075/0. 1 5 . b)  0. 1 5/0 .3 ,  c) 0 .3/0.6 and d)  0 .6/ 1 .2 of Fe2+ and Fe3+, respectively. 
8 1  
Table 5 :  Effect of different conditions on the agglomerate average particle size and 
urface area of MNP prepared by a co-precipitation i n  an aqueous solution. 
l Fe2+J lFe3+ )  Feed i n g  St i rri n g  oa king Average S u rface 
Rate Tem perat u re Tem pe ra t u re Particle A rea 
( m l/h r) 
(0C) 
(0C) Size ( n m )  ( m
2/g) 
0 .3010.60 20 60 60 76 1 97 
0 .3010.60 40 60 60 5 5  2 1 5  
0 .30/0.60 60 60 60 85 1 67 
0. 30,0 .60 40 60 60 5 5  2 1 5  
0 .3010.60 40 70 60 1 65 1 40 
0 .3010.60 40 80 60 290 8 1  
0 .30 0.60 40 90 60 350 72 
0.3010.60 40 60 60 5 5  2 1 5  
0 .3010.60 40 60 75 1 65 1 40 
0 .30, 0.60 40 60 90 1 89 1 22 
0.075,0. 1 5 40 60 60 25 460 
0. 1 5/0. 30  40 60 60 40 230 
0 .30 0.60 40 60 60 5 5  2 1 5  
0 .60 l . �O 40 60 60 1 75 1 62 
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Figure 1 4  ho\\ XRD pattern of MNP pr pared u ing different initial 
con ntration of the tart ing iron ion . Peak appeared at 28 values of 29.9° (220) .  
" 5 ,2° ( 3 1 1 ). 43 . 1 °  (400), 53 .4° (422 ), 57 . 1 °  ( 5 1 1 ) . and 62.8° (440) were ob ryed in 
al l  ampl . and \\ re con i tent with the standard data of phase-pure MNP hown 
in Figu re 9 [ 1 02. 1 74 ] . De pite the fact that the current experiments v,;ere carried out 
in air. no ign of 0 idation of the fom1ed MN wa found, reflecting its chemical 
tabi l i t  . The relative broadening of the peak at 29.9°, 3 5 .3° and 62.8° in  amples 
made of olutions containing Fe2+lFe3+ 0.075/0. 1 5  ratio is attributed to relatively 
mall part ic le size. which is known to be as a re ult from di lute olutions [ 1 74] ,  and 
hO\\TI in Figu re 1 3a .  The absence of maghemite in the XRD patterns of the 
MNP pr pared in the current study confim1S the phase purity of the prepared MNPs. 
Figure 1 5  shows a FTI R spectrum of a selected MNPs sample prepared in 
olution conta in ing in i t ial concentrations of 0.3 and 0.6 M of Fe2+ and Fe3+ ions. 
re pectiYely. Bands at wa en umbers of 430, 584and 622 em- I are characteri tic to the 
Fe-O tretching absorption in MN phase. while the broad band around 3400 em- I is 
characteristic to the stretching mode of absorption of the O-H bond in the physical ly  
ad  orbed \ ater molecules [ 1 78 ] .  Being prepared i n  aqueous media, MNPs show the 
pre ence of physical ly adsorbed water molecules even after drying in air, since there 
is no possib i l ity for water molecules to be included within the crystal l ine structure of 
MN . 
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Figure 1 4 : X RD  patterns of MNPs prepared using different in i tial concentrations of 
the start ing i ron ions F e2+ IF e3+ . 
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F igure 1 5 : FTlR spectrum of MNP sample containing init ial concentrations of 0 .3  
and 0.6 M of Fe�+ and Fe3+ ions .. respectively . 
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The pre ence of ph) icall ad orb d water \\'as al 0 confinned by TG 
anal)  i : Fioure 1 6. \', hich how th percent v. ight los of olid MNPs when heated 
up to 6000 in air. The e TGA curve were col lected for MNPs samples that were 
prepared from solution containing variou concentrations of the initial FelT and Fe3-
solution . 1 1  ample how d weight los alues in  the range of 1 4- 1 7% taking 
place at a mid-temperature of 1 00 °C. This i s  attributed to the evaporation of the 
physical ly  ad orbed water. This los continued to take place with a slower rate as 
temperature increa ed. Thi could be attributed to the presence of multi layer of 
water of hydration onto the surfaces of the NPs. It should be mentioned that after 
complete dryne s of al l  powder , NPs were highly agglomerated. which a conU110n 
characteri t ic of mal l  P i prepared i n  aqueous media [ 1 0 ] . 1 1 1 ] . 
The MNPs prepared in  the current study are intended to be used as drug 
del ivery vehicles to treat hepatic cancer. Therefore, in addition to biocompatibi l i ty of 
the P .  size and surface area of the Ps are considered important parameters that 
wi l l  determ ine the affinity towards the immobi l ization of drugs onto their surfaces as 
wel l  as the efficiency of drug del ivery. MNPs prepared from solutions containing 
various i ni t ia l  concentrations of the Fe2+ and Fe3+ ions were subjected to surface area. 
porosity and pore size distribution measurements using l i quid itrogen adsorption 
technique. Figure 1 7  shows the adsorption i sothenns of N2 on agglomerated 
powders prepared under these conditions. Al l  samples showed hysteresi s loops of 
type I V  where the lower curve represents the adsorption of 2 gas on the surfaces of 
the NPs. whi le the upper curve represents the progressive withdrawal ; desorption, of 
the adsorbed 1 gas [ 1 79] . 
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Figure 1 6 : TGA analy i of ol id MN Ps samples prepared in  solutions containing 
d ifferent in it ial concentrations of Fe2+ lFe3+ ions. 
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Figure 1 7 : d orption i sothemls of MN Ps samples prepared in  solutions containing 
d ifferent i nit ial  concentrations of Fe2+ fFe3- ions. a )  0.075/0, 1 5 , b )  0. 1 510 .3 ,  c )  0 .310 .6 
and d )  0 ,6/ 1 .2 of Fe2+ and Fe3.,. ,  respectively .  
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A a r ult of the i otheml In Figu re 1 7 . por lze di t ribution were 
calculakd u ing th BJ I I meth d � r the de orption gment of the h) teresi CUf\ e . 
Re ult are plotted in  Figure 1 .  I I  ample hov" d h mogeneou pore ize 
di tribution' \\- i th maxima in  the range of 30-+0 nm. Thi range denote the pr enc 
f me p ro i t)- in the aggI m rate of the prepar d P [ 1 79] . me oporou 
material i a material containing pOl' v;ith diameter between 2 and 50 nm. The 
m nodi 'per ity in the pore ize di tribution \v itl1 in the agglomerate relat ively 
refl ct the hom g neit) of the particle ize di  tribution in  the e sanlple . 0 
pronoun ed di ffer nee 1 11 the pore ize or it di tribution wa obsef\'ed among 
ample prepared from olution containing ariou concentrations. The homogenous 
di tribution of me op re in the aggregate of the prepared NP offers an advantage 
for the P i f  the) are u ed for envirOlIDlental appl ication . 
Detai led morphology of the MNPs prepared in  solutions contain ing 
O.OT. 0. 1 5  and 0.3 0.6 con entrations of Fe2+ and Fe3+ ions. respectivel ' i  shown 
in the TE if micrograph in  Figu re 1 9 . MNP hown i n  the TEM micrograph are 
pherical i n  hape with a homogeneous size distribution . The average ize of the e 
indi\ idual P were 1 2  ±5 and 25 ±5 nm. for ample prepared from relativel d i lute 
olution ( Fe2-lFeJ- = 0 .075/0 . 1 5 ) and relati el more concentrated solution 
(Fe2-/Fe3- = 0 .3/0 .6) .  re pectively .  The relatively smal ler particle size ho",n in 
Figu re 1 9a explains the relatively smal l  crysta l li te size of this sample that wa 
previou Iy hO\\11 in Figure 1 4 . 
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F igure 1 8 : Pore ize d i  tribution in MNP ample prepared in  olution containing 
d ifferent i nit ial  concentration of Fe:!+ e3+ ion . a )  0 .075/0 . 1 5 , b )  0 . 1 5/0 .3 .  c) 0.3/0.6 
and d) 0.6 1 .2 of Fe:!� and Fe3+. re p ctively .  
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Figure 1 9 : TEM micrograph of MNP prepared in  olutions containing d ifferent 
i nit ial concentration of Fe:?· and Fe3+ ion . a) 0.075/0. 1 5  and b) 0.3/0.6 M of 
Fe:?+/Fe3- ions. I n  ets :  i ndividual round shaped MNP. 
9 1  
The magn tic u ceptib i l it) re ult o f  �f\l P  ample prepar d at differ nt 
start ing concentration of Fe:! and Fe} ion are h \\ n in Figu re 20. i\1agnet ic 
su')ccpt ib i l it) i the degree t \\ hich a material can be magnetized in  an external 
magnetic field. and i directl)  prop rt ional to it magnetization [ 1 80] . 10r 0\ er, the 
magnetic ile i kno\'\ n to be direct l) proport ional to the magnetic u ceptibi l it) of 
sol id P [ 1  1 ] . 
u ceptibi l i t) re ult indicate an oppo ite behaviour. but are t i l l  explained b) 
their aggl meration and ize characteri tics. Prev iou re ult b Thapa et al . [ 1 8'2 ]  
attributed the incr  a e i n  the magnetization of MN with the decrease of part ic le size 
to the decrea e in  th OX) g n cont nt in  the MN ample and the ub equent increa e 
of [ Fe:! ] i n  the 1N lattice. \\ h ich i the main cause of magnetic character of MNP . 
10reo\ er. \1a and L iu  related the decrease in  magnetic  properties with increasing 
ize of iNP to the agglomeration of the part ic le . which is cau ed by the 
hydrophobic  i nteraction bet\\een th m [ 1 83 ] .  
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Ba d on the previou r ult . MNPs prepared u ing the fol lov,ing optimum 
condit ion v. ere u ed for th next tage of experimentation where organic coating 
material \\ ere developed onto their surfaces: 
a )  Fe:! IFel� = 0.3/0.6 M 
b )  Feeding rate of 40 m1lhr 
) t i rring temperature of 60°C 
d)  oaking temperature of 60°C 
nder the condit ion . monol ithic MNPs with a spherical hape that exhibited 
uperparamagnetic behavior at room temperature [ 1 84 ) .  The average particle size of 
the e MNP were in  the ize of 25 nm with the high surface area: around 2 1 5  m2/g as 
een in Table 5. However. and due to smal l size of MNPs that fonn high surface-to­
volume ratio and magnetic properties of the Ps. agglomeration took place giving 
rise to me oporous agglomerates with an average size of 55  nm. MNPs prepared 
under these optimum conditions were further subjected to magnetization 
mea urements as a function of appl ied field at a room temperature. Results are 
shown in  Figure 2 1 .  A maximum magneti zation of 25 emu/g was obtained. which is 
lower than that mentioned in  the l iterature for Ps prepared under sim i l ar conditions. 
This could be attributed to agglomeration of the Ps. 
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F igure 2 1 :  I\1agnet ization of MN P prepared under opt imum condition a a 
function of appl ied magnetic field at room temperature. 
3.2 .  haracterization of d i fferent  urface coa t ing material  
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M1\ P have been v. ide ly  e 'plored for their appl ications a MRI contrast 
agent . in immunoa say , in the detoxi fication of biological fl uid . in hyperthem1 ia. 
drug del i yery , cel l  eparati n. in addition to their environmental appl ication in the 
remo\ al of i norganic  contaminant from the aqu ou media [ 1 02. 1 85 ] .  Howeyer, 
P tend to aggl merat in olution. which may l imit their appl ications. For 
example. neat MNPs undergo non-spec i fic interactions with the serum proteins in 
rira leading to thei r  rapid el imi nation from the body. Therefore. it ha been 
recognized by re earchers that the urfaces of the MN Ps need to be hydrophi l i c  in  
natur for in  rifro and in  vivo appl ications. so that i t  i l l  be stable for prolonged 
c i rculation inside the body [95 ] .  
I n  order to  widen the scope of  these applicat ions. researchers have explored 
the functiona l ization of the urfaces of these N Ps using various organic and i norganic 
coating [ 87. 92. 1 78 .  1 86- 1 89] .  The choice of coating i s  appl ication driven . In 
b iomedical appl ications. a pre-requi i te i s  to have a biocompatible coating. In 
addition. i f  these coated N Ps are to be used to del iver certain bioactive drugs into 
infection or tumor s ites, the chemical characteristics of the coating should match 
those of the bioactive drugs to ensure bonding between them unti l  deli very takes 
p lace [ 1 86. 1 90.  1 9 1 ] . 
Applying an orgaruc coati ng onto the surfaces of MNPs takes place by 
synthesizing the Ps i n  the presence of these organic molecules or by chemical ly  
treating the fresh MNPs i n  solutions of these organic compounds by  direct 
i mmersion. The first route provides two advantages over the second one. F irst, when 
organic molecules are in it ial ly added to the preparation solution, they tend to act as 
capping agents. They adsorb onto the surfaces of the freshly formed MN nuclei ,  
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hence l imit ing their ize and size di tribution. econd. the presence of organic 
funct ional i t ie onto the urface of al l  formed MNP helps eparating the P .  
c n equent ly  minimize th i r  aggregat ion. To ummarize. the presence of organic 
fun ti nal it ie onto the urface of MNP provides the fol lowing advantage : 
1 )  Reduce th aggregation between the MN P , therefore increa es the stabil i ty 
of the MNPs in  variou 01  ent . 
- )  Contr I the ize of the MNP and might help in  detennine their shape. 
3 )  Improv th biocompat ib i l ity of coated MNPs. 
4 )  L imit non- pec ific cel l  binding i n  biomedical appl ication. 
5 )  Provide� functional groups for further modi fication, such as attachment of 
ptical d. e , therapeutic and targeting molecules. 
In the current study, coat ing of the optimal ly prepared MNPs was 
i nvestigated i n  deta i l s  in order to choose the type of functional i ty that wi l l  be further 
modified for targeted drug del ivery application. Three organic compounds were 
studied: D . chitosan and dextran. Chemical structure of these organic compounds 
is shovm i n  Figure 5. SDS is a known ionic organic compound that has been 
previously hown to stabi l i ze Ps i n  solutions by providing surface charges onto 
their urfaces [ 1 65 .  1 66 ] .  Chitosan and dextran are natural polymers, and both have 
also been shown to stab i l ize MNPs i n  solution [ 1 1 4. 1 1 7, 1 1 8 ,  1 44, 1 47, 1 48 ] .  The 
fol lowing sections discuss the characterization of the coated MNPs with each of 
the e compounds. 
S-MNPs and D-MNPs were prepared by addition of Fe2+ and Fe3+ solutions 
into an aqueous aOH solution that was pre-adj usted at pH 1 3  and containing 0.2. 
0.5.  1 .0 and 2 .0% by weight of SDS or dextran. After precipitation of NPs. they were 
centrifuged. washed, dried, and then subjected to characterization. Due to the 
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in  olubil i t} of chito an i n  aqueou and basic media, C-MNP were prepared by a 
di fferent approach. In it ial ly, chito an olution containing 0 .2 .  0 .5 ,  1 .0 and 2.0 % by 
weight '"ere pr pared by di 01 ing the corre ponding weight of chi tosan in 0.2 % 
ac tic acid o lution. n equal olume of each of the chi tosan solutions was then 
added and vigorou Iy mixed with the Fe2+/Fe3+ solutions ( pre-coat ing procedure). 
then inj cted into th aOH olution at a feeding rate of 40 mllhr at 60°C in  air 
( optimal cond it ion ) .  t the end of  addition. e tra chitosan was washed out by cycle 
of wa hing and decantation with de-ionized water and confirmed by Benedict ' s  test . 
,vhich i u ed to detect carbohydrate . The formed C-MNPs were eparated by 
decantat ion. centri fuged, wa hed, and then dried before being characterized for its 
compo it ion. 
3.2. 1 .  FTI R  o f  coated M N P  
Figures 22-27 show FTIR spectra o f  S-MNPs, C-MNPs, and D-MNPs. 
respective ly  a a function of the i nit ial concentrat ion of the organic coating: 0.2-2 
weight %. A spectrum of pure organic coating; SDS, chitosan and dextran, is  also 
shown i n  the respecti e graph for comparison. I n  a l l  spectra, MN is represented by 
its bands at 430. 5 84 and 622 cm' ] , with band intensities decreasing and shifting to 
lower wavenumbers with i ncreasing the concentration of the organic coating. This  is  
attributed to possible chemical interaction between the functional it ies of the organic 
coating and the underl ing MNPs surfaces. On the other hand. bands of each of the 
organic coating compounds were shown to dominate the spectra with increasing the 
i nit ial  concentration of the organic coating. 
The FTI R spectrum of pure SDS in Figu re 22 shows the presence of bands at 
998 . 5 .  1 0 1 9 .3 and 1 082.2 cm' ] for its symmetric absorption, and at 1 223 . 1 and 
1 248 .9 cm' ] for its asymmetric absorpt ion of the -OS03'- in the -OS03Na groups in 
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o [ 1 92 ] .  Po it ion. hape. and harpn of the e band in the FTlR spectra of _ 
1 Ps ample in Figu re 22 changed a a re ult of the interaction betvveen the D 
coating and the underlying MN P . Detai ls  of the e changes are given in  Table 6. 
hift in  the band po it ion of th COlTe ponding bands in  -MNPs are attributed to 
the formation of ionic bond between the sulfate group and the Fe2+ and Fe3+ ions 
along th surface of the underl ing MN Ps ( Figu re 23 ). \ hich was previously shown 
in comparable o. ide sy tems [ 1 92 ] .  This h i ft was hown to increase with increasing 
the oncentrat ion of D init ia l ly added to olution, and was more evident i n  the 
FTIR pectra of -MNP samples containing 1 .0 and 2 .0% of SDS. I t  should be 
mention d that un-ad orbed D was removed from all amples by washing. which 
confinn that th ob en'ed band are solei related to SDS coat ings. 
Table 6: Wa enumber of the absorption bands characteristic to the sulfate group in  
D as appeared in pure SDS and S-MNPs FTIR spectra. 
S (-OSOJ) as ( -OS03-) 
SDS 998 . 5  I 1 0 1 9 .3 1 082.2 1 223 . 1  I 1 248 .9 
0.2 % 1 0 1 0 .2 * * *  * * *  
0.5 % 1 005 .3  * * *  1 247.6 
1 .0 % 969.2 1 062.8 1 242. 1 
2 .0  % 957 .8  1 062 .8 1 229.9 
* * *  bands were not observed in the FTIR spectra of these samples 
1 400 1 200 1 000 800 600 
- 1  
Wavenum bers (em ) 
99 
400 
F igure 22 :  FTIR spectra of pure SDS and MNPs coated with various concentrations 
of S D  . 
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F igure 23 : Diagrammatic representation of the interaction between SDS functional 
groups and i ron ions of MNPs to form S-MNPs. 
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The chara teri t ic band of pure chito an are hO\<\'11 in  Figu re 2�.  Those 
band appeared at 1 082. 1 3 82 and 1 65 5  cm- I . and are attributed to the ab orpt ion of 
- . and C=O group , re pectively .  In addit ion. a weak-medium intensit) 
broad band appear at 3449 cm- I , ",·:hich i attributed to the ab orption of both O-H 
and -H group . a ho\\ n in the chemical tructure of chito an. summary of these 
band a a function of coating concentration is ShOW1  in Table 7. 
h ift.  toward a shorter wavenumber was observed 1 11 the bands 
characteri tic to C-O. and O-H -H groups, whi le no pronounced shift was ob erved 
in th band characteristic to the C- bond of the amide group. Moreover, another 
hift was obser d in the ab orption band of the anlide C=O group. Variation of the 
band of MNPs and tho e of chito an in the FTI R spectra of C-MNPs collectively 
indicate the formation of bonds between the chito an coating, as a capping 
molecule. and the w1derlying MNP surface . 
The e chemical interactions are expected to take place between the MN 
urface Fe:!+ and Fe3 ... ions and the C -0- groups that result from the ionization of the 
C-OH groups under the high basic conditions of the experiments ( Figu re 25) .  I n  
addition. coordination bond i s  expected to  form between the C=O group and both 
MN Fe2+ and Fe3"'- cations. as a result of the extra electronic density on the oxygen 
atom of the C=O group. According to the chemical structure of chitosan, it can be 
concluded that this i nteraction takes place at the pending primary alcoholic group 
along the chitosan chains as wel l  as the term inal OH groups in every chitosan chain .  
econdary alcohol ic  groups; d irectly attached to  the hexagonal rings of chitosan, are 
sterical ly  hindered and are therefore sl ightly expected to part ic ipate in thi s  interaction 
with the MN surfaces. It should be mentioned that un-adsorbed chitosan was 
removed by successive centrifuge and washing to el iminate the possibI l ity of un-
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The characteristic band of pure chito an are ho""'n in  Figu re 24.  Tho e 
band appeared at 1 082, 1 3 82 and 1 655  cm, l , and are attributed to the ab orption of 
- , and C=O group . r pecti vely .  In addition, a \veak-medium intensity 
broad band appear at 3449 cm' l , which is attributed to the absorpt ion of both O-H 
and -H group , a hown in the chemical tructure of chitosan. A ummary of these 
band a a function of coating concentrat ion is shown in Table 7. 
A shi ft toward a horter wa\'enumbers was ob erved I II the bands 
characteri tic to C-O, and O-H -H group , whi le no pronounced shift wa observed 
i n  th bands characteri tic to the C-N bond of the amide group. Moreover, another 
hi ft was observed in the absorption band of the amide C=O group. Variation of the 
band of MNP and tho e of chitosan in the FTIR spectra of C-MNPs col lecti el 
indicate the formation of bonds between the chitosan coating, as a capping 
molecule. and the underlying MNP surfaces. 
These chemical i nteractions are expected to take place between the MN 
urface Fe2- and Fe3+ ions and the C-O' groups that result from the ionization of the 
C-OH groups under the high basic conditions of the experiments ( Figure 25) .  In  
addition, coordination bond i s  expected to form between the C=O group and both 
MN Fe2+ and Fe3-'- cations. as a result of the extra electronic densit on the oxygen 
atom of the C=O group. According to the chemical structure of chitosan. it can be 
conc luded that this i nteraction takes place at the pending primary alcohol ic group 
along the chitosan chains as wel l  as the terminal OH groups in every chitosan chain. 
Secondary alcohol ic groups; d irectly attached to the hexagonal rings of chitosan, are 
sterical l h indered and are therefore sl ightly  expected to part icipate i n  thi s  i nteraction 
with the MN surfaces. It should be mentioned that un-adsorbed chito an was 
removed by successive centrifuge and washing to el iminate the possibi l i ty of Ul1 -
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reacted hit an remain in  the p wd r. Th r fore. the relatiy increa e in  int n i t)' of 
the band haract ri t i  to chit an. menti ned in Table 7 \\ ith the increa in the 
c n entration of chit an indicate the ad orption of mor chito an molecule or the 
dc\ cl pnlt:nt f thi ker hito an oating on the urface f the M P [ 1 1" . 1 93 ] .  
Table  7 :  \\'a\ enumb r f the ab rpt ion band characteri t ic o f  chito an. both a 
neat and differ nt concentration coat ing the urface of MNP . 
[Chi to an] Band location ( cm,l ) 
( Weight 0 0 ) US (C-O) U S  ( am ide)  U S  (C=O) US (O-H & N-H ) 
1 00 ] 08'  1 3 82 1 655  3449 
0.2 1 076.3 1 3 84.7 1 630.4 3399.8 
0.5 1 074. 7  1 3 84 .7 1 628 .8  3399.8 
1 .0 1 074 .7  1 384 .7 1 630,4 3402.6 
2.0 1 069.4 1 3 84. 7  1 63 1 . 1  3402.6 
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F igure _-l :  FTIR of pure chito an and MNP coated with \ arious concentration of 
chito an. 
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F igure 2 � :  Diagrammatic representation of the interaction between chitosan 
functional groups and i ron ions of MNPs to foml C-MNPs. 
Figu re 26 
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mpar th FTI R pe tra f pure de. tran and different 
c nc ntrat i n of d tran coating onto MNP . The p ctra pre ent vibrational 
mode haracteri t i  f the organic tructure f d 'tran. uch a th a-glucop) ranO e 
ring of de\.tran at 907 cn'- ' . Th a-glucop) rano e ring in a pure d xtran i al 0 
repre ented b) t,,_ o band at 759 and 83 cm" . In addition. band of pure dextran at 
1 _79 and 1 " T  cm" are du to -1 I vibrational mod . "" hi le band at 1 0 1 9  and 1 1 52 
m" an; attributed t \ ibration ( Figu re 2 7 ) . ibrational band at 1 64 � and 
3400 cm" are repre entat ive f -H gr up of ad orbed water in the ample . II 
de:-.tran band were hi fted and changed their inten it ie upon the formation of 
coat ing ont �fN P . a a re ult f th interaction betv"een dextran and Fe2+ and Fe3+ 
ion i n  the .\fNP urface . a ummariz d in  Table 8 [ 1 78, 1 94. 1 95 ] .  
Table : \Va\ enumber o f  the ab orption bands characteri t ic o f  dextran. as een 1 11 
the pure and di tTerent concentrations coating the urface of MNP . 
[ Dextran] Band location ( cm" ) 
( Weight �o) v (a-glucopyrano e) v (C-O) V S  (C-H)  
1 00 907 1 0 1 9  1 1 52 1 279 1 3 73 
0.2 9 1 7 1 0 1 9  1 1 52  1 328 1 3 86 
0.5 9 1 7  1 0 1 9  1 1 52 1 328 1 3 86 
1 .0 9 1 7  1 0 1 9  1 1 52 1 328 1 386 
2.0 9 1 7  1 0 1 9  1 1 52 1 328 1 3 86 
2 .0% 
1 .0 0/0_ 
0 .2% 
Dextran 
O-H 
-woo 
, 
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Figure 26 :  FTIR spectra of pure dextran and d ifferent concentrations of dextran 
coating onto MNPs. 
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Figure 27 :  Diagrammatic representation of the interaction between dextran functional 
groups and i ron ion of MNPs to fonn D-MNPs. 
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3.2 .2 .  TG ana ly i of coated M P 
Pure MNP how d an average weight 10 of 1 4%. a was previousl,  ho\'"n 
I n  Figu re 1 6 . Thi was attributed to the removal of water that \ a ph sical iy  
ad orbed onto th urfaces of the P .  Figu re 28-30 show TG curves of -MNPs. 
-MNP . and D-MN P  . re pect ivel . as a function of the concentrat ion of each of 
the organic c mpound in i t ia l ly added to the preparation reaction medium. Weight 
10 of pur organic  coat ing ha been added to each of these figures for comparison. 
D hows a major ingle tep weight los at a temperature of 1 80 °C. which 
denot it degradation: Figure 28 .  This process increases unti l  it levels off at a 
temperature of 470°C with an 0 eral l  weight loss of 75 .3% where SDS wa 
completely degraded. Pure chitosan shows an overal l  weight loss of 80% took place 
after heating it to 600°C ;  Figu re 29 .  This weight loss takes place 0 er two stages. 
where the fir t 10  around l OOoC and i s  attributed to the removal of physica l l  and 
chemical l y  adsorbed water. This was fol lowed by a major weight loss around 300DC 
due to the degradation of chitosan that takes place through thermal and oxidative 
decomposition [ 1 92] . 
Pure dextran. on the other hand, shows an init ial  weight loss at 1 00 - 1 50  DC, 
and i attributed to the removal of physical ly and chemical ly adsorbed water. 
accounting for 1 0% of total weight loss. This was fol lowed by a major weight loss 
around 30QDC that corresponds to the degradation of the polysaccharide dextran 
chains: Figu re 30. The overal l weight loss at the end of heat ing of pure dextran 
amounted to 92% due to the complete bum out of dextran [ 1 96] . 
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Figure 28 :  TG analysis of MN Ps coated with various concentrations of SDS.  Insert : 
TG pattern of pure SDS .  
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Figure 29 :  TGA analysis of MN Ps coated with various concentrations of chitosan. 
In ert : TGA pattern of pure chitosan. 
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F igure 30 :  TGA analysi s of MNPs coated with various concentrations of dextran. 
In ert :  TGA pattern of pure dextran. 
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ith the pre ence of the e organic compound a coatings onto the urface 
of \t1 P .  TG thermogram howed variable behaviour ba ed on the type of coating 
and its concentration that was in it ial ly added during preparation. Figu re 28  indicates 
that all -MN P ho\\ ed t\-\ o tep of \\:eight 10 s :  an ini tial tep that started at a 
temperatur sl ight lJ  below 1 00 ° . and a econd tep that started at a temperature 
cl e to 200 °C . The fir t tep i related to the evaporation of phy ical ly and 
chemical lJ attached water, while the econd step is related to the degradation of the 
o coat ing the MNP . The e results confirm the presence of SDS as a coating on 
the urface of the prepared MN P . as was pre iously shown in  the FTI R spectra of 
the e anlple i n  Figure 22.  These findings also confirm the presence of multi - layers 
of 0 coating the MNPs on which water was adsorbed . 
imi larly, TGA them10grams of C -MNPs showed i n  Figu re 29 indicated the 
pre ence of tw stages of weight loss. The first e ent of weight loss accounts for the 
evaporation of physical ly and chemical ly adsorbed water; around 1 00°C,  whi le the 
second event took place at 300± 1 0°C and is attributed to the degradation of chitosan 
l i nked onto the surfaces of the MNPs. 
D-MNPs showed simi lar pattern, where two stages of weight loss were also 
observed: Figu re 30.  The first weight loss took place at 1 00-200°C,  and is attributed 
to the evaporation of physical ly and chemical ly adsorbed water molecules. The 
second step, on the other hand, appeared at 2S0± J  OO°C with a h igher temperature 
achieved in samples containing higher concentration of dextran. I n  addit ion to these 
events, a third e ent was observed around SOO±SO°C,  which was sl ightly evident i n  
the TGA thermogram of pure dextran. This event appeared i n  an  i ncreasing manner 
in the thermo grams of samples containing � O .S  weight % of dextran, and could be 
attributed to a delayed degradation of dextran-bonded MN Ps. I n  addit ion, the overal l  
1 1 3  
earl) degradat ion of  dextran coat ing . a compared to  pure dextran could be 
attribut d to the effect of MNP in  catal zing the thermal decompo ition of dextran. 
V\ hich \\ as pre\'iou J) reported in the l i terature [ 1 96 ] .  
Figure 3 1  how a d tai led anal i of  the removal of  water and orgamc 
coating from the urface of the MNPs during their TGA anal s is .  These data wer 
deriv d from the TG them10gann in Figu re 28-30. In the absence of organic 
coating . the \vei ght 10 i s  related to water only. A the concentration of the organic 
coating \\ a i ncreased. a pronounced decrea e in  the weight loss owing to water was 
ob er\ed and a con equent increa e in the weight loss owing to the organic coat ing 
wa ob en ed. Thi behavior cont inued up to 0 .5% of D . As the percentage of D 
\'v as i ncreased to 1 %. its contribution to the 0 eral l weight loss was decreased with a 
ub equent increa e i n  the contribution of water to the overal l  weight loss: Figu re 
3 1 a. The arne cri terion wa al 0 observed when 2% of SDS was init ial l  added. 
Figu re 3 1 b  shows, on the other hand, that the amount of water ad orbed onto 
the MNPs was largely  reduced by the presence of chitosan, and that this amount 
sl ightly decreased concurrently  with the i ncrease of concentrati on of chitosan 
in i t ia l ly added to the system. The decrease in the slope between 1 and 2% chitosan as 
compared with lower percentages of chitosan may i nd icate a relative decrease in the 
affinity of the MNPs towards fUl1her addition of chitosan on their surfaces after 1 % 
concentration. 
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Figure 3 1 :  A detai led TGA analysis of the removal of water and organic  coatings 
from the surfaces of the MN Ps. a) SDS, b) chitosan and c) dextran, 
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In  the pre ence of dextran a a coating, a imi lar pattern wa ob erved where 
the amount of ad orbed water wa highly  reduced a the MNP coated with dextran; 
Figu re 3 1 c. the concentration of dextran increased up to 1 % the amount of water 
decrea ed. Thi wa fol low d by a l ight add ition of dextran onto the MN P urfaces 
from 1 to 20 0 as compared to lower dextran concentrations. This indicates the 
decreased affin i ty of MNP toward further addit ion of dextran on their surfaces after 
1 % concentration. 
The e re ult ugge t that at DS percentages abo e 0.5 %, its molecules 
d ta h from the coating and are replaced by water. Detaclunent of adsorbed 
molecule take place when the e molecules are weakly bonded to the substrate, i .e .  
the MNP . Thi i ndicates that the desorbed molecules are in  the outermost la er of 
D coati ng the MNPs. It should be mentioned that the primar layers are 
thern10dynam ical ly  known to strongly bond to the underlying substrate, whereas this 
bonding decreases in strength for molecules in the external layers of the coating. The 
ame concept could be appl ied to the first layers of chi tosan and dextran, which are 
directly  bonded to the underlying MNPs' surfaces as was explained i n  the previous 
ection: FTIR analysis of coated MNPs. 
In the presence of chitosan and dextran, a possible increase i n  the thickness of 
the chi tosan coat ing layer was observed, and could be attributed to the development 
of i ntem10lecular forces, such as H -bonding and di spersion forces, among t chitosan 
molecules and dextran molecules in their coat ings, respect ively. I n  a l l  cases, the first 
layer(s) of organic  coatings are secondari ly covered with an external hydrated layer 
through H -bonding. These findings explains the removal of water. as a first event, 
from the surfaces of  the organic-coated N Ps, fol lowed by the removal of the organic 
coati ng, as shown in the TGA thermogran1s in Figu res 28-30. Based on these 
1 1 6  
discu lon . a diagram ho\\ing the po ible con truction of  coatings onto MNP 
gi\  en in  Figure 32 .  
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Figure 32 :  D iagrammatic representation of the possible construction of water and 
organic coat ings onto the surface of MNPs. 
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3.2 .3.  Morpbo logy of coa ted M P 
pre\·j 
TEM micrograph of coated MN Ps are hov-11 in Figu re 33. eat MN P were 
hO�11 in Figure 1 9b a pherical in  shape. uniform in  size and with an 
average particle ize of around 25 run . I n  the pre ence of organic coat ing in the 
reacti n m dium, P maintained their hape and size di stribution. but an overal l 
deer a e in  th part ic l  ize of the P was obser ed. This decrease wa sho�1  to 
increa e with increa ing the concentration of the organic coati ng init ial ly added to 
the reaction medium: Figu re 34 .  The lowe t sizes of coated NPs achieved were 9. 
1 0. and 1 0  run when :2 weight % of D . chitosan or dextran. respect ively. were 
added to reaction medium during the precipitation of MNPs. These results confim1 
the role of these organic compounds as capping agents that l imited the size of MNPs 
nuclei formed during precipitation in the aqueous medium.  It is also evident that the 
ize of part ic le could be control led by adj usting the type and concentration of the 
organic material added during the formation of MNPs. 
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(a) 
(c) 
F igure 3 3 :  TEM micrographs of MNPs coated with 0 .2% of different organIc 
coatings. a )  SDS.  b) chitosan and c) dextran . 
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d ifferent concentrations of organic  coati ng materials. a) SDS, b)  chitosan and c )  
dextran. 
3.2 .4 .  T2 ad orpt ion and  pore ize d i  tr ibu t ion of coa ted MN P  
1 20 
rganic-coated MNP were ubjected to 2-ad orption measurement to 
a e their urface area. pore siz and pore size di tribution. These mea urements 
al 0 pro\'id in� rmation about the te 'tur and topography of the Ps. e pecial ly i f  
their ultimate appl ications require special urface characteristic . 
Figure 35 show adsorpt ion-de orption hystere is of MNPs coated with 
di iTerent con entrat ions of D . chitosan and dextran. All samples showed hysteresis 
loop of t 'Pe IV 'Nhere the lower cw-ve represents the adsorption of N2 gas on the 
urfa e of the P .  v·:hi le  the upper curve represent the progressive withdrawal , i .e .  
de orption. of the ad orbed 2 gas [ 1 92 ] .  As a result of these experiments. and 
applying the BJH method of calculations. pore size distribution in each of the 
examined MNP ystems wa calculated . Results are shown i n  Figure 36.  I t  should 
be mentioned that these measurements are usual ly carried out on dry samples. where 
. P tend to agglomerate a a result of thei.r magnetic characterist ics in addition to 
po sible i nteml01ecular forces between the organic-coated NPs. 
Figu re 36a i ndicates that NPs coated with 0 .2% SDS appear to ha e 
macroporosity with a larger pore volume of 1 50 nm , which i s  a reflection of the 
l arger part icle size of these particles. By i ncreasing the concentration of SDS, all 
samples showed the presence of mesoporosity as a sole type of porosity. In the 
presence of chitosan and dextran, al l samples showed the presence of mesoporosity 
with a urufied monodisperse pore size distribution; Figure36b,c. Comparing the 
results of adsorption i sothenns and pore size distri bution curves of organic-coated 
MNPs with those in pure MNPs, indicates that the mesoporosity of the neat MNPs 
aggregates is maintained even after coating with various concentrations of SDS. 
chitosan and dextran. Both monodispersity in  par1 icle size and mesoporosity i n  these 
1 2 1  
aggJom rate are considered advantageous if  these coated P are to be used a drug 
deli \ er) vehicJ or ad orbent or catalysts for variou chemical reactions with 
potential envir nmental importance [ 1 79 ] .  
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Figure 3 5 :  Adsorption-desorption hysteresis of MNPs coated with different 
concentrations of organic coat ing materials. a) SDS. b) chitosan and c )  dextran. 
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Figure 36 :  Pore SlZe d istribution of MNPs coated with different concentrations of 
organic  coat ing materials .  a) SDS,  b) chitosan and c) dextran, 
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3.2.5.  Magnet ic propertie of coated M P 
The pre nce of an organic coating onto the urface of MNP provides more 
ad\ antage to the P v, here the newl, establ ished urface functional i ty could be 
u ed t immobi l ize oth r reagent to be used in  drug deliver appl ications. However. 
increa ed thickne of the coat ing might lead to a decrea e in the magnetic propel1ie 
of the P .  which i expected to decrease their potential for biomedical appl ication . 
Th refore. the effect of varying the concentration of organic  coatings on the 
magn tic propert ies of th oated MNP 
in trument. 
as inve tigated u ing a common V M 
Re ult are hovm in Figure 37, where magnetization was measured as a 
function of the appl ied magnetic field at room temperature ( 300K) .  eat MN Ps and 
P coated with 0.2 and 1 .0 weight % coating were selected for these measurements 
and for compari son. A l l  Magnet ization curves exhibited a typical behaviour of an 
ideal superparamagnetic material with zero coerci it and zero remanence .  This is 
al 0 confil111ed with the fact that the a erage particle size of the neat and coated 
MNPs is below 3 0  nm, which is considered a maximum threshold for 
superparamagnetic character [ 1 97 ] .  
The superparamagnetic behaviour means the MNPs are a single-domain core 
and the magnetization at room temperature is reduced to zero, but when an external 
field is app l ied. the magnetic moments al i gn with the field having magnetic field. 
on-coated MNPs showed a saturation magnet ization (Ms) of 25.9 emu/g. The 
presence of SDS as a coati ng onto the MNPs surprisingly resulted in an increase in  
the magnetization of the coated NPs. The Ps coated with 0 .2 weight % SDS 
showed a magnetization of 5 0  emu/g, whi le increasing the SDS coat ing 
concentration to 1 .0 weight % showed a magnetization of 3 8  emu/g; Figure 37a. 
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The increa e in magnetization with the pr  ence of D could be related to 
the urface charge of th lomc D groups on the coating. I ncreasing the 
conc ntrati n of D results in the formation of mult i layer of D coat ing. which 
might decrease th surface harge a a re ult of the interlocking between the D 
molecule in  th coating \\lith increa ed thickne  s. This behaviour was not ob erved 
i n  the magnet ization of hito an and dextran-coated MNP � Figure 37b,c .  
Th pr ence of chito an and dextran coatings with ariable weight 
percentage howed a range of magnetization of 7 .0 - 2 1 .3 emu/g. This could be 
related to the charge neutral it of the chitosan and dextran molecules. It was 
ob erved that the pre ence f chito an and dextran resulted in  a decrea e in  the 
partic le ize of the coated MN Ps, the de elopment of a non-magentic organic coating 
on the urfaces of these Ps in the presence of chitosan could be considered the main 
rea on for the decrease in  magnetizat ion. This  is  al 0 a common phenomenon in 
coated MNPs [ 1 73 ,  1 93 ] .  
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Figure 37 :  Magnetization of neat MNPs and MNPs coated with d ifferent concentrations 
of organic coating materials. a) SDS. b)  chitosan and c) dextran. 
3.3. e lect ion of organ ic-coated M P 
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Ba ed on the previou r ults. MNP coated with 1 % by weight of dextran 
\\ re elected 1 be fUliher functional ized for drug delivery objectiv s. These were 
lect d ba ed on the fol lowing cri teria :  
1 )  De. tran i biocompatible and biodegradable. 
2) Chemical tructure of dextran provides sites for further functional ization. 
3 )  Dextran i a natural l  occurring pol saccharide that can provide teric 
hindrance for furiher stabi l ization of the Ps in aqueous media. 
4) Average ize according 10 TEM was around 1 4  nm, which is reasonable for 
drug del iver appl ication [88 ] .  
5 )  Wa hing the extra unattached dextran was much easier than chitosan and 
D . duri ng preparat ion. 
In order to increase the ie ld of D-MNPs while maintaining the phase purity 
and monodisper i ty of the NPs, preparat ion of the dextran-coated MNPs was further 
modified and optimized. In the modified procedure, MNPs were pre-formed from 
more concentrated Fe::!-t- and Fe3+ solutions, MNPs were post-coated with 1 % dextran. 
tart ing i ron solutions were 1 .2M Fe::! and 2 .4M Fe3-'- .  After precipitation of the 
MNPs i n  a highl alkal i ne aOH solution, they were soaked at a temperature of 
60°C for 38 hrs. MNPs suspensions were then centri fuged and subjected to 
successi e decantation/centrifugation using steri le de-ionized water. Solut ions 
contain ing suspended MNPs were separated by centrifuge, to be coated by dextran . 
A highly alkal ine solution of NaOH containing 1 weight % dextran was used, so that 
the weight rat io of MNPs-to-dextran was 3 :  1 .  Extra un-attached dextran was 
removed by successive centrifugation and decantation, and was confimled by 
Benedict ' s  test. It should be mentioned that al l  preparation were carried out under 
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teri le condit ion in  a biological hood u mg teri le equipments and reagents. To 
c nfim1 pha e compo it ion, D-MNP were eparated by centrifuge, dried and 
haracterized u ing FTIR and TGA technique . 
Figure 38 hov. FTIR of pure MNPs (0 .0  % coating) and the D-MNP 
( 1 .0° 0 coat ing) ,  Bands repre enting pure MNP Fe-O bond were appeared at 429, 
56 1  and 6 1 8  mo l in  the pectrum of pure MNPs. These bands were shifted to at 428, 
5 7 1  and 6 1 9  cm' l band , re pectively, in  the FTIR pectrum of 1 % D-MNPs, In 
addition, the pre ence of dextran a a coat ing was confirmed by its bands at 1 0 1 0  and 
1 1 50 mo l for C-O group, and 1 342 cm' l for C-H group in  D-MNPs. 
Moreover, the presence of dextran a a coating onto MNPs was confirmed by 
TG analysis:  Figu re 39, where weight loss of D-MN P  indicated the presence of 
dextran a a coating, Thi was evident through the major weight loss around 200°C. 
and the m inor weight los around 450°C,  which were attributed to the degradation of 
dextran, I t  should be mentioned that TEM analysis of these Ps showed an average 
particle i ze of 1 6  nm Vo.rith and without the coating. which may indicate the presence 
of a thin coat ing of dextran onto the MNPs, 
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Figure 3 8 :  FTIR o f  pure MNPs and the D-MNPs. 
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3 .4 .  roc in  load i n g  characteriza t ion 
Cro in  wa chemical l y  conjugat d. via uccinic anhydrid as a cro l inker, 
onto the urface of functional ized D-MN P  ynthe ized in  this tud . Re ults o f  three 
fom1Ulation are pr ented in thi di ertat ion. Each fonnulation was numbered 
accord ing t the croc in  c ncentration that wa used in ritro or in vim experiments 
( Tab le  9) .  The i ron conc ntration u ed. was considered safe based on our previous 
tudie . 
Th remained attached crocm was 70 mg/ml in 3 mg/ml formulation, 3 3  
mg/ml attached crocin wa in  2 mg/ml fOlmulation. and in 4 mg/ml fOlmulation the 
attached cr c in wa 40 mg/ml ( Tab le  9 and Figure 40) .  The difference in attached 
crocin might be because of the d ifference in the percentage of the coat ing with 
dextran among the NP them sel f. 
Table 9 :  Anal)" is of crocin  and 1 ron content i n  different D-MNPs formulations. 
Crocin Attached on-toxic Fe Tested croci n  In i t ia l  crocin  loading concentration CroCll concentration concentration efficiency concentration (NPs with and (mg/ml )  (%) (mg/m l )  without crocin )  
3 mg/ml 1 00 70 70 0 .09mg/ml-
( in vitro ) 9�g/ 1 00�l 
2 mg/ml = 1 7mg/kg-1 1  mg/kg 1 00 3 3  3 3  0 . 3mg/ 1  00�1 
( in vivo) 
4 mg/ml = 1 7mg/kg-
22 mg/kg 50  80  40 0 .3mg/ 1 00�1  
( in viro) 
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The re u l t  of FT - IR  spectrum of pur crocin howed the band at 1 5 1 5  and 
1 63 1  cm- I due to =c . I 0 i t  shov. 1 697 cm- I because of C=O [ 1 53 ] .  2933 cm- I 
band cau ed by -H  and the broad tretch between 3262 and 344 1 cm- I corresponds 
t the presence of O-H groups [ 1 98 ] .  FTI R  pectrum of D-MN P  with crocin shows 
the unique band of at 1 534 and 1 63 7  cm- I which is only present in  crocin,  
confinning the ucce fu l addition of crocin in the D-MNP as een in Figu re · n .  
Th nthe i reaction of crocin-loaded D-MNPs was as fol lows. Free 
h) droxyl group on dextran reacted with succ inic anhydride to form covalent ester 
bond and a fre carbo ' l ic acid .  The latter is used to l ink the hydroxyl group of 
crocm VIa terification. Succinic anh dride is an organic compound with the 
molecular fonnula C.tH103 ( Figu re 42 ) .  I t  can fom1 a strong ester bonds between 
it e lf  and crocin or dextran a mentioned earl ier .  These bonds can break specifical ly 
in  acidic environment a in  cancer site to release croc in in  act ive form. dextran and 
uccinic acid .  E DC I  was used dur ing the esterification reaction as the coupling 
reagent to activate succinic acid enabl ing crocin to bind. I t  did not interfere in  the 
chemical structure and its end product ( urea derivative) can be washed out easi ly by 
\vater F igu re .t2. 
F igure 43 shows the TEM of D-MNPs and 4 mg/ml crocin- Ioaded D-MN Ps 
a representative formulation. The size of synthesized crocin conjugated D-MNPs by 
esterification process was uniform and monodisperse. The average d iameter of D­
MNPs v.i th and without crocll was 1 6  nm, i ndicat ing that the addition of dextran and 
croci n  layers were very thin and did not affect the main core size of MNPs. 
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Figure 4 3 :  TEM micrographs of Ca) D-MN Ps and (b) 4 mg/ml crocin-loaded 
D-MN Ps. I nsets: i ndividual round shaped MNP.  
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3.5. 111 vitro relea e of crocin 
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The cumulat i \ e r lea e of crocin from the prepared D-MNP carner v,,'a 
i m e  tigated at pH values of 5 . 5  and 7.4 at the physiological temperature of 37 °C . 
The cumulat i \  e drug relea e \I, a expre ed a the percent of de-attached crocin from 
D-MN P and released to the surrounding aqueous media as a function of time. The 
drug release act ivi ty depends on many characteristics of the NPs. such as surface 
characteri t ic and force of interaction between crocin and the underlying D-MNPs. 
The in \'itro drug release behaviour of crocin loaded D-MN Ps was studied in  PB at 
pH 7.4 and a temperature of 3 7°e to maintain the experimental condit ion imi lar to 
the phy iologic condition . The tumour t issue ha acidic nature with pH 5-6 
compared to the healthy ti ssues at pH 7 .4 [ 1 68 , 1 99, 200 ] .  because of that the release 
tudy \\"a investigated at pH 5 .5 at temperature of 3 7°e to understand the release 
mechani m i n  cancer site. 
Figure .U shows the percentage of cumulative release of crocin from 2 and 4 
mg/ml crocin loaded D-MN Ps fOffi1Ulations and both with 3 mg Fe/ml .  The release 
behaviour of 2 mg/ml crocin  loaded D-MNPs at 0 .0  hr was 1 6% at pH 5 . 5 ,  whereas 
at pH  7 .4 it showed a percent release of 4%. The release increased as the t ime 
i ncreased to reach 47 % and 3 8  % at pH  5 . 5  and 7.4, respectively after 1 5  day. 
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Figure 44 : Release profiles of crocin from the prepared two fonnulations. a) 2 mg/ml 
and b)  4 m g/ml croc in  conjugated D-MNPs with 3 mg Fe/ml in  PBS at pH 5 . 5  and 
7 .4 .  
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n another hand , there was in itial burst relea e in -+ mg/ml crocin loaded 0-
MJ\ p  \\'ith 33°'0 at pH 5 .5 compared v, ith 9% at pH7.4 .  The relea e rate at 5 .  - pH 
increa ed to reach 46% in the fir t 4 hrs. Then i t  wa accelerated constant l a the 
t ime pr long d to rea h 88% in day 1 5 th and 92% in day 1 th o In addition, the crocin 
relea e at pH 7 .4 wa lower than 5 . 5 .  In  the first 4 hr it was 21 %. and then the 
relea e "va incr a ed regularly t i l l  day 1 5 th to be 75%. But it started to i ncrease 
10\\ 1 )  to reach 76% after 1 7  days. I n  General . the release behaviour in 4 mg/ml 
crocin loaded D-MN P  were fa ter than 2 mg/ml formulation. 
In thi study croc in  relea e in both buffer solut ions showed sustained release 
beha\ iour with t ime in both formulations. Release of crocin might be attributed to 
the 10\\ c leavage or hydrolysi of hydrogen bond bet\veen crocin and cross l i nker 
that wa directly attached to the D-MNPs. A maximum percentage of crocin release 
\yas 92° 0 and was obtained under ac idic conditions (pH 5 . 5 )  compared to 76% in 
phy iological condit ions (PH 7 .4)  after 1 7  days. This difference in  release i s  
ignificant ( P  = 0 .0 1 27< 0 .05 ,  student t-test) .  The higher percentage of release was 
obtained due to the i ncrease i n  hydrolysis of carboxyl ic esters l i nkage between crocin 
and succinic acid that bound to D-MNPs. After hydrolysis each compound returned 
to its original structure producing; crocin .  succinic anhydride. and dextran attached to 
MNPs, \ ru le the MNPs might degrade to free iron that wi l l  bind to fenit in protein  in  
the cel ls .  
Because of leak and pre-mature b lood vessels of cancer t issues. the chance 
of crocin  loaded D-MN Ps to accumulate inside these t i ssues by passive targeting wi l l  
be h igher than nornlal t issues. Leading to an i ncrease i n  the concentration of crocin 
loaded D-MN Ps to 1 0- 1 00 t imes h igher in  cancer t issues within  1 -2 days compared 
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to normal on . Con equently. thi \\ i l l  increa e the h) drol), i and relea e of crocin 
in  cancer ti ue [90. 20 1 -203 ] .  
Th current re ult are consi tent with the finding o f  pre ious researcher . 
\\ ho dem n trated that acidic condition accelerate the cl avage of the bond 
connect ing the l i nker to the crocin and underlying D-MNP , and the passive target ing 
can a cumulate th Ps in  tumour t i ue more than nonnal one [ 1 68, 200 ] .  
3.6. III pitro cytotoxic ity 
In  thi tud . the human hepatocellu lar carCl l10ma cell l ine HepG2 was 
eJected a a model of cancer cel ls for in vitro experiments. Cel l  prol iferat ion and 
viabi l ity were evaluated by MTT a say. HepG2 cel l were incubated for 72hrs with 9 
different concentrat ions of crocin inc luding 0 .025,  0 .05,  0 .5 ,  3 .  5 ,  8, 1 0. 1 5  or 20 
mglml a wel l  as croc in-free contro l .  Compared to control group, microscopic 
examinat ion of croc in  treated cel l  showed morphological changes such as rounding 
of cells, reduced c)iopla m. cell hrinkage and p knotic nuclei ,  suggesting apoptosis 
i nduction [68, 204] . 
im i lar apoptotic-related changes have been reported in  He La cel l s  after 
being treated with crocin .  IC50 of crocin-treated HeLa cel ls was 3 mg/ml (3mM ) 
1 8hrs po t i ncubation.  Crocin  wa also found to be more effective than other saffron 
b ioacti ve ingredients such as crocetin  and safranal [205 ] .  
MTT assay results showed that crocin decreased the cel l  viabi l i ty in  a dose­
dependent manner. There were significant reductions ( P :S 0 .00 1 ) from 3 to 20 mg/ml 
concentrations compared with control as in Figu re 45. The IC50 of crocin was around 
6 mgjmL which is equivalent to 6 mM . 
oureini  et al . reported that crocin has a significant cel l viabi l i ty inrubitory 
impact i n  both dose- and time-dependent manners on HepG2 cel ls .  This anti­
pro l i ferative effect was proposed to be due to the telomerase inhibit ion that resulted 
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from do\\ n r gulating hTERT ( catal 'tic ubunit of telomera e gene ) [_06] . tudies 
have hown that the crocin ha the potential to inhibit growih of different types of 
cancer cell l ine . The ICso of crocin on HL-60 leukemic cel l s  was 2 11 ( Ilg/ml ) .  
ther ce l l  l i ne including K562. HeLa. HCT- 1 1 6  and HT-29. had ICso of  0.4. 3 .  1 0  
and 1 mg/ ml .  re pecti\ 'ely [ 67. 207] . 
un et a l .  uggested that crocin (0 .625-5 mg/m l )  reduced ce l l  prol iferation in  
human leukemia H L-60 ce l l  l ine, and caused apoptosis and cel l cycle  arrest at  00/0 I 
pha e. in  cone ntration- and time-dependent manners [208 ] .  These results are in  
agreem nt  wi th the i nvest igation of Hoshyar et  a! . who also found that crocin 
triggered the apoptosis through increa i ng the BaxlBcl-2 ratio and caspase activation 
in human ga tric adenocarcinoma. AOS cel l s  [209] . 
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Figure 45 :  M TT ce l l  viabi l ity assay of HepG2 cel l s, which were incubated with 
different concentrations of cracin  for 72 hrs. A l l  the alues are expressed as mean 
± EM:  * * *  P :S  0 .00 1 . 
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r cm al 0 i nhibit d the pro l iferat ion of human tongue squamou cell 
carcinoma cel l l i ne, Tca8 l 1 3 . through reducing the nucleic acid synthesi and 
inducing apopto is [ 2 1 0 ] .  It al 0 induced apopto i s  and G I -pha e c 1 1  cycle arrest in  
a human pancreat ic cancer cell l ine. BxPC-3 .  and colorectal cel l l ine. HCT- 1 1 6. 
\\ h i le decrea i ng cell viabi l i ty in do e-and time-dependent manner [207. 2 1 1 ] . 
However. crocm ha no tox ic effects on nom1al cel l uch as human normal 
fibrobla t k in cel ls .  HF F-PI3 [67. 209] . 
MTT a sa was then used to study the effect of D-MNPs on viabi l ity of 
Hep 2 cel l . Different concentration of i ron contents of appl ied D-MNPs were 
incubated with HepG2 c II for 72 hrs and the corresponding cell viab i l i ty were 
plotted i n  Figure 46.  The cel l  v iabi l i ty decreased as the i ron concentration increased 
i n  a concentrat ion-dependent manner. There wa no significant inhibition at 0.05 
mg/ml compared to the contro l .  The cel l  iab i l ity was obtained at 90 to 60% in  a 
broad concentrat ion range of 0.05 mg/ml to 0. 1 mglml .  This demonstrated that the 
1NPs carrier coated with dextran had good biocompatibi l ity due to its sugar 
components. The i ncrease in cytotoxic ity m ight be because of some MNPs lost their 
dextran coat ing. consequently exposing MNPs to the cel l s  [200 ] .  
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F igure 46 :  C ytotoxicity of d ifferent iron concentrations i n  D-MNPs on HepG2 cel ls  
after 72 hrs .  Al l  values are expressed as mean ±SEM; **P � 0.0 1 ,  * * *p � 0.00 1 .  
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Kumar et al . demon trated that the cell viabi l i ty of human breast cancer cell 
l i ne M F-7 cel l wa obtained at 90 to 78% in concentration range of 0 .0 1 -0. 1 
mg/ml for 24 hr compared with control cel ls .  They al 0 concluded that the MNP 
coat d w ith dextran had good biocompatib i l i ty [200 ] .  In  other stud , a range of 
P v" ith varying ph} ico-chemical properties primari l demonstrated low 
c)10to. ic i t} at doses of 0 . 1 mg/m] or higher [ 3 ] .  Therefore. 0 .09 mg/ml (9 1lg/ 1 00 ".tl )  
i ron-content D-MNPs were loaded with crocin for fUliher in vitro studies. 
MTT as ay at 72 hrs of HepG2 cel l s  was also used to e aluate the anti -cancer 
effect f 3 mg/ml crocin- Ioaded D-MNPs with 0 .09 mg Fe/ ml  and compare i t  with 
contro l .  3 mg/ml crocin or D-MN Ps with 0 .09 mg Fe/ml as in Figu re 47. Three 
mg/ml crocin was elected from the previous free crocin screening to test if crocin­
loaded D-MN Ps enhance the crocin- inhibitory effect over free crocin by reduce the 
pro l iferation of HepG2 cel ls .  I nverted microscope observations showed that the cell 
v iab i l i ty of the HepG2 i ncubated with free crocin and crocin-loaded D-MNPs 
decreased as incubation t ime increased from 24 to 72 hrs. However, D-MN Ps had no 
significant effect on the cell v iabi l i ty compared to control . V i l lanueva et al . revealed 
that the v iabi l ity of cel l  culture of D-MN Ps with HeLa cells at 24 hIS was not 
ignificant ly affected by the presence of the NPs compared to control [2 1 2 ] .  
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F igure 47 :  Cytotoxic i ty effects of ruedia alone as a control ,  3 rug/ru l crocin alone, D­
MNPs with 0 .09 rug Fe/rul and 3 rug/ru l crocin- loaded D-MNPs with 0 .09 rug Fe/ru l 
on HepG2 cel ls .  Values are expressed as ruean ±SEM; *P � 0.05,  * *P � 0.0 1 .  
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In  the pre ent tud . TT a ay at 72 hrs incubat ion of HepG2 cells re ulted 
in cro in  onj ugated D-MN P significantly decreased (P :s 0.0 1 ) the ce l l  viabi l ity to 
650 0 compared to non- igni ficant i nhibitions 82% of free crocin. and 87% of D­
MNPs and al l compared to contro l .  The decrea e in ce l l  viabil ity as  ociated with D­
MN P group might be due to the degradation of dextran and exposure of MN Ps to 
the cel l . There \'Va ignificant deer a e ( *  P :s 0 .05 ) between crocin-loaded D-MNP 
and D-M Ps groups. Howe er. there was no significant d ifference in cel l  v iabi l i ty 
bet\\ een D-MN P  and control groups. 
The D-MNP either alone or with crocin were stable i n  the DMEM medium 
a wel l  a in th deionized or auto-c leaved water ( storage solution ) during the t ime of 
te t ing and after week of storage. i ndicating that these Ps have stabi l izing shel l  
'which not only decrease agglomerat ion but a lso protect them from extemal factors. 
A carrier l ike D-MN Ps has been shown to increase the uptake by cancer cel l s  
v ia adsorption. fusion. and endocytosis [90 . 2 1 2 . 2 1 3 ] .  The increased toxic ity of the 
croc in  coated D-MN Ps on HepG2 cel ls might also be due to the anti -prol iferation 
effect of crocin that might be released as shown earl ier in the release study ( Figu re 
44). anol iposomes containing croci n  ha e been shown to improve cytotoxic and 
apoptotic properties of crocin  on HeLa and MCF -7 cancer cel l  l i nes compared to free 
crocm. 0 C )10toxic effects were however reported on the non-mal ignant mouse 
fibroblast cel l l i ne L929 [67. 2 1 4] .  To confirm the cytotoxic effect of the crocin­
loaded D-MN Ps. further i n  vivo study was performed. 
3.7. lit vivo ant i-tumour  efficacy 
Balb/c mice strai n  was chosen for this study as it has been used as a model 
for carc inogenicity in other studies [42. 46, 48 ,  49, 2 1 5 -2 1 7] and it is  relat ively 
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ensit ive to th induction of h pat ic tumor b chemical carcinogens uch as DE 
[ 48 ] .  
o p r  viou tud has b en u ed multiple injections of DE to induce pre-
ne pIa t ic foci  or H in pre-weaning Balblc mice of 3 week old. 0,  in this study 
V\ e ar charact rizing a modi fied pre-cancerou mice model that can be produced in 
two month only.  This model al 0 mimics the human pre-cancerous procedure. as it 
is  a mult ist p model where c cles of de-generation and re-generation might acti ate 
pre-neoplastic transfomlation . The progre sion of early dysplastic lesions to 
malignant tumours is a oc iated with an increased occunence of genomic alterations 
[ 1 7. 5 1 ] . 
Th younger the mice are the faster BCC wi l l  de elop because of the high 
hepatocyte prol i ferat ion rates of young animals. Also. HCC deveolps in male more 
than female is because of the st i mulating effect of androgens and the inhi bitory effect 
ofe  trogens on hepatocarcinogenesis [ 1 3 . 1 6, 1 7. 4 1 ] . 
3.7. 1 .  Genera l  Observat ion,  Body and Liver Weight 
I n  this study. 50  mg/kg DE " as used to induce hepatic carc inogenesis in  3 -
weeks o ld  pre-weaning male Balb/c mice. DE administration caused reduction in  
the body and l iver weights as  shown i n  DEN -induced group compared to nonnal 
group as in Figu re 48 . This reduction in body and l iver weights was because of the 
cytotoxic  effect induced by DE . Some animals could not tolerate DEN induced 
cytotoxic  effect and died. D EN exposure affects l iver at two stages: init ial ly it 
reduces the hepatocytes cel l  pro l iferation, then cel l pro l i feration and DNA synthesis 
increase to ult imately form pre-cancerous lesions and cancer. Such init ial  depression 
in  cell pro l iferation and DNA synthesis was combined with amount of cell damage or 
death that was enough to cause some animal to die, before the regenerative response 
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\\ a triggered . Thi reduction m th hepatoC}1e prol iferat ion might decrease the 
o\eral l body and l iver v" eight in  pite of ome pre-cancerou changes wa taking 
place in  the l iver a confirmed by I H  tudie section later [ 3 1 ] . 
] n  addition. cel l pro l i�  ration reduction of hepatocyte was associated with 
the in i tial interval of cytotoxicit  . that wa reported by Rajew ky et aJ . in 1 966. Male 
rat \\' re expo ed to 5 mg/kg DE per day in  drinking water for 1 1  week . The 
init ial  reduction of hepatocyte pro l i feration wa for 3 -5 da s. After thi s period. cel l 
pro l iferat ion increa ed to 2-3 t imes [ 4 1 ] .  Figu re 48 shows the body and l iver weights 
in 1 1  and _2 mg g crocin-loaded D-MNPs with 1 7  mg Fe/kg treated groups 
recovered and i ncreased compared to DE - induced or free crocin groups. I ndicating 
better ffectivenes of crocin- Ioaded D-MNPs than free crocin .  Crocin-conjugated 
PEGylated nanol ipo omes have been shown to increase the weight of Balb/c mice 
with C26 tumor when compared with free crocin [ 2 1 8 ] .  
30 
25  
:JJ i 20 :JJ o 1 5 3 
-6' 10 
� 
(a 
(c) 
30 
� 2 5 
21 
� 2 0 :i.. :> 
3 1 5 
� 1 0  
ciS 
5 
o 
.. 
(b) 
1 .4 
� 1 .2 
co i 1 .0 
� 0.8 
3 '- 0.6 
o :3 OA 
0.2 
0.0 
1.4 
� 1.2 
eJ) � 1.0 
:IJ ·5 0.8 � 0.6 
'" :J 0.4 
0.2 
0.0 
(d) 
-, . 
r-----o 
� t-'l,
� 
"::"O<,,<$' .�<:>�
� 
� � �<t; 
150 
• •  
Figure 48 :  Body and l iver weights of Balb/c mIce treated with different 
treatment . a) Body and b) l iver weights of normaL DE i njected mice treated 
\",ith sal i ne ( DE - induced group). 1 1  mg/kg croein, and 1 1  mg/kg crocin- loaded 
D-MNPs with 1 7  mg Fe/kg. c )  Body and d )  l iver weights of normaL DE injected 
miee treated with sal i ne ( DEN-induced group), 22 mg/kg crocin,  and 22 mg/kg 
crocin- loaded D-MN Ps with 1 7  mg Fe/kg. Values are expressed as mean ±SEM;  
*p S 0 .05 .  * * P  S 0 .0 1 .  * * *P  S 0.00 1 . 
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3.7.2. H i  topatho logica l e 'am inat ion 
Figu re -49 and 50 ho\\ normal tructure and hi tology of l iver a een in  th 
normal group of mice. The l iver i divided histological ly  into lobules: each lobule 
appear hexagonal in hape. Th center of the lobule include the central vein, 
howner the portal triad are located at the periphery. The portal triad consist of 
branche of hepat ic artery, portal vein .  and bile duct. It also include lymphatic 
ve e l . The hepatoc}1 s appear mono or bi -nuclear with round and central ly located 
nuc le i .  HepatoC}1e are al 0 alTanged in single-cel l thick plates that radiate out from 
the c ntral \ e in .  Th se plates are epa rated or sUlTounded b ascular sinusoids [ 1 0] .  
I n  the animal model that ha been de eloped i n  this study. no gross or 
macro copic tumor was observed in the l ivers of any DE injected group. Howe er, 
micro copic h istological examination of l ivers of mice in DEN -induced group 
howed clear pre-neoplastic changes inc luding large and smal l  cel l  d splasia such as 
altered hepatocel lular foc i  (AHF) .  and accumulation of lymphocytes. intrahepatic 
bi le ducts and oval cel l s .  AHF were also considered by some researchers as i slands 
of cel lu lar alteration [42. 2 1 7, 2 1 9 ] .  
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Figure -l9: D iagrammatic representat ion of l iver nom1al structure and blood flow. 
Hepatic lobules of l iver are repre ented by hexagonal hepatocytes cel ls structure 
and surrounded b portal triads at the comers. CV;  central vein .  
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Figure 50:  Liver's normal 
histology (H&E stain). a )  
Portal triad area consists of 
branch of portal vein and bile 
duct, scale bar = 100�m. b)  
central vein and hepatocytes. 
scale bar = 1 OO�m. and c )  
hepatocytes are surrounded by 
sinusoids. endothelial and 
kupffer cells. scale bar = 
50�m. 
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Other chang \vere al 0 determined uch a hepatocyte with vacuolated 
nucleu . nuc lear pleomorphi m. multi -nucleation. mitotic activit . increa ed 
pr Ii [erat i \  e index. giant cell and hepat ic cyt Iy is ( Figu re 5 1 ) .  Apoptotic bodie 
were detected in the portal area. sugge ting that apoptosis a contributory to clonal 
growth \ ia remO\ al of adjacent normal cel l s  [42, 2 1 7. 2 1 9] .  In this stud , there were 
al 0 other feature of cel l s  undergoing apoptosis and characterized by cell shrinkage, 
membran bl bbing. chromatin  conden ation and nuclear fragmentation. imi lar 
features w re repOlied in other DE model studies [220 ] .  
rodent 
imi lar to tumorigene i in  other organs. hepatocarcinogenesis in  humans and 
a mult i  tep proce characterized by the development of cel lular 
intermediate that progressively cau e genetic al terations that regulate transfom1ation 
of nom1al cel l into malignant cel ls .  AHF is one of the major cel lular alterations 
[2 ] 9] that are knO�l1 to occur in  consequence of l iver injury. and are considered to 
be one of the pre-neoplastic predictive markers associated with HCC. AHF can be 
categorized into basophi l ic, eosinophi l ic .  clear, vacuolated, or mixed [22 ] -223 ] .  
I n  the present study, most of the l iver foci  i n  mice of the DE - induced group 
\vere i dentified to be consisted of mixed of basophi l ic ,  vacuolated and c lear cel ls 
( Figu re 5 1 ) .  The distribution of all types appeared to be at random with respect to 
the hepati c  lobule. AHF are general ly  dist ingui shed as c i rcular areas of hepatocytes 
with altered staining properties. Basoph i l ic AHF are composed of cel ls that are 
usual ly smal ler than adj acent normal hepatocytes. In vacuolated AHF, hepatocytes 
are enlarged with l arge or smal l l ipid vacuoles i n  the cytoplasm and mostly central 
nuclei due to displacement by vacuoles. The cytoplasm of vacuolated AHF showed 
patchy cytoplasmic staining as seen in Figu re 5 1 . Cells in clear AHF are normal 
s ized or enlarged with central, often hyperchromatic nuclei ,  and clear whitish 
i S S  
C) topla m that mu t be di t ingui hed from vacuolated one by lack of cytopla mic 
l i pid \ acuole . HepatoC)1e in  eo inophi l ic  HF are general l ,  larger than nonnal 
hepat cyte and have diffu ely eo inoph i l ic c)10plasm . The cytopla m in  
eo inophi l ic  HF \ ane from mild to intense. The mi ld eosinophi l ic  foc i  were 
difficult to di t ingui h in the taining from surrounding parenchyma. 
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Figure 5 1 :  Fonnation of AHF in  the l iver of DEN-induced group. a )  Mixed cel l  
AHF composed of  basophil ic ,  vacuolated and clear cel ls ,  scale bar = 500 ).UTI, b) 
vacuolated and clear cel l s. scale bar = 1 00 /lm, c) cholangioma. lymoocytes 
hyperplasia and apoptoti c  bodies, scale bar = 1 00 /lm,  d )  cholangioma, scale bar 
= 1 00 /lm.  e) vacuolated nuclei and the cel l ,  scale bar = 50 /lm. and f) mitotic 
figure i n  Metaphase stage, scale bar = 50 /lm .  
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D i a carc inogenic chemical that is  found in  tobacco smoke. cured or 
fried meal co m tic . agricul tural chemical and ome pharmaceut ical agent . 
Pre\ iou tudie have hown that DE ma induce carcinogenicity by e eral ways .  
i )  lk) lating D A tructures leading to the fOffilation of mutagenic D A ad ducts 
[ 1 3 . ] 6. 1 7. 3 " ] .  i i )  Generating RO that cau es carcinogenesi s by danlaging D A. 
protein  and l ipid molecule [ 1 3 . 1 6. 1 7. 3 3 ] .  i i i )  I nducing mutations in  H-ras proto­
oncogene leading to unl imited c 1 1  divi sion and. e entual l  . cancer development [ 1 3 , 
1 7. 3 5 ] .  iv )  I nducing 0 er-expre sion of the Bcl-2 gene [ 1 7] .  v )  Stimulating the 
prol i feration of hepatic oval cel ls and bile duct cel l s  leading to hyperplasia and the 
fomlation of micro copic intrah patic cholangioma [ 38 . 39 ] .  
previou study has ut i l i zed pre-\veaning Balb/c mice strain where a single 
dose DE T wa u ed as in it iator [ 2 1 6] fol lowed by a promoter such as phenobarbital 
[48]  or partial hepatectomy [2 1 5 ] to accelerate growth of pre-neoplastic focal lesions 
[42 ] .  I n  the pre ent study. pre-weaning Balb/c mice were i njected with multiple 
doses of D E  for two months which is considered a modified protocol to i nduce pre­
neoplast ic foc i  and cholangioma. 
S imi lar pre-neoplastic cytological alterations that were observed in  this study 
v,'ere also observed in the transgenic mice model .  G i l let et a l .  generated several l ines 
of transgenic m ice that develop hepatocarc inoma in response to expression of wi ld­
type V40 early sequences. under the control of the regulatory sequences of human 
anti -thrombin I I I  gene ( TAg mice, previously nanled ASV mice) .  As of second 
month of l i fe. transgenic l ivers are characterized by pre-neoplastic cytological 
alterations, inc luding anisocytosis, anisokaryosis. increased pro l iferative i ndex, giant 
cel l s  and hepatic cytolysis .  These pre-neoplastic foc i  become macroscopic from the 
second month onward. But all animals die before the age of 7 months [2 1 9] .  
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In  the combined treatment group of D-MNPs loaded with crocin  at 1 1  mg 'g 
and 22 mg/kg concentrat ion , th re were reduction in  the pre-neopla t ic changes 
compared to groups of DE - induced or  fr e crocin ( Figu re 52 and  53 ) .  The 0 erall 
pre-n opia t ic reduction were better in  22 mg/kg than 1 1  mg/kg crocin-Ioaded D-
P fomlulation. 'W hich might be because of high concentration of crocin .  The 
brown col r in the combined treatment in Figure 53 indicated the presence of D­
MNP that attached to the 1 1  mg/kg or 22 mg/kg crocin .  To confirm the presence of 
the e P .  Pru sian blue stain was u ed with and without H&E stain.  
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Figure 52 :  H istological examination of AHF arising in l ivers of Balb/c mice after 
DE administration and treated with 1 1  mg/kg or  22 mg/kg free cracin. a)  Portal 
area and b) central vein of 1 1  mg/kg crocin treated animals, each scale bar = 1 00 
11m.  c )  Portal area and d )  central vein of 22 mg/kg crocin treated animals, each 
scale bar = 1 00 11m.  
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Figure 5 3 :  H istological examination of AHF aris ing in  l ivers of Balb/c mice post 
DE administration and treated with 1 1  mglkg crocin- loaded D-MNPs or 22 mglkg 
crocin-loaded D-MNPs, both doses contained 1 7  mg Felkg. a) Portal area and b )  
central ve in  of 1 1  mg/kg croci n- Ioaded D-MN Ps treated animals, each scale bar = 
1 00 �m. c )  Portal area and d )  central vein of 22 mglkg crocin-Ioaded D-MNPs 
treated animals, each scale bar = 1 00 �m. The arrow indicates presence of D-MNPs 
loaded with 1 1  or 22 mg/kg crocin i n  l iver t issues. 
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3.7.3. Detect ion of D-MN P  in vivo 
To confim1 that the pre-n opla t ic le ion ize reduction correlated with MNP 
accumulation after _4 hr of la t i .v .  injection. we used Prus ian blue stain to analyze 
MN P in l i \ er of normal and 22 mglkg croc in-Ioaded D-MNPs contained 1 7  mg 
F Ikg a repres ntative groups ( Figu re 54) .  Prussian blue staining showed more 
M P accumulation in l iver ti ue, mostl in kupffer cel ls, treated with crocin­
loaded D-MNPs in the 2 formulation . Howe er, NPs were neither observed in the 
normal ( Figure 54a ) ,  th DE - induced nor in the free crocin group (data not 
ho\\-n ).  
De pite this widespread distribution of crocin- Ioaded D-MNPs in vivo. i t  
hould be emphasized that \\'e did not have any fatal it ies due to the blocking of blood 
ve sel at the MNPs dose used i n  thi tud . The size of D-MNPs with crocin is 1 6  
1U11 which sti l l  i in  the acceptable size range to be i .v .  injected in the mice [ 3 ] .  MNPs 
in the size range 1 0- 1 00 nm have been considered to be optimal for i . . 
administration. Part ic les more 1 00 run and less than 1 0  run are isolated by the spleen 
or removed via renal c learance, respectively [ 3 ] .  D-MN Ps admini stration and its i ron 
oxide concentrat ion used in  this study caused neither adverse effects nor death to any 
of the examined mice. Thus. the data suggest that D-MN Ps are biocompatible and 
adequate for b iomedical experiments. 
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Figure 54 : Prussian blue stammg of l iver sections. a) N0n11al I i  er and b) l iver 
section of mouse treated with 22 lTIg/kg crocin-loaded D-MN Ps, each scale bar = 1 00 
fllTI . 
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The bright blue cloud around D-MNPs cluster with crocm ( Figure 55)  
ugge t d free i ron relea e from the clu ters. The fate of D-MNP fol lowing i .v .  
admini  tration wi l l  mainly be in  l iver and spleen a a fi l tration sy tern. which also 
con firn1ed b) hi tological tudie done b . other re earchers. I ron-release evidences 
ob er\'ed more in the I iv r ti ue compared to pleen . The clu ters of D-MNPs were 
re tricted to pleen red pulp. The primary function of red-pulp is to fi lter the blood 
from variou compon nt and it include granulocytes and macrophages [224 ] .  While 
\\ hite pulp mainly contain lymphocytes, such as T cells .  Lacava et al. observed that 
D-MNP decrea e in number tlu'oughout 6 months in l iver and spleen of nonnal 
mice [224 ] .  In pite of the pI' ence of D-MNPs in both I i  er and spleen tissues, no 
damaged cel ls or any other alterations were observed in  the investigated normal 
ti ue . Thus, D-MN P have proven to be safe and they are current ly used cl inically 
in  d ifferent forn1s uch as Feridex IV and Reso ist [ 90. 9 1 .  1 46] . 
Magneti c  core may cause toxic effects to organisms i f  it was left directly 
exposed to the cel ls .  This may occur if weak bonding between dextran and MNPs 
exist .  Uncoated magnetic cores tend to aggregate and may lead to the precipitation 
of MNPs that eventual ly block the blood vessels and k i l l  the organism. Furthennore. 
uncoated MNPs can i nduce genotoxici ty v ia generation of ROS. Upon internal ization 
of MNPs i nto the cel l ,  MNP s  might degrade in the lysosomes by hydrolyzing 
enzymes i nto free ferrous ion ( Fe2+ ) .  These free ions might cross the mitochondrial 
membrane and react with hydrogen peroxide and oxygen to produce highly reactive 
hydroxyl radicals and fenic ions ( Fe3+) .  The generated hydroxyl radicals can damage 
D A proteins. polysaccharides and l ipids. Thus, iron overload and its subsequent 
homeostatic imbalance may have direct cel lular responses includ ing, but not l imited 
to. D A damage. and inflanunatory processes. Ensuring the surface coating of 
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MN Ps j therefore ential to pre\ent the relea e of tox ic ions from magnetic core 
It i al 0 known that MNP i one of the mo t iron oxide-ba ed partic les u ed 
in vim. That i becau e the are ea i ly degraded and cleared from circulation by the 
endogenou iron metabol ic pathwa . The relea ed iron is nom1al ly metabol ized in 
the l iver and ub equ ntl u ed in the formation of red blood cel ls .  bind to ferri tin or 
excreted \ ia kidney [ 3 . 2 1 2. 2 1 3 . _25 ] .  I n  pre ious section of this study. both TGA 
and FTIR  anal}  es have b en uti l ized to in  ure the presence of dextran as a coating 
material . Al o. the in rifro release tudy confinned the relea e of crocin not dextran 
at d ifferent condi t ion ( Figu re 44 ) .  
The di tribution of MNPs local ized in  the l iver t i ssue might i ndicate presence 
of endo orne that could  merge with lysosomes at later stage of endocytosis .  MNPs 
have already been reported inside endo omes around nucleus in the cytoplasm. but 
not i nside the nucleus of the cel ls  [2 1 2 ] .  Lyso omal enzymes might break the bond 
betv,:een the crocin  and the cross- l i nker attached to D-MN Ps, and thus releasing the 
crocin as its intact active structure. The D-MNPs entrapped by Kupffer cel ls 
indicates an efficient e l imi nation process of MNPs through phagocytosis in  the mice 
treated with Ps. 
(a) 
• 
• • 
Figure 5 5 :  Subce l lular local ization of 22 mglkg crocin-loaded-DMN Ps and 
stained with Prussian blue. The ti ssues were counterstained with a) neutral red, 
and b) H&E stain, each scale bar = 50�m. Crocin loaded-DMNPs are local ized 
in the cytoplasm. Red arrow: D-MNPs in hepatocytes, and Black arrow: D­
MNPs in Kupffer cel ls .  
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nce In  the blo d tr am Ps are rapidly coated by component of the 
c i rculation. uch a pia ma protein in proces known as op onization. Tlus proce 
ritical in determining the circum tance and the fate of the injected Ps. ormall ,  
op onizati n make the particle identifiable b the body' major defen e y tem. the 
reticuloendothelial ystem [226] .  It i a ystem of special ized cel ls  that are 
phagocytic and can be found in connective t i ssues area of the l i ver, spleen and lymph 
node [90. 203. 2 1 2 ] .  Kupffer cel l  and the macrophages of the spleen and 
irculation play a critical role in the removal of op onized particle . As a re ult, the 
appl ication of MNPs in vh'o would require surface modification that would ensure 
that part ic les are non-toxic. biocompatible and stable l ike hydrophi l ic compounds 
[88 .  92. 1 88.  227] . Hydrophi l i c  compounds such as dextran polymer have been used 
i n  thi study. and dextran was shown to resist the opsonization process and to slowly 
c lear thus increasing the half- l i fe of MNP and the crocin .  
The leaky nature of vasculatures 1 11 pre-neoplastic and tumor 
microenvironment faci l i tates the extravasation of Ps ( 1 0-500 nm ) from the blood 
c i rculation and selective penetration into the cancer microenviromnent . However, the 
poor lymphatic drainage system helps them to be retained [228-230] . 
3.7.4. I m m u nohistochem istry studies 
This section was designed to analyze the anti -cancer efficacy of free crocin 
versus crocin- Ioaded D-MN Ps on l iver has pre-cancerous lesion in  Balb/c mice. 
I mmunohistochemistry staining for GST-P was employed to ident i fy the presence of 
pre-neoplastic foci  after DEN administration, which was fol lowed by treatments with 
sal ine ( DEN-induced group). free crocin or crocin- Ioaded D-MN Ps as detai led in  
materials and methods section. 
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3 .7.4. 1 .  G T-P expre ion 
Glutathion -tran ferase (G Ts) are a major group of phase II enzymes. 
and among the mo t povv'erful cel lu lar detoxify ing ystem . Thi fami ly faci l i tate the 
catal; i of thioether bond between gl utathione and el ctrophi l ic compound 
includ ing carcinogens. drug and a ariet of products of cel lu lar metabol ism ( both 
endogenou and ex genous compounds) .  This fami l  is grouped into six c lasses 
according to the number of chromosome. lpha (chromo ome 6 ), Mu (chromosome 
1 ) . Omega (chromo orne 1 0 ). Pi ( chromosome 1 1 ) . Theta (chromosome 22) ,  and 
Zeta (chromo ome 1 4) .  There are both structural and functional redundancies 
bel'.\ een i ozyme fami l y  member . 
G T-P form belong to the Pi c la s of GSTs. GST-P was first identi fied in  rat 
placenta and was henc nan1ed the placental form. The GST-P in the rat is  markedl 
i nduced 111 pre-neopla tic foci  and nodules induced by experimental 
hepatocarcinogenesis [23 1 .  232] . GST -P could be detected in a single cell as early as 
2-3 day after the i .p .  administration of DEN. This gene is expressed in response to 
almo t al l  of the chemical carci nogens. and can be found as a predominant protein in  
other tumors l ike breast cancer [23 1 -23 3 ] .  
GST-P levels in  nonnal rat t issues including fetaL adult and regenerating 
l ivers. and even in the placenta are very low compared to l ivers bearing pre­
neoplasti c  foc i  [232] . This enzyme is not i nduced by the same eletrophi l i c  
xenobiotics which induce the expression of other GST isozymes. The expression 
patterns of GST-P is closely associated with the early stage of hepatocarcinogenesis 
[23 1 ] .  
GST-P expression was estimated as the percentage o f  cel ls posit ively stained 
by the antibody and detected by the DAB substrate (brownish color) i n  the cytoplasm 
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and nucIeu of the cel l  . Tv" o month po t DE admini  tration. the expre ion of 
G T-P in DE -- induced group increa ed with trong inten ity compared to the 
nom1al gr up. Both tested fonnulation 1 1  and 22 mg/kg crocin-loaded D-MNP had 
more pre-ne pIa tic foci  inh ibition compared to DE -induced or free croc in 
( Figure 56 and 57) e pecial ly in  22 mg/kg croc in  formulation . 
The percentage of the G T -P posit ive foci  was quanti fied from relative I HC 
taining cel ls  f pre-neopla t ic foci  i n  twenty fields per group. The quantification 
analysi v. a p rfom1ed using Image Pro 6 software, and was confinning the IHC 
analy i . The percentage of e pression of  GST-P foci  was significantly i ncreased in  
DE - induced group (P S 0 .00 1 ) compared to nOlmal group as i n  Figu re 58 . 
he\'v eita et al . demonstrated that DEN increased the activity of GSTs by 50% after 1 
hr only of i .p .  injection with 20 mg/kg in  Balb/c mice [234] .  Also Narumi et a l .  
reported that the expression of GST -P posit ive single hepatocytes appeared after the 
i ni tial DE treatment with 1 2 . 5  mg/kg/day and their numbers i ncreased as the 
number of days of DE administration increased to 1 4lh days. GST-P posit ive mini­
foc i  existed on the ill day of DE post-treatment and i ncreased prominently on the 
1 4th day post-DE treatment [23 5 ] .  
Amin et al . indicated that saffron-mediated reduction o f  nodular hepatocytes 
that was associated by sign ificant decrease in the number of GST -P positive foci 
induced by DE in rats [68 ] .  On the other hand, the percentage of expres ion areas 
i n  the combined treatment group crocin-attached D-MNPs i n  both 1 1  and 22 mg/kg 
fonnulations were reduced compared to DEN-induced or free crocin groups ( Figure 
58). This might be because of the role of Ps as a carrier in  improving the ant i ­
cancer effects of crocin .  
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Figure 56: Effects of 1 1  mg/kg crOCll1 and its P formulations on GST-P 
expression in  l iver. a) onnal ,  b) DE - induced. c) free 1 1  mg/kg crocin, and d) 
1 1  mg/kg croc in-loaded D-MNPs. Each scale bar = 1 00 �m. 
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Figure 57 :  Effects of 22 mg/kg crocin and its NP formulations on GST-P 
expression in l iver. a) onnaL b)  DEN-induced, c )  free 22 mg/kg crocin, and d) 
22 mg/kg crocin- Ioaded D-MN Ps. Each scale bar = 1 00 !lm. 
(a) 
c... 1 0  I 
E-
en I I  
0 8 
<..-0 
c<! 6 Q) 
� 
c 
. Q  4 
C/) 
C/) 
� 2 0.. >< 
l=.J 
� 0 
� q,,� � �\,; ..;:;.0
' 
. �?S 
�,... 
�� 
(b) 
i · '7 1 8  
E­
CIJ 
o 1 5 
<-, 
, . o 1 2 c<! 
� 
a , . 9 c 
. 2 
, . � 6
� 
0.. 3 >< 
W 
� 0 
. 
* * *  
I I I  
-� 
� 
• 
17 1  
* *  
* * *  
* 
i 
� 
----r-
I 
Figure 5 8 :  Quantification of percent stai ned GST -P area i n  the two tested croc in  
formulations. a )  1 1  mg/kg crocin-loaded D-MNPs, and b) 22 mg/kg crocin-loaded 
D-MNPs. Values are expressed as mean ±SEM;  * P :s 0.05,  * *  P :s O.O L * * *  P :s 
0 .00 1 . 
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3.7A.2. K i-67 ex pre ion 
I I  pro l iferation play an important role in everal steps of carcinogene is 
process. In it iaI J;  carcinogen interact with D A leading to mutant nucleotide 
equence . I t ·  however the induced prol iferat ion of such mutant D A that wi l l  lead 
to th format ion of pre-canc rou Ie ion , that \\; ould. at a later stage, form HCC 
[ 236 ] .  The examination of the pre ence of cel l  c c le-related proteins may ield 
important information about the biological beha ior of a tumor. Ki-67 is a nuclear 
protein that has be n u ed a pro l i ferative marker of both nom1al and cancer cel ls .  I t  
i expre ed in al l  active pha es of the cel l cyc le, i ncluding G 1 ,  S, G2, and mitosis. 
\\ i th the highe t expre sion seen in G21M . Ki-67 is however lacking in  resting cell 
(GO) .  The name of ki-67 i derived from the city of origin ( Kiel ) and the number of 
the original clone in  the 96 wel l  plate [23 7-24 1 ] . 
In  the present study, Ki-67-spec ific antibody has been u ed to evaluate the 
cel lu lar pro l iferation rates and anal ze l iver regenerat ion and carc inogenesis 
processes. i n  the d ifferent treated animal groups. Ki-67 immunoreactivity was 
detected and local ized in the nuclei  of cel ls ( Figu res 59 and  60)  and the I HC results 
were quantified ( Figu re 6 1 ) . Ki-67 expression was estimated as the percentage of 
expression area that was stained by the ant ibody and visual i zed by DAB substrate as 
dark-brown colour in 20  fields. In normal l i ver sections a l imited number of Ki-67 
positive cells was observed. but the number of K i-67 posit ive cells was i ncreased 
ignificant ly (P <0.000 1 )  i n  DEN-induced l iver t issues. According to Youssef et a l .  
the Ki -67 expression was increasing after 6 and 1 2  weeks. The highest increasing in 
the number of Ki -67 posit ive cel ls  was after 1 8  weeks post DE injection with 75  
and 1 00 mglkg. each one a weeks for 3 weeks [ 24 1 ] . Also Narumi e t  a l .  observed 
that the number of Ki-67-positive hepatocytes i ncreased gradual l y  after DEN 
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, po ur In  t ime- and do - dependent manner compared to control prJ .  The 
expres ion of Ki-67 po itive c I I  in I I  and 22  mg/kg crocin- Ioaded D-MNPs group 
v, a reduced compared t DE -induced or free crocin treated groups. am'on 
howed anti -pr l i ferative act ivity by decreasing the number of Ki-67 positiYe cel l s  in 
DE -treated rat . 0 thi tudy indicated that attaching crocin on D-MNPs as a 
del i\er) v ehicle could enhance the anti -pro l iferati e acti it ies of crocin reported 
earl i r in [68 ] .  
.. 
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Figure 59 :  Effects of 1 1  mg/kg crocm and its P formulations on Ki -67 
expression i n  l iver. a) Normal , b) DE -induced e) 1 1  mg/kg eroei n  and d) 1 1  
mg/kg croein-loaded D-MNPs. Each scale bar = 1 00 /-tm. 
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Figure 60 : E ffects of 22 mglkg crocin  and i ts  P formulations on Ki-67 expression 
in l iver. a) onnaL b) DE - induced, c) 22 mglkg cracin, and d) 22 mg/kg crocin­
loaded D-MNPs. Each scale bar = 1 00 )llTI . 
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F igure 6 1 :  Estimated expression areas of K i -67 posit ive cel ls  in  the two examined 
croc in  fOffi1Ulations. a) 1 1  mg/kg crocin-loaded D -MNPs, and b) 22 mg/kg crocin­
loaded D-MNPs. Values are expressed as mean ± SEM; * P :S  0.05, * *P :S 0.0 1 ,  
* * *  P :s 0.00 l .  
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3.704.3.  M30- ytodeatb  expre ion 
e\'eral tudie indicate that apopto i e ential in  the modulation of 
hepatocarcin gene i and pr -neopla tic hepatocyte de\,elopment. poptosis i a 
ph) iological cel l  d ath that ha been suggested to play an important role in  the 
maintenance of hom 0 tasi [2 1 9 ,  2�0, 242-245 ] .  
Dy r gulation of apopto i i s  an important component of the multi tage 
hepato arcinogene i . This dy regulation ma result in the decreased abi l i ty of cel ls  
to undergo apopto i and provide a selective sur i al advantage for those cel ls. 
therefore leading to alter d gro�ih. cel lu lar tran formation and tumor progression. 
During hepatocarcinogene is, altered hepatic foci  display increased rate of cell 
pro l i feration and cel l  death relative to unounding normal hepatocytes. This increase 
in the apoptotic proce . al 0 cal led compensatory apoptosis, and occurs ine pective 
of the oncogenic events generating pre-neoplast ic and neoplastic lesions. However, 
the rate of cel l  repl ication process exceeds the apoptosis leading to hyperplasia [2 1 9. 
243, 246 ) .  Some l iver injury l ike chronic hepatit is is characterized by continuous 
e l imination of hepat ic cel ls ,  which could lead to cancer formation by 
c)10 Iysis/regeneration phenomena [2 1 9. 243 .  246 ] .  
Apoptotic pathways have been shown to  be  activated i n  several fOlTI1S of 
chronic li er inj uries including l iver cancer. Liver cel l  apoptosis can be ini tiated by 
d ifferent complex pathways, the majority i nvolving activation of the caspases. 
Caspases-2. -8 ,  -9. and - 1 0  are in it ia l ly activated and, in tum, activate a cascade of 
do\\nstream effector caspases such as -3 ,-6, and-7 [220, 242. 244 ) .  
Recently, there has been a growing i nterest i n  the role of cytokerati n  proteins 
during apoptosis. I t  has been suggested that caspase cleavage of the cytokerati n  
proteins fac i l itate the formation of  apoptotic bodies and ampl ify the apoptotic signal . 
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)10keratin  1 8 , for e ample, i an intermediate fi lament protein  repre enting about 
5% of total protein in th Ii er and oth r ti ues uch as pancrea and inte tine. 
During earl) apopto i cytokeratin ] 8 i c leaved by ca pa e 3 and 6 ( Figure 62 at 
t\\ O di t inct site ( partate 238  and A paI1ate 396 . Thi clea age pattern is highly 
pec i fic to apopto i and leads to the c l lular relea e of caspase-cleaved cytokerati n  
1 8  fragments into the e tracel lular pace and final ly to  blood trearn causing the 
characteri tic morphologic change of apoptosis [247, 248 ] .  
The computerized estimation of  the cytokerat in positive cel l s  has confirmed 
the r ults of the IHC analysis of cytokerat in  1 8 . As shown in Figu res 63 and  64 
normal group showed weak cytopla mic cytokerati n  1 8  positive cel ls .  This 
expre s ion increased igni ficantl (P  S 0.00 1 )  in the DE - induced compared to 
nom1al group ( Figu re 65) .  The increa ing in the apoptosis expression might be 
becau e of the process of replacing the nom1al l iver cel l s  by pre-neoplast ic cel ls .  
Thi continuou e l imination of hepatic cel ls could lead to cancer formation by 
cytol)' i s/regeneration phenomena. The increased apoptosis, also cal led 
compensatory apoptosis, occurs i rrespective of the oncogenic events triggering pre­
neoplasti c  and neoplasti c  lesions [2 1 9. 243 ] .  Amin et al. demonstrated that saffron 
treatment increased the number of M30-Cytodeath positive cel ls in DE - induced 
rats [68 ] .  Moreover. the numbers of posit ive cel ls were increased in groups treated 
with 1 1  mg/kg and 22 mglkg crocin- Ioaded D-MN Ps formulations compared with 
DE -induced group (P  S 0 .00 1 ) or  free crocin .  
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Cytokeratin 1 8  
Caspases : 3 a nd 6 
Neo-epitope 
M30-antibody 
Figure 62 : Diagrammatic representation of caspases c leavage of the cytokeratin  1 8  
[249] . 
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Figure 63 :  Effects of 1 1  mg/kg crocin  and its P fom1Ulations on M30-Cytodeath 
expression in I i  er. a) ormal ,  b )  DE -induced, c )  1 1  mg/kg crocin .  and d )  1 1  
mglkg crocin- loaded D-MN Ps. Each scale bar = 1 00 �m. 
F igure 64: E ffects of 22 mglkg crocin and its P formulations on M30-Cytodeath 
expression in l iver. a) NormaL b) DEN-induced, c )  22 mg/kg crocin, and d) 22 
mg/kg crocin- loaded D-MN Ps. Each scale bar = 1 00 /-lm. 
181  
I (a) -' 
U 1 .0 
0 r. 0.8 2 
� 
c 
� 0.6 
e � 
c::: 0,4 
. 9  
VJ 
� 0.2  
c.. 
� � 0.0 
o 
I (b) 
>- 2  U 
o 
("') 
� 1 c­
o 
C'd 
� 
C'd 
c::: 
. Q  
Uj 
r/j 
� 
0.. X 
w '#. 0 .0 
182 
* * *  
* *  
* * *  
* * *  
* * *  
F igure 65 :  Estimated expression of M3 O-Cytodeath area in  the two examined crocin  
formulations. a )  1 1  mg/kg crocin- loaded D-MNPs. and b) 22  mg/kg crocin- loaded D­
MNPs. Values are expressed as  mean ±SEM; * P :s 0.05.  * *  P :S  0.0 1 ,  * * *  P :s 0.00 1 . 
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3.70404.  Bcl-2 e x p re ion 
uch attenti n ha been given to the detect ion of molecular target that are 
al 0 jm 01 \  d in the regulation of apopto i and that might be al tered in tumor . Bcl-2 
oncog ne \\ a original ly identi fied a overexpressed in mo t human B-cel J fol l icular 
l y  mphomas. caused b a chromosomal tran location in  olving chromosomes 1 4  and 
1 8 . The nan1 of Bcl-2 is deri ed from B-cel 1  lymphoma 2. Bcl-2 prolongs cell 
un ivai by blocking apopto i rather than regulation of cell repl ication. There are 
e\ eral Bcl-2 fami ly  member that ha\'e been identified. including proteins that 
induce apopto is (pro-apoptotic ). and those prevent apoptosis ( anti -apoptotic ) .  Pro­
apoptotic protein . includ s Bax and Bak. The anti -apoptot ic proteins such as Bcl2 
and Bc1- L.  Ho\,,:ever. the cellular equi l ibrium betw'een the promotor and the blocker 
fan1i I )  members is knov\J1 to be es ential in determining cel l fate ( figure 66). Bcl-2 i s  
normal ly  expres ed  in  abundance in the thymus, spleen, and cerebnlm but not in  the 
l iver [2 1 9. 220. 243 . 250-252 ] .  
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Bcl-2 was how n to be overe pre ed in DE -induced mou e neoplasia 
[ 250] . The obj ctive of the pre ent investigation was to determine v,hether 
expre ion of B 1-2 was alter d in " ivo fol low ing treatment with different cro in  
fom1ulation . 
ccording to th I HC anal is  ( Figu res 67 and  68) that was confirmed by 
c mputerized anal_ is of 20 field of THC,  most of the AHF in DE -induced group 
were po it i, e for Bcl-2 and wa ignificantl (P :S 0.00 1 ) i ncreased compared to 
normal group. which was weakl tained ( Figu re 69) .  The staining was spec ifIcal ly 
een in  the cytoplasm of th cel ls .  The expression of Bcl-2 in  hepatic ti ssue of 
normal animal could not be detect was examined by immunohistochemistry. but 
posit ive tain ing of thi protei n  wa located in the cytoplasm of hepatocytes in  
animal treated with 200 mglkg DE [254 ] .  Also Lee et a 1 .  concluded that normal 
mou e hepatocytes did not express Bc1-2, most DE - induced tumours \�,:ere po i t ive 
for tlli protein [25 1 ] . 
un et al . reported that animal injected i .p .  with 6 .25 and 25  mglkg crocin 
showed reduction in  the tumour weight and size of HL-60 xenografts in  nude mice. 
These treated animals showed i nh ibited Bcl-2 expression, and increased Bax 
expression in xenografts [208] .  In the 1 1  and 22 mglkg crocin- Ioaded D-MNPs 
formulations. the expression of Bcl-2 posit ive cell in crocin- loaded D-MNPs was 
reduced compared to DE - induced or free crocin .  indicating that the Ps could 
induce apoptosi s  by  enhances the suppressIon of Bcl-2 .  
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F igure 67: Effects of 1 1  mglkg crocin and its P formulations on Bcl-2 expression in 
l iver. a) onnaL b) DE - induced, c) 1 1  mg/kg crocin, and d) 1 1  mg/kg crocin­
loaded D-MNPs fonnulation. Each scale bar = 1 00 11m. 
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Figure 68 : Effect of 22  mg/kg crOCill and its P formulations on Bcl-2 
expression in l iver. a) Normal, b )  DE -induced, c) 22 mg/kg crocin and d) 22 
mg/kg crocin-loaded D-MN Ps formulation. Each scale bar = 1 00 11m .  
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F igure 69 : Quantitative analysis of Bc1-2 expression i n  relative to IRe fields i n  the 
two tested crocin  formulations. a) 1 1  mg/kg crocin- loaded D-MNPs, and b) 22 
m glkg crocin- loaded D-MN Ps. Values are expressed as mean ±SEM; * P S 0.05 .  
**p S 0.0 1 ,  * * *p S 0 .00 1 . 
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3.7.4.5. CO -2 expre ion 
Liver cancer development a ociated with chronic cytotoxic and 
in flammatory event , indicating that in flammation mediators ( such as pro taglandin ) 
are involved in  it pathogene is .  Prostaglandin are produced from arachidonic acid 
by either OX- l or CO -2. COX- l i normal ly  and con tantly expres ed in  mo t 
ti ue and i important for the maintenance of homeostatic functions. COX-2. 
hov.:ever. i an inducible enzyme that is normal ly associated with tumorigenesi 
e\·ents. uch as cel l pro l iferat ion, angiogenesis, invasi eness and resi stance to 
apopto i . Variou tudies ha e reported that increased COX-2 expression may 
contribute to l iver damage and tumorigenesis  in animal models and HCC in humans. 
s CO T_2 i thought to contribute to inflammation-mediated cancer development. 
the expre ion level of thi enzyme ha been repOlied in the different animal studies 
[2_3 . 255-257 ] .  
COX-2 has been local ized to  the neoplastic cel ls .  endothelial cel ls, inunune 
cel ls ,  and stromal fibroblasts with in  the cancer. The downstream targets of COX-2 
include: (1 ) production of VEGF ; ( 2 )  promotion of vascular sprouting, migration, 
and tube formation: ( 3 )  enhanced endothel ial cel l survival via Bcl-2 expression and 
Akt signal ing; (4)  i nduction of matrix metal loproteinases (MMP) 2 and 9, and ( 5 )  
activation o f  epidermal growth factor receptor-mediated angiogenesis  [258 ] . 
I n  this study, I HC results of COX-2 ( Figu res 70 and  7 1 )  was quanti fied and 
confim1ed as sho"JIl in Figu re 72. COX-2 expression was found to be significantly 
increased (P :S 0 .00 1 ) in DE - induced group compared to nom1al group. Dietary 
feeding with crocin ( 50-200 ppm) for 4 weeks was able to inhibit colonic 
adenocarci nomas in mice and decrease the mRNA expression of inflammation 
regulators such as COX-2, NF-KB, TNF-a, I L- I P  and I L-6 as reported by Kawabata 
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et a1 .  [259] .  Therefore, fre crOCln ha a role in inh i bit ing COX-2 expre ion in 
animal 'v\ ith cancer. COX-2 e. pre ion was ign ificantly reduced in crocin  attached 
O-M P of the 1 1  and 22 mg/kg [onnulation compared with DE -induced (P :S 
0 .00 1 ) or fre crocin (P :S 0.00 1 ) . The e indicate the role of P in improving the 
anti-cane r act ivity f rocin .  CO -2 xpre sion in  all the treatment groups was 
prominent tain ing around central vein and portal area. 
Im e tigations by ivaramakri hnan et a1 . [257 ] .  Amin et a1. [68] and 
Ka\\ abata et a1. [259]  ha\'e hO'vvn nuclear translocation of F-KB-p65 in DEN­
induced animals wa important for the act ivation of COX-2 and thereby 
inflammation and carc inogenesis . Thus, it is possible that crocin-loaded D-MNPs 
uppress th nuc lear local ization of F-KB p65 in DE injected animal , thus 
leading to the dov;n-regulation of COX-2 and angiogenesi s .  
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Figure 70 :  Effects of 1 1  mg/kg crocm and i ts  P formulations on COX-2 
expression in l iver. a) ormal .  b) DEN-induced. c) 1 1  mg/kg crocin and d) 1 1  
mg/kg crocin-loaded D-MNPs. Each scale bar = 1 00 11m 
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Figure 7 1 : Effects of 22 mglkg croCIn and its P formulations on COX-2 
e. pression in l iver. a )  orma!. b)  DE - induced, c )  22 mglkg crocin and d )  22  
mglkg crocin-loaded D-MNPs. Each scale bar = 1 00 !-Lm .  
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F igure 72 :  E st imated expression areas of COX-2 posit ive cel l s  in  the two 
examined crocin  formulations. a) 1 1  mg/kg crocin-loaded D-MNPs, and b) 22 
mglkg crocin- loaded D-MN Ps.Values are expressed as mean ±SEM; * P ::::; 0 .05.  
* * P ::::; O .OL * * *P ::::; O.OO l .  
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3.7.4.6. V E G F  e x p re ion 
Angiogene i i a compl icated and critical proce involving prol iferation and 
migrati n of endothel ial cell to fOID1 ne\ blood yes el . Thi phenomenon i 
required for heal ing of inj ured ti ue, and pro l iferat ion of tumor cel l s, in order to 
upply the growth factor . nutrients. and oxygen. Recently, it was demon trated that 
angiogene i tart at a very earl ( 1 00-300 cel ls)  tage of tumor fOID1ation. Various 
angiogenic factor have been identi fied, but vascular endothel ial growth factor 
( VEGF) i the most p tent and specific growth factor for angiogenesis . VEGF has 
been demon trated to play a critical role in division. migration. invasion and tubule 
formation of va cular endothelial cel l s  [260-265 ] .  
Chronic l iver inj ury promotes the progress of genetic al terations leading to 
d} pIa tic foci/nodule fom1ation, which can develop into HCC later. Angiogenic 
gene expre ion in the dysplastic foci faci l i tates the carcinogenesis pathway leading 
to the highly vascularized lesion, which is  characterized by the presence of sinusoidal 
capi l larization and ubsequently ,  HCC development [260] . Several studies have been 
shown that VEGF is  secreted abundantly in  several human tumors and animal 
experimental models .  VEGF-induced tumor development and angiogenesi s  are 
mediated through several receptors, such as VEGFR2 and kinase insert domain­
contain ing receptor/fetal l iver k inase ( KDRlFLK- l ). Through the 
Ras/RafIMEKlERK pathway, activate V EGFr2 triggers cel l cycle progressIOn. 
extracel lular matrix remodel i ng, apoptosis resistance, and angiogenesi s  [260-264] . 
Pro l iferation of sinusoidal endothel ial cel l s  i s  main ly regulated by VEGF 
[263 ] .  Folkman was first to suggest that inhibit ing angiogenesis might have 
therapeuti c  potential for treating cancer [266] and since then many anti -angiogenic 
agents have been introduced as potential therapeutic agents to block angiogenesis 
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proce s [262 ] .  In  thi tud)\ the anti -angiogenic effects of crocin- Ioaded D-MNP 
ha\ e be n i l1\ e tigated in c mpari on \\ ith free crocin .  
� GF I H  re ult ( Figure 73 a n d  74)  was quanti fied and confirmed a 
hov,n in  Figu re 75. VEGF expre ion was sign i ficantly increased ( P  :s 0.00 1 ) 
during hepat arcinogene is in DE -induced group compared to normal group. This 
wa s imi lar to the results of Liu et al . that demon trated that VEGF expression, in 
rat gi\  ing DE at th dosage of 1 0  mg/kg every day for 1 6  weeks was highl 
increa ed compared to normal animal [26 1 ] . 
migai et al . indicated that crocetin  (aglycone of crocin carotenoids) might 
suppre the EGF-induced angiogenesis by i nhibit ing the phosphor lated-p3 8 and 
protection of V E-cadherin expr ssion [267] .  Moreo er. VEGF e 'pression was 
attenuated after the treatment with 1 1  and 22 mg/kg crocin-Ioaded D-MNPs 
fom1Ulations compared to DE - induced or free crocin .  These data highl ighted the 
role of Ps 1 11 enhancing the ant i -angiogenesis act ivit ies of crocin .  
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F igure 73 : Effects of 1 1  mg/kg croci n  and its NP formulations on V EGF expression 
in l iver. a) omlal, b )  D EN-induced, c) 1 1  mg/kg crocin, and d) 1 1  mglkg crocin­
loaded D-MNPs. Each scale bar = 1 00 11m. 
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Figure 74:  E ffects of 22 mg/kg crocin and its P formulations on VEGF expression 
in l iver. a) annal, b )  DE - induced, c) 22 mg/kg crocin, and d) 22 mg/kg crocin­
loaded D-MNPs. Each scale bar = 1 00 �m. 
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F igure 75: Quantitative analysis of V EGF-expression m the two 
examined crocin  fonnulations. a) 1 1  mglkg crocin- loaded D-MNPs. and 
b) 22 mg/kg crocin- loaded D-MNPs. Values are expressed as mean 
± EM;  *P � 0.05.  * * p  � 0.0 1 ,  * * *P � 0 .00 1 . 
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3.7.5. Propo ed mecha n i  m 
T achieve effective target ing of pre-cancerou ti s ue . y temical ly del ivered 
'P mu t fi r t extra\ a ate [r m the blood tream and bind to cel ls .  Then Ps mu t 
ro the cel l membrane of the target cel l  to reach appr priate intracel l ular ite . 
T\\ o targ t ing trat gie . pa sive and activ ha e been reported by researchers to 
explain P d l ive!) to the twnors. cti e targeting. al 0 cal led l igand-mediated 
target ing. involve the ut i l i zation of specific l igands on the surface of NPs that bind 
pec i fic urface molecules or r ceptors overexpre sed on the membranes of cancer 
cel l s  [90.  _0 1 -203 . 268 ] .  
Pa ive targeting ( u  ed in  th i s  study) util izes the dist inctive pathological 
characteri tics of tumor b lood vessel s :  highly immature. di sorganized and di lated 
"'i th a high number of pore or f, nestrae. These ascular changes may even lead to 
the formation of wide gaps between endothel ial cel ls and enabl ing NPs to 
accumulate in pre-cancerous and cancerous t issues. Therefore. the ' leaky' 
\'a cularization enhances pem1eabi l ity and al lows migration and entry of Ps ( 1 0-
500 nm) into the pre-cancerou ti ssues ( Figu re 76). Moreover. the deficiency of the 
lymphatic ystem in the newly fonned pre-cancerous t issue does not al low the 
recapture of these Ps and improves the retention or preservation effect [ 90. 20 1 -
203 ] .  
Endothelial  cell of new 
blood ve el 
/ • 
Bi le d uct cell  
B i le ductu le 
(oval celJs) 
/ 
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F igure 76: A diagram representing the changes that occur in  bi le ductule and oval 
cel l s  due to DE . Prol i feration of ova] cel l s  leads to evagination of the 
epithel ium and formation of pre-cancerous lesion. ew blood vessel s  also develop 
(angiogene is) around the hyperplast ic t i ssue . These changes might lead to 
enhanced i nternal ization of crocin-loaded D-MNPs by passive targeti ng.  
201 
nee extra\ a ated from the blood tream. D-MNP internal ization into the 
val cel l  and hepatocyte start b ' their b inding or adsorption to cell membranes 
foi l  \\ ed b) the fI nnation of endoc totic ve ic Jes or Ps-containing endo orne 
[269J . Thu . i t  i po i ble that in thi tudy. endo omes and ly 0 ome fu e to fonn 
endo-I} 0 orne \ e  icJe in  \\ hich the crocin i s  released from croc in-loaded D-MNPs 
in it active fonn a il lu trated in Figu re 77.  Most of the P were captured by 
kupffer cel l ,ia phagoc}10 i ( Figu re 55) .  and then the fonnation of a phagosome. 
Phago-I) 0 orne i forn1ed after fusion of phagosome with lysosome, where the 
crocin i al 0 relea ed from crocin- loaded D-MNPs in  its act ive fonn.  
Dextran wi l l  be  degraded into sugar components and MNPs wi l l  be  degraded 
into free iron I I  and I I I .  Free I ron in the hepatocytes cytoplasm can be used in  
e ential physiological function . uch as  mitochondrial adenosine triphosphate 
(ATP) generat ion and D A dan1age repair. Meanwhi le. unused i ron is stored in  the 
i ron-binding protein  such as feITit in. hemosiderin .  and transferrin .  I ron might exit  
the cel l  by exoC)10sis .  b ind to transfeITin in  blood, and get transported throughout 
the body as d ifeITic transferrin .  I ron homeostasi s  is preserved by the loss of about 1 
mg of i ron per day through the sloughing of i ntestinal mucosa and skin .  On the other 
hand. 20-25 mg of iron is essential each day for the hemoglobini zation of new 
erythrocytes [270] . 
Crocin + D- 1 Ps 
,.. L) 0 orne 
o \J 
Endo o� J 0 0 / 0 
E ndo-l) so orne f.\ � � . " / � . . . .. 
0 � � .,/'f ' . ' � Crocin Release + 
D-M N Ps Biodegradation 
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F igure 77: d iagram represent ing the proposed steps of endocytosis of crocin­
loaded D-MNP into the oval cel l and hepatocyte . The Ps go through ( 1 )  cel lular 
a ociation. (2 )  internal i zation of via endocytosis. ( 3 )  endosomal escape or (4) 
1yso omal degradation, ( 5 )  free crocin release into the cytoplasm and D-MN Ps 
b iodegradation. (6 )  cytoplasmic transport of crocin to effect organel les such as 
nucleus and mitochondria. modified from [27 1 ] . 
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oreO\'er, the microenvironment surrounding pre-cancerou ti ue 
di fferent [r m healthy ti ue. a ph) iological phenomenon that al 0 support pa si \'e 
targeting, Due to h igh metabol ic rate of fast-growing tumor cel l . the require more 
o. 'ygen and nutri nt . n equently. gl colysis i t imulated to obtain extra energy, 
re ult ing in an acidic nvironment . The pa si e d iffusion mechanism wi l l  faci l i tate 
th cr cin- l  aded D-MN P entry to the acidic environment of cel l s  thus releasing 
cr c in in  it active form. 
The pre ent study how that the crOClll release rate i n  acidic cancerous 
c ndition wa higher than the physiological condition (PH 7.4) a in Figu re 44, This 
fa t crocin relea e could be explained by induced h drolysis [3, 200, 272J of ester 
bond between crocin and cross- l i nker conjugated to D-MNPs in the acidic 
m icroenvironment. Fol lov;ing the uccessful loading and releasing of crocin in  its 
acti\' from D-MN Ps in  pre-cancerous lesions location, crocin can affects such 
lesions \' ia d ifferent mechanisms; some of these mechanisms have been i nvestigated 
i n  thi study, Crocin could decrease G T-P expression i n  DEN-induced m ice 
( Figure 58). This reduced level of GST-P might be due to crocin ' s  anti-antioxidant 
effect though suppressing the D E  -induced ROS, Ochiai et a l .  reported that crocin i s  
considered promisi ng for neuroprotection due to  their potential ROS-suppressing 
abi l it ies. Treatment of PC- 1 2  cel l s  with crocin has been reported to i nJlibit cell 
membrane l ip id peroxidation and to restore intracel l ular superoxide dismutase and 
glutathione peroxidase (anti-oxidant enzymes) activity [273 ] .  
The anti-pro l i ferative act ivi ty o f  crocin in  this study was also associated with 
the inJ1 ibi tion of Ki -67 ( Figu re 6 1 )  and induction of apoptosis .  Crocin stimulated 
apoptosis by up-regulation of caspase c leaved cytokerati n  1 8  ( Figu re 65) and down­
regulation of Bc l -2 expression ( Figu re 69) .  Crocin might reduce the Bcl-2 through 
de-a t i \  ating P I3  
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KT ignal ing pathway [27-+ ] .  Other studi showed that crocin 
induced broad change in  the expre ion profi le of gene modulating cel l cycle via 
do\\ n-r gulat ing the BcJ-2 expre SlOn and up-regulating Bax expres ion.  
Furtheml re, crocin ha be n hO\\1  to incr a e the number of cel l s  at GO/G 1 phase. 
thu increasing th percentage of apoptot ic cel l through G 1 cel l  cycle arrest [67, 
207. 275 ] .  
Li ver cancer development i s  combin d with chronic cytotoxic i ty and 
inflanlmation. In thi tud . crocin  di played an efficacy in  significantly reducing 
DE -induced l iver inflammation by decrea ing Ie el of expression COX-2 in the 
cel l s  a in  Figu re 72. COX-2 is  a key enz me involved in producing inflammatory 
ignal [276] . The overal l  proposed anti -cancer mechanisms of crocin are shown in 
Figu re 78 . 
To our knowledge this study i s  the first to show that cracin  has an i nh ibitory 
effect against angiogenesis and does significantly decreases VEGF expression in 
DE -induced m ice ( Figure 75) .  This effect might be  because of suppression of p3 8 
pho phorylatioI1 s imi lar to croceti n  [267 ] .  
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Angiogenesis 
VEGF 
Endocyto is 
Crocin+D-l\J::\'Ps � Crocin 
Ca pase 
COX-2 t 
Cleand-C)1okeratin 1 8 1 
Apoptosis Proliferation Inflammation 
F igure 78 :  Diagrammatic representation demonstrat ing the proposed anti -cancer 
activity of crocin  on pre-cancer/cancer celL in , ilro and in vivo. Crocin has mult i ­
effects on the cel l i nc lude inhibition of pro l iferation and i nflammation and 
enhancement of apoptosis. Crocin  exhibits i nhibitory effect on pro l iferation by 
decreasing Ki-67 nuclear protein. whi le  apoptosis activi ty increases through up­
regulation of caspase c leaved cytokeratin  1 8  and down-regulation of Bcl-2. The 
anti- inflammator and anti-angiogenesis effect of crocin is due to down-regulation 
of COX-2. Anti-angiogenesis also includes i nh ib ition of VEGF growth factor. 
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C h a pter  4 :  Con c l u  IOn 
H i one of the m t wide pread cancer worldv" ide and it incidence and 
mortal i ty rate are n the rise in many countrie . Tbe major drawbacks in current 
modal i t ie of l iver cancer tr atment are associated \;\,'ith higb toxic i ty and the lack of 
spec i ficit: to cancer cel l . Thu . d ifferent control led drug del ivery systems have been 
developed and natural anti-cancer ources have been investigated to overcome those 
hortc m ing . 10di fied co-precipitation method in  air at 10\ temperature was used 
to manufacture pure and coated MN P . After invest igating different reaction 
paramet r and coatine materials, 1 .0 % of dextran as selected as an ideal coat ing 
material u ing a 1 o v,: fe ding rate at 40 m llhr whi le maintaining the sti rring and 
soaking temperatures at 60°C . Crocin was chemical )  conjugated to D-MN Ps Ja 
cro - l i nker. Crocin i s  a saffron-based natural product that has hown anti -tumour 
activi ty both in \'itro and in "h'o. 
To our knowledge this is tbe first report i ndicating that i .v .  administration and 
the contro l led release of crocin conjugated onto D-MNPs could impro e the ant i ­
cancer therapeutic effect than free crocin  i n  in vitro and in , ivo l i ver cancer models .  
HepG2 cel l s  treated \.""ith crocin- Ioaded D-MN Ps reduced the cel l  pro l i feration when 
compared to control ( non-treated cel l s )  or those treated with free crocin or D-MNPs. 
In m ice i njected with diethyln itosamine, and developed several pre-cancerous 
changes and m icroscopic  intrahepatic cholangioma, i mmunohistochemical results 
indicated that D-MNPs conj ugated with crocin could increase the anti-cancer act ivity 
over free crocin .  Thus, to obta in an optimal dose for use i n  humans, these NPs 
require further i nvesti gation. These results provide insights for designing new 
modal i t ies for treatment of l iver cancer which would hopeful ly reduce its high 
mortal ity rate. 
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C h a pt e r  5: F u t u re P ro pect a n d  Li m i tat ion  
T reduc th  toxic ide effect indue d by traditional chemotherapy. thi 
di ertat ion demon trated a potential mean of pa i e del i  ery for croc in a a 
natural anti-cancer agent peci fical ly into cancer ites. With the promising anti ­
cancer re ult of crocin attached on D-MNPs r ported in  thi study both in 1'ilro and 
il1 '-;1'0. it would be u eful to inve tigat other path\ ays and possible mechanism by 
\\; hich crocin in this P ystem could inhibit the cancer de elopment. Key markers 
of path\\ay of interest i nc lude, but not l im ited to. p53 and caspase 3 for apoptosis, 
and F-KB. I L- I I3, I L-6 and TNF-a for inflanm1ation. 
I n  addit ion, it would be i nteresting to evaluate the effect of crocin-attached D­
lvfN P  ystem o n  other cel l l i nes and i n  d ifferent animal models  o f  HCC. Hep3 B, 
-398 and PLHC- I are examples of other HCC cel l  l i nes. Alternative HCC 
animal models include chemical ly-induced with aflatoxin B 1 or carbon tetrachloride, 
xenograft modeL and transgenic mice such as TAg mice. Being synthesized with 
magnetite core would make it beneficial to track these nano-carTier using MRI whi le  
simultaneously acting as anti-cancer agent in  ,'itro and in  l'i1'o . MRI can be used to 
evaluate the reduction in cancer t issues after treat ing with crocin-Ioad D-MNPs. 
Despite the success of developing D-MNPs that enhanced the del ivery and 
act ivity of crocin ,  there are st i l l  several obstacles to be overcome. F irst . there was 
minor cytotoxic ity because of de-attachment of dextran as a coating material 
exposing MNPs core to the cel l s .  econd, crocin release rate was slow and took two 
weeks to reach 92% at pH 5 . 5 .  Third .  there was d ifficulty to reproduce the effective 
crocin- loaded D-MN Ps due to fact that not a l l  MNPs could be coated with dextran 
and attached to crocin s imi larly and effectively (heterogeneous production) .  
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Further r finement are needed for the P to be u ed for drug del ivery .  I n  
pite of  that. th developed D-MN P have important properties that qual ify them to 
be u ed for cancer treatment, uch a . hyperthermia. 
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